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Abstract 
Sphingosine 1-phosphate (S1P) is a potent vasculo- and neuro-protective signalling lipid that pro-
motes neurotrophic growth factor expression and pre-synaptic acetylcholine and glutamate release. 
It signals through its own family of five G-protein coupled receptors. S1P is synthesised by 
sphingosine kinase 1 and 2 (SK1/2). Our research group demonstrated pronounced loss of S1P and 
SK2 activity early in Alzheimer’s disease (AD) pathogenesis, leading us to speculate that loss of 
S1P sensitises to AD development. Paradoxically, SK2 was reported to mediate amyloid β (Aβ) 
formation from amyloid precursor protein (APP) in vitro, which implies a role for this enzyme in 
promoting AD pathology. In this study we investigated the consequences of global SK2 knockout 
(SK2Δ) on neurological functions, particularly in the context of myelination and Alzheimer’s 
disease. We first examined behavioural effects of SK2 deletion in the absence of pathology. We 
then crossed SK2Δ mice to the J20 mouse model of familial AD amyloidosis to test whether SK2 
deficiency synergises with amyloid beta (Aβ) in promoting AD. 
S1P levels were reduced 85-90% in brains of SK2Δ mice, indicating that SK2 is responsible for 
the majority of S1P synthesis in the brain. SK2Δ mice displayed notably higher freezing response 
when placed in a novel context in the fear conditioning paradigm, independently of the fear 
stimulus, indicating a general anxiety phenotype in this strain.  
In agreement with a role in amyloid formation, SK2 deficiency reduced Aβ content, plaque burden, 
and reactive astrogliosis in J20 mice. This was associated with significant improvements in hyper-
synchronous activity and cross-frequency coupling measured by hippocampal electroencephalo-
graphy. However, SK2-deficient J20 mice exhibited severe hypomyelination in the 
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hippocampus and cortex, hippocampal atrophy, and significant deficits in the Y-maze and social 
novelty memory tests, when compared to the J20 or SK2Δ strains. 
We also uncovered a significant hypomyelination phenotype in SK2Δ mice, leading us to 
investigate the role of S1P receptors in myelination, and particularly the oligodendrocyte-specific 
S1PR5 receptor. Female SK2Δ mice were administered the S1PR5-selective agonist A-971432 or 
S1PR1/5 dual-agonist Siponimod, to determine if activation of these receptors would preserve 
myelination. Despite observing pronounced myelin depletion in male SK2Δ mice, no such 
impairments were identified in female SK2Δ mice. Nonetheless, a significant increase of 
understudied 18:2 base sphingadiene lipids was observed in both male and female SK2Δ mice. As 
myelin is comprised 80% of lipids, further investigation on the potential impact of these 18:2 lipids 
on myelin structural integrity is required.  
In summary, SK2-generated S1P was required for oligodendrocyte survival in an AD mouse 
model, yet was paradoxically also an important endogenous regulator of Aβ formation. These 
results urge consideration of the importance of myelin loss as a driver of neurodegeneration in AD. 
Future work should further investigate the different hypomyelination phenotypes in male and 
female SK2Δ mice, including any potential interaction between sex hormones and SK2-generated 
S1P in myelination. 
iv 
Thesis statement of originality 
This thesis has not been submitted for any other degree or purposes. I certify that the intellectual 
content of this thesis is the product of my own work and that all the assistance received in preparing 
this thesis and sources have been acknowledged.  
Mona Lei | 13 December 2019 
As supervisor for the candidature upon which this thesis is bases, I can confirm that the authorship 
attribution statements above are correct.  
Anthony Don | 13 December 2019 
v 
Acknowledgments 
This thesis and the work presented within could not have been possible without the guidance and 
support of my supervisor Anthony Don. I’d like to thank you for taking me on as a student, the 
knowledge that you have passed down to me throughout the years has been invaluable. I am 
grateful for the opportunities you have provided and for your mentorship, patience and dedication 
during this journey. Thank you for taking me on as a student. 
I would like to extend an additional thanks to my lab mates: 
Jon Teo, you are such an amazing person, lab mate and friend. I will miss our morning tea breaks 
where we sample your exotic tea collection whilst mulling over the latest collect of Hermès 
scarves. In all seriousness, thank you for being genuinely caring, kind and understanding. You 
have provided counselling and advice over those tea breaks that has really helped me through the 
tough days. I don’t know where the future will take us but I hope that our friendship will never 
waiver.   
Collin Tran, thank you for your boundless energy and humour. I will miss your shenanigans in and 
out of the lab. I could not have asked for a better travelling companion to the ISN conference in 
Montréal and New York. I will forever treasure the times we got Ooyoo banana bubble tea. You 
kept things light and happy in the lab and thank you for being a friend. 
I would also like to thank Huitong Song, Jun Yup Lee, Holly McEwen and Tim Couttas for their 
help throughout my candidature. Thank you for being such a great team and I am immensely 
grateful for your help towards the latest paper. And extend a thanks to past lab members, Adeena 
Shafique, Xin Ying Lim, Hua Zhao, Laura Hunter and Anna Pijning for their contribution and 
Acknowledgments 
vi 
 
support. In addition to this, I would like to thank Rose Chesworth, whose help has been 
instrumental for the behavioural data produced for this thesis. It was a pleasure working with you 
and I am glad to have you as a friend.  
I would also like to extend my gratitude to my co-supervisors Tim Karl and Thomas Fath.   
I express the deepest appreciation for my partner Malcolm, who has been immensely patient and 
supportive during these years. Your positive outlook on life provided me with the confidence I 
needed during trying times of my candidature where I doubted myself. Thank you for being there 
when I needed you the most, I am so grateful to have you in my life.        
I also owe a special thanks to my family, my brother Andy, and my parents, Wen Yi and Rong Le 
for their relentless support throughout my life. You taught me the value of hard work and 
dedication and I am proud to have you as parents.  
Table of contents 
vii 
 
Table of Contents 
 
Author Attribution ........................................................................................................................... i 
Abstract ........................................................................................................................................... ii 
Thesis statement of originality ....................................................................................................... iv 
Acknowledgments........................................................................................................................... v 
List of Figures ................................................................................................................................. x 
List of Tables ................................................................................................................................. xi 
Abbreviations ................................................................................................................................ xii 
Chapter 1 Literature Review ......................................................................................................... 1 
1.1 Alzheimer’s disease .............................................................................................................. 1 
1.2 Pathological Hallmarks of AD .............................................................................................. 3 
1.2.1 Amyloid beta .................................................................................................................. 3 
1.2.2 Tau ................................................................................................................................. 6 
1.2.3 Gliosis and AD ............................................................................................................... 9 
1.3 Current treatments for AD: ................................................................................................. 10 
1.3.1 Issues with current treatments ...................................................................................... 11 
1.4 Genetic risk factors of Alzheimer’s disease ........................................................................ 12 
1.5 Genes involved in lipid transport and metabolism ............................................................. 14 
1.5.1 Apolipoprotein E .......................................................................................................... 14 
1.5.2 Clusterin/apolipoprotein J (CLU/APOJ)...................................................................... 15 
1.5.3 Adenosine triphosphate-binding cassette transporter 7 (ABCA7)............................... 15 
1.6 Genes involved in endocytosis............................................................................................ 16 
1.6.1 Bridging integrator 1 (BIN1) ....................................................................................... 16 
1.7 Genes involved in the immune/inflammatory response: .................................................... 17 
1.7.1 Triggering receptor expressed on myeloid cells 2 (TREM2) ...................................... 17 
1.8 Myelin and neurodegeneration ........................................................................................... 18 
1.8.1 Myelin .......................................................................................................................... 18 
1.9 Lipid metabolism and neurodegeneration ........................................................................... 20 
1.9.1 Sphingolipids ............................................................................................................... 20 
Table of contents 
viii 
 
1.9.2 Ceramides .................................................................................................................... 24 
1.10 Sphingosine-1-phosphate (S1P) ........................................................................................ 25 
1.10.1 S1P and AD................................................................................................................ 26 
1.11 S1P receptor agonists ........................................................................................................ 28 
1.11.1 Fingolimod ................................................................................................................. 29 
1.12 Second generation S1P receptor agonists ......................................................................... 30 
1.12.1 Siponimod (BAF312/A)............................................................................................. 30 
1.12.2 A-971432 S1PR5 agonist ........................................................................................... 30 
1.12.3 Ponesimod (ACT-128800) ......................................................................................... 31 
1.12.4 Ozanimod (RPC1063) ................................................................................................ 32 
1.13 Rationale for the studies described in this thesis .............................................................. 33 
1.14 Aims .................................................................................................................................. 34 
Chapter 2 Contextual fear conditioning is enhanced in mice lacking functional sphingosine 
kinase 2 ......................................................................................................................................... 35 
Chapter 3 Sphingosine kinase 2 potentiates amyloid deposition but protects against hippocampal 
volume loss and demyelination in a mouse model of Alzheimer's disease .......................................... 44 
Chapter 4 Do S1P receptor agonists reverse hypomyelination in SK2 knockout mice? ............ 60 
4.1 Introduction ......................................................................................................................... 60 
4.1.1 Specific Aims of this chapter: ...................................................................................... 61 
4.2 Materials and Methods ............................................................................................................ 62 
4.2.1 Animals ............................................................................................................................ 62 
4.2.2 Drug treatment ................................................................................................................. 62 
4.2.3 Flow cytometry ................................................................................................................ 63 
4.2.4 Behavioural phenotyping ................................................................................................. 65 
4.2.5 Novel object recognition test ....................................................................................... 65 
4.2.6 Fear conditioning and extinction ................................................................................. 66 
4.2.7 Western blotting ............................................................................................................... 66 
4.2.8 Lipidomic Analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS)
................................................................................................................................................... 67 
4.2.9 Scanning electron microscopy (SEM) ............................................................................. 68 
4.2.10 Statistical analysis .......................................................................................................... 69 
4.3 Results ..................................................................................................................................... 71 
Table of contents 
ix 
 
4.3.1 Prototypical myelin lipids are depleted in 12-month old male mice lacking SK2. ......... 71 
4.3.2 Myelin thickness is reduced in SK2Δ mice. .................................................................... 73 
4.3.3 Investigating hypomyelination in SK2Δ mice. ................................................................ 78 
4.3.3.1 Siponimod treatment effectively induced lymphopenia in blood. ............................ 78 
4.3.4 S1P receptor agonists did not alleviate the freezing deficit in SK2Δ mice. .................... 80 
4.3.5 Neither WT nor SK2Δ mice showed a preference for the novel object in the novel object 
recognition test. ......................................................................................................................... 87 
4.3.6 Hypomyelination was not evident in mice lacking SK2. ................................................. 89 
4.3.7 No loss of major myelin lipids, but elevated sphingadiene-containing lipids in SK2Δ 
mice. .......................................................................................................................................... 91 
4.5 Discussion ............................................................................................................................. 103 
4.6 Conclusion ............................................................................................................................ 112 
Chapter 5 Conclusion and Final Remarks .................................................................................. 113 
References ................................................................................................................................... 118 
 
 x 
 
List of Figures 
Figure 1.1 APP processing pathway. .............................................................................................. 5 
Figure 1.2 Hyperphosphorylated tau and neurofibrillary tangle formation in AD. ........................ 8 
Figure 1.3 Overview of the sphingolipid pathway [189]. ............................................................. 22 
Figure 4.1 Decreased levels of myelin lipids in the hippocampus of 12-month old male SK2Δ 
mice. .............................................................................................................................................. 72 
Figure 4.2 MBP expression is reduced in the hippocampus of SK2Δ male mice ........................ 72 
Figure 4.3 Myelin sheath integrity is compromised in 12-month old male SK2Δ mice. ............. 74 
Figure 4.4 Age-related myelin deficits observed in SK2Δ male mice.......................................... 77 
Figure 4.5 Female mice treated with Siponimod exhibit peripheral lymphopenia. ...................... 79 
Figure 4.6 WT and SK2Δ mice show equivalent freezing response in the conditioning phase of 
the fear conditioning paradigm. .................................................................................................... 82 
Figure 4.7 Contextual fear-associated memory to altered context and auditory cue across 
treatment groups............................................................................................................................ 83 
Figure 4.8 Contextual fear-associated memory and contextual fear extinction across drug 
treatments. ..................................................................................................................................... 86 
Figure 4.9 Behavioural interactions with novel and familiar objects. .......................................... 88 
Figure 4.10 Loss of myelin markers was not detected in female SK2Δ mice and agonist treatment 
did not affect myelin protein expression. ...................................................................................... 90 
Figure 4.11 Altered sphingosine and S1P levels in SK2Δ hippocampus. .................................... 93 
Figure 4.12 Hippocampal sphingadiene and 18:2 sphingadiene base lipids are increased in SK2Δ 
mice. .............................................................................................................................................. 98 
 
 xi 
 
List of Tables 
 
Table 1.1 The top five genetic risk factors associated with LOAD, according to the alzgene 
website. ......................................................................................................................................... 13 
Table 3.2.3 Antibody list for flow cytometry ............................................................................... 64 
Table 4.2 Increased sphingosine and decreased S1P 18:1 base levels in SK2Δ hippocampus. ... 97 
Table 4.3 Total sphingadiene base lipid levels are increased in mice lacking SK2Δ. ................ 100 
Table 4.4 Main effect of genotype affects sphingadiene base lipids in hippocampus. ............... 102 
 
 xii 
 
Abbreviations
 
3/4R 3 or 4 conserved repetitive domains 
Aβ  Amyloid beta 
ABCA7 Adenosine triphosphate binding cassette subfamily a member 7 
ACK Ammonium-chloride-potassium 
ACT-128800 Ponesimod 
AD  Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase 
AGD Argyrophilic grain disease 
AICD APP intracellular domain 
AKT Protein kinase B 
ANOVA Analysis of variance 
APH-1 Anterior pharynx defective 1 
APOE/J/M Apolipoprotein E or J or M 
APP Amyloid precursor protein 
BACE1 Aspartyl protease β-site APP cleaving enzyme 1 
BAF312/A Siponimod 
Abbreviations 
xiii 
 
BBB Blood brain barrier  
BDNF Brain-derived neurotrophic factor 
BIN1 Bridging integrator 1 
C1P Ceramide-1-phosphate 
CBD Corticobasal degeneration 
CGT Ceramide galactosyltransferase  
CLIP-170 Microtubule-associated protein 
CLU Clusterin 
CNS Central nervous system 
CR1 Complement receptor 1 
CSF   Cerebral spinal fluid 
CTE Chronic traumatic encephalopathy 
DAG Diacylglycerol  
DAP12 DNAX-activation protein 12 
DAPI Diamidino-2-phenylindole dihydrochloride 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
EAE Experimental autoimmune enchephalomitis 
Abbreviations 
xiv 
 
EDTA Ethylenediaminetetraacetic acid 
EOAD Early onset Alzheimer’s disease 
ER Endoplasmic reticulum 
ERK Extracellular signal–regulated kinases 
FACS Fluorescence activated cell sorting 
FBS Foetal bovine serum 
FCE Fear conditioning and extinction  
FDA Food drug administration 
FDG-PET  Fluorodeoxyglucose positron emission tomography 
FTDP-17 Frontotemporal dementia and parkinsonism linked to chromosome 17 
FTY720 Fingolimod 
GABA Gamma-Aminobutyric acid 
GalCer Galactosylceramide  
GCS Glucosylceramide synthase  
GFAP Glial fibrillary acidic protein 
GluCer Glucosylceramide 
GPCR G-protein coupled receptors 
GSL Glycosphingolipids 
Abbreviations 
xv 
 
GTP Guanosine triphosphate 
GWAS Genome wide associated studies 
HD Huntington’s disease 
HDAC Histone deacetylases 
HDL High density lipoprotein 
HPLC High performance liquid chromatography 
IL-1β Interleukin-1β 
ITAM Immunoreceptor tyrosine-based activation motif 
ITI Intertrial interval  
LC-MS/MS Liquid chromatography-tandem mass spectrometry 
LDLR Low density lipoprotein receptor  
LOAD Late onset Alzheimer’s disease 
MAPK Mitogen-activated protein kinase 
MBP Myelin-binding protein 
MRI  Magnetic resonance imaging 
mRNA Messenger ribonucleic acid 
mL Microliter 
MOG Myelin oligodendrocyte glycoprotein 
Abbreviations 
xvi 
 
MS Multiple sclerosis 
MTBE Methyl-tert-butyl ether 
NaN3 Sodium azide 
NF Neurofilament 
NFT   Neurofibrillary tangles 
NMDA N-methyl-D-aspartate receptor  
NORT Novel object recognition test 
NRG-1 Neuregulin-1 
PBS Phosphate buffered saline  
PEN-2 Presenilin enhancer 2  
PI3K Phosphoinositide 3-kinase 
PLP Myelin proteolipid protein 
PNS Peripheral nervous system 
PSEN1/2 Presenilin 1 or 2 
PSL Phosphosphingolipids 
PSP Progressive supranuclear palsy 
RPC1063 Ozanimod 
rpm Revolutions per minute  
Abbreviations 
xvii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S1P  Sphingosine-1-phosphate 
S1PR1/2/3/4/5 Sphingosine-1-phosphate receptor 1-5 
sAPPα/β Soluble amyloid precursor protein α or β 
SEM Scanning electron microscopy 
SGPL1 Pyridoxal phosphate-dependent S1P lyase 
SK1/2  Sphingosine kinase 1 or 2 
SM Sphingomyelin 
SNP Single-nucleotide polymorphisms 
SYK Spleen tyrosine kinase 
TNFα Tumour necrosis factor α 
TREM2 Triggering receptor expressed on myeloid cells 2 
UDP Uridine diphosphate 
 1 
 
Chapter 1 Literature Review 
 
1.1 Alzheimer’s disease 
AD is the most common form of dementia and afflicts approximately 50 million individuals 
worldwide [1]. Dementia is a neurocognitive disorder characterised by the deterioration of 
memory, speech, judgement, planning, reasoning and other abilities related to cognition [2]. These 
impairments result in a loss of one’s ability to carry out everyday activities and often negatively 
impacts the individual’s psychological wellbeing, leading to early clinical symptoms such as: 
depression and apathy [3]. Individuals with AD typically require permanent round the clock care 
which has a substantial economic burden on healthcare [4]. Symptoms become more pronounced 
as the condition progresses where extended neuronal damage results in the loss of basic bodily 
functions such as communicating, swallowing, or walking, as well as hallucinations and seizures 
[5]. Death as a result of AD occurs from secondary causes such as pneumonia as individuals 
typically become bed-ridden, making then susceptible to infections [3]. Mortality occurs, on 
average, eight and a half years from presentation of the disease [6].  The main risk factor of AD is 
age. The disease generally affects individuals >65 years old, and prevalence doubles every five 
years thereafter [7]. Though AD can occur in individuals <65 years, its prevalence is less common 
and only accounts for approximately 6% of AD cases [8]. The pathological hallmarks of AD are 
extracellular, insoluble amyloid beta (Aβ) plaques, and intracellular neurofibrillary tangles (NFT), 
comprised primarily of hyperphosphorylated tau protein [1, 9]. Demyelination of white matter 
regions, dysregulated lipid metabolism and activation of glial cells in the brain are also evident 
[10-12]. The downstream pathological features include loss of synapses and neuronal atrophy, 
which lead to cognitive decline [13].  
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There is no single test for the diagnosis of AD and diagnosis requires a battery of cognitive, 
neurological and physical examinations. Neuropathological tests include examining blood or 
cerebral spinal fluid (CSF) for biomarkers, magnetic resonance imaging (MRI) and 
fluorodeoxyglucose positron emission tomography (FDG-PET) analysis to determine neural 
atrophy, dysregulated metabolic activity, tau pathology and amyloid deposits in the brain [14, 15].  
 
Current approved therapeutics for AD are cholinesterase inhibitors (to boost acetylcholine levels) 
and the N-methyl-D-aspartate (NMDA) receptor antagonist Memantine [16]. Experimental 
therapeutics have focused overwhelmingly on inhibitors of beta- or gamma-secretase to block 
amyloid formation, or anti-amyloid antibodies to promote amyloid clearance [17-19]. These have 
all failed to meet efficacy targets in clinical trials. The amyloid cascade hypothesis centres on the 
metabolism of the human amyloid precursor protein (APP) into Aβ peptides, which form 
insoluble, toxic oligomers that are believed to cause to the neuropathological effects of AD [20]. 
Interestingly, the APP gene has been mapped to chromosome 21 and individuals with trisomy 21 
(Down’s syndrome) develop AD at an earlier age and are at increased risk of developing AD [21]. 
The prevalence rate of AD in these individuals is approximately 50% by the age of 60 [22].  The 
additional chromosome is believed to drive more Aβ production. However, the correlation between 
occurrence of amyloid plaques and AD pathogenesis can be varied. For example, it is not 
infrequent for biopsied brains to show extensive amyloid pathology, whilst those individuals 
exhibited no indication of cognitive impairment [23].     
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1.2 Pathological Hallmarks of AD 
 
1.2.1 Amyloid beta  
Aβ aggregation and plaque deposition leading to Aβ cytotoxicity, synaptic dysfunction, and 
neuronal death are key pathological features of AD. Aβ peptides are a derivative of the APP, which 
is a transmembrane protein that can undergo two proteolytic pathways. APP can either be cleaved 
by α-secretase in the non-amyloidogenic pathway or it can be directed towards the production of 
neurotoxic insoluble Aβ-40 and Aβ-42 peptides (Figure 1.1) [24]. In the non-amyloidogenic 
pathway, full length APP is cleaved within the Aβ-domain by α-secretase, consisting of members 
of the a disintegrin and metalloproteinase (ADAM) protein family, generating soluble APPα and 
the C-terminal fragment C83 [25]. The C83 fragment undergoes further intramembrane proteolysis 
by γ-secretase, which consists of the presenilin 1 or 2 (PSEN1/2), nicastrin, anterior pharynx 
defective 1 (APH-1) and presenilin enhancer 2 (PEN-2), proteins to form the p3 peptide and 
cytosolic APP intracellular domain (AICD) [26, 27]. Under the amyloidogenic pathway, APP is 
processed by the β-secretase enzyme aspartyl protease β-site APP cleaving enzyme 1 (BACE1, 
a.k.a β-secretase) [27]. BACE1 is a member of the pepsin-like family of aspartyl proteases, and is 
the rate limiting enzyme involved in the formation of amyloid beta (Aβ). The formation of Aβ 
occurs when full length amyloid precursor protein (APP) is cleaved at its C-terminal region by β-
secretase [28]. This produces a C99 c-terminal fragment (CTF) that spans the membrane and 
releases soluble amyloid precursor protein β (sAPPβ) into the extracellular space. The second 
proteolytic step is catalysed by γ-secretase, which generates Aβ and AICD peptides from the C99 
fragment [24, 28]. At high concentrations, Aβ monomers self-assemble to form oligomers, 
protofibrils and mature insoluble fibrils which become components of Aβ plaques that accumulate 
in the extracellular space between neurons [29]. Of the two main Aβ peptides found in human 
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brains, Aβ42 is more prone to aggregation and the formation of toxic plaques, whereas Aβ40 is 
more abundant in blood plasma [25]. These plaques cause astrogliosis, distended neurites, 
dendritic spine loss and clustering of microglia [30, 31]. The pathological outcomes of Aβ 
formation and aggregation are believed to play a central role in AD pathogenesis and disease 
progression. The amyloid cascade hypothesis proposes that formation of Aβ is the initial event that 
triggers AD pathogenesis [20]. Although of late, the validity of the amyloid cascade hypothesis is 
considered outdated, due to a litany of failed clinical trials centering on Aβ as a therapeutic target 
for AD.  
 
In addition to its role in amyloid beta generation, BACE1 is an important regulator of myelination. 
BACE1 is highly expressed in neurons and oligodendrocytes in the CNS [28, 32, 33]. Active 
BACE1 regulates myelination of the nervous system, through proteolytic activation of the 
neurotrophin neuregulin-1 [34]. Its role is evident during instances of traumatic brain injury, where 
BACE1 levels are elevated [32]. Moreover, BACE1 protein activity also increases in the brain of 
individuals in late-stage AD [35, 36]. Due to its proteolytic role in Aβ formation, BACE1 has been 
a targeted as a potential therapeutic treatment of AD. Unfortunately, all β-secretase inhibitors have 
failed in clinical trials thus far, which is likely attributed to inhibition the normal physiological 
(non-amyloidogenic) functions of BACE1 [37].  
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Figure 1.1 APP processing pathway. 
APP can undergo two pathways of processing. The non-amyloidogenic pathway involves cleaving of APP by α-secretase, which generates soluble APPα and C83 
segments, γ-secretase then cleaves the C83 segment to P3 and AICD. The amyloidogenic pathway involves β-secretase cleavage of APP to form soluble APPβ and 
C99. The C99 segment is then processed by γ-secretase which form AICD and Aβ. Aβ aggregates form extracellular insoluble Aβ plaques which are considered 
neurotoxic and associated with neuronal death. 
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1.2.2 Tau 
Another pathological hallmark of AD is hyperphosphorylated tau protein, which aggregates to 
form NFTs (Figure 1.2). Tauopathy is also a pathological feature of other neurodegenerative 
diseases including frontotemporal dementia and traumatic brain injury. Tau is a member of the 
microtubule-associated protein family [38]. In the central nervous system (CNS), tau is localised 
to neuronal axons where it is involved in microtubule assembly and stability, along with 
microtubule mediated vesicle transport [38]. Tau is also found in somatodendritic compartments 
of neurons, in the nucleus associated with the nucleolus, and in oligodendrocytes [39-41]. The 
binding of tau to microtubules is dependent on their conserved repetitive domains which are also 
referred to as their microtubule-binding domain (MBD). These MBDs influence the ability of tau 
to bind to microtubules through tandem repeat sequences within MBDs [42]. Phosphorylated tau 
around these MBDs is believed to neutralise its positive net charge, and change the MBD 
conformation, leading to uncoupling of tau from microtubules [43]. As a result, unbound tau 
aggregates within the neuronal soma and neurites, forming insoluble filaments and NFTs [42, 44].   
 
The tau protein consists of six isoforms which differ based on the presence of either three (3R) or 
four (4R) conserved repetitive domains and the occurrence of amino-acid inserts in the N-terminus 
domain [45]. 3R and 4R aggregates are associated with primary tauopathies, along with isoform 
specific tauopathies. For instance, 3R aggregates are specific to Pick disease and 4R tauopathies 
include progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease and 
frontotemporal dementia and parkinsonism linked to chromosome 17 [46, 47]. A combination of 
3R and 4R tau aggregates result in disease states that are associated with NFTs such as AD and 
chronic traumatic encephalopathy [47].  
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The Braak staging system for NFT pathology defines the anatomical spread of this pathology 
throughout the brain during the pathogenesis of AD [48]. In Braak stages I and II NFTs initially 
develop in the entorhinal cortex and go on to spread to the dentate gyrus [48, 49]. The progression 
of the disease to Braak stages III and IV is defined by the propagation of NFTs to the hippocampus. 
In Braak stage V and VI the tangles become established throughout the neocortex/cerebral cortex 
[48]. Furthermore, tau phosphorylation and mis-sorting within dendritic spines has been reported 
to cause synaptic dysfunction through disrupting glutamate trafficking, a process that occurs prior 
to overt neurodegeneration [50].  
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Figure 1.2 Hyperphosphorylated tau and neurofibrillary tangle formation in AD. 
Tau protein assists in the formation and stabilisation of microtubule structure of neurons. In AD, tau protein become hyperphosphorylated, which disintegrates the 
microtubule cytoskeleton of neuronal axons. Free hyperphosphorylated tau aggregate to form NFT which is associated with synaptic dysfunction and neuronal 
death. Adapted from [51]. 
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1.2.3 Gliosis and AD 
Inflammation is recognised as a hallmark of AD and other neurodegenerative diseases [52]. A key 
regulator of neuroinflammation are astrocytes, which are the most abundant glial cell in the CNS 
[53]. They are also involved in regulating glutamate uptake to prevent glutamate toxicity, protect 
neurons from oxidative stress, and play a role in synaptic function [54-58]. Under conditions of 
neurodegeneration or brain injury, astrocytes undergo morphological changes which result in an 
activated state [59]. Astrogliosis is characterised by upregulated glial fibrillary acidic protein 
(GFAP) expression, and S-100B protein. Increased expression of these markers has been described 
in post-mortem tissues from AD individuals [60-63]. In cases of AD or brain injury, reactive 
astrocytes and active microglia assimilate around areas of the brain that have undergone injury or 
trauma forming a glial scar [64, 65]. Here, they secrete proinflammatory factors that promote 
phagocytosis aimed to alleviate damaged tissue and breakdown misfolded Aβ [66, 67]. However, 
in the case of AD, chronic activation of proinflammatory conditions are also thought to exacerbate 
the disease [68]. Upregulated concentrations of proinflammatory cytokines such as tumour 
necrosis factor α (TNFα) and interleukin-1β (IL-1β) have been reported in AD brain samples and 
transgenic mouse models [69-71]. This leads to the generation of arachidonic acid metabolites and 
nitric oxide which are key inflammatory mediators that also contribute to chronic astrogliosis [72, 
73]. Inflammation that is sustained over time is thought to spread from sites of injury to the 
surrounding healthy tissue, thereby inducing secondary injury [74-76].  
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1.3 Current treatments for AD: 
At present there are only five drugs approved by the Food and Drug Administration (FDA) for the 
treatment of the cognitive symptoms associated with AD. These include cholinesterase inhibitors: 
Donepezil (Aricept), Galantamine (Razadyne), Rivastigmine (Exelon), Tacrine (Cognex); and the 
N-methyl-D-aspartate receptor (NMDAR) antagonist Memantine (Namenda) [77, 78]. 
Cholinesterase inhibitors slow the loss of cholinergic function in AD, which is attributed to loss 
of cholinergic neurons, particularly in the basal ganglia of the brain, and reduced choline 
acetyltransferase and acetylcholinesterase activity in the cerebral cortex, which result in memory 
and cognitive deficits [79, 80]. Cholinesterase inhibitors function by inhibiting 
acetylcholinesterase, the enzyme that degrades acetylcholine, thereby increasing the amount of 
acetylcholine within the synaptic cleft [80]. The efficacy of cholinesterase inhibitors is varied. 
Individuals undertaking treatment display mild cognitive improvements within the initial three 
months and the decline of cognitive function decelerates over nine months compared to those 
taking placebos [81]. Yet clinical trials based on long-term cholinesterase inhibitors in patients 
with mild cognitive impairment were unsuccessful in reducing the risk or inhibiting the onset of 
AD [81]. Overall, cholinesterase inhibitors provide temporary and modest cognitive improvement 
to individuals with mild AD, but fail to improve long-term quality of life [77].  
 
The drug Memantine is a non-competitive NMDAR antagonist that functions by preventing the 
excessive glutamate-mediated excitatory influx of calcium ions through NMDARs which results 
in cortical and hippocampal neuronal death [82]. It is the first pharmacological compound 
approved for the treatment of moderate to severe AD. In a placebo-controlled trial, memantine 
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improved cognition, behaviour and activity in individuals with moderate to severe AD at 6 months 
of treatment [82, 83].                   
 
1.3.1 Issues with current treatments 
The success rate of drugs for AD in clinical trials is remarkably low, with failure rates at 99.6% 
between 2002 and 2012 and remaining consistently poor to date [84]. The current approved drugs 
for the treatment of AD appear to target the symptoms, rather than modifying the course of the 
disease [85, 86].  
 
Most experimental therapeutics for AD have focused on inhibiting Aβ formation or promoting 
clearance, with many being effective in reducing Aβ levels but ineffective in mitigating cognitive 
decline in clinical trials. Moreover, novel drugs that target microglial activation are also failing in 
clinical trials [87-89]. Treatments that have been deemed unsuccessful thus far include: 
bapineuzumab, solanezumab, tarenflurbil, EVP-0962 and gammagard [90-94]. A possible issue 
with Aβ targeted therapies may be that treatment is offered too late in the progression of illness. 
Patients involved in clinical trials are usually mildly cognitively impaired or have been diagnosed 
with AD. In these cases, it is likely that the process of Aβ accumulation occurs decades prior to 
the diagnosis of dementia [9, 95]. Thus, the clearance of Aβ will not impact disease progression, 
as by then, downstream insults such as tau pathology, neurodegeneration and myelin degradation 
would have occurred. As a replacement for Aβ clearance, therapies targeting these later-stage 
pathologies may be useful to slow disease progression. Biomarkers for early disease detection are 
therefore vital if Aβ-targeted therapies are to succeed. Alternatively, these failures indicate that 
the amyloid hypothesis is inaccurate or over-simplified, and AD is a multi-factorial disease in 
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which Aβ is just one important component. At the other extreme, some argue that Aβ is a 
biomarker of disease, rather than a causal influence. However, the genetics of inherited AD argue 
for some involvement of Aβ or proteolytic APP cleavage.    
 
 
1.4 Genetic risk factors of Alzheimer’s disease 
AD is a multi-faceted, heterogeneous disorder that has a strong genetic association. The disease is 
classified into two subtypes: Early onset AD (EOAD) and late onset AD (LOAD). EOAD occurs 
before 60 years of age and follows a Mendelian pattern of inheritance. EOAD is caused by 
autosomal dominant mutations in amyloid precursor protein (APP), presenilin-1 (PSEN1), and 
presenilin-2 [96]. These familial risk genes generally promote amyloid beta peptide formation 
[97]. LOAD occurs after 60 years of age and, unlike EOAD, genetic risk for LOAD is not fully 
penetrant. An APP mutation that reduces amyloid formation and reduces LOAD risk has been 
identified, which suggests that Aβ produced from APP is central to AD [98]. The strongest risk 
factor for LOAD is inheritance of the ɛ4 allele of the apolipoprotein E gene (APOE). Genome 
wide associated studies (GWAS) have identified single-nucleotide polymorphisms (SNP) in a 
number of genes that are linked to AD (Table 1.1). Given the heterogeneous polygenic pattern of 
expression in LOAD, it is unsurprising that a variant of genes linked to AD are also involved in 
regulatory pathways such as lipid metabolism, endocytosis, immune regulation and the 
inflammatory response.     
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Gene Polymorphism OR (95% CI) P-value 
APOE rs429358 3.685 (3.30-4.12) <1E-50 
BIN1 rs744373 1.166 (1.13-1.20) 1.59E-26 
CLU rs11136000 0.879 (0.86-0.90) 3.37E-23 
ABCA7 rs3764650 1.229 (1.18-1.28) 8.17E-22 
CR1 rs3818361 1.174 (1.14-1.21) 4.72E-21 
 
Table 1.1 The top five genetic risk factors associated with LOAD, according to the alzgene website.  
Table was derived from alzgene.org.   
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1.5 Genes involved in lipid transport and metabolism 
 
1.5.1 Apolipoprotein E 
Apolipoproteins are lipid transport proteins which mediate lipid transport between cells and 
regulate lipid degradation by phagocytic cells. Common variants of apolipoprotein E (apoE) are 
the most significant genetic modulators of risk for AD. ApoE is highly expressed in the liver and 
the brain, where it is responsible for the redistribution of lipids to aid cell proliferation and 
remyelination [99, 100]. In the brain, apoE is primarily produced by astrocytes, followed by 
microglia [101-103]. It is expressed in neurons as a response to excitotoxic injury [104, 105]. ApoE 
lipoproteins interact with the adenosine triphosphate binding cassette subfamily member A1 
(ABCA1) transporter to accrue lipid from a cellular efflux mechanism [106]. Ablation of the 
ABCA1 gene increases Aβ accumulation and reduces ApoE levels [106]. There are three major 
alleles of the APOE gene, ɛ2, ɛ3 and ɛ4 [107]. Inheritance of the APOE4 (ɛ4) allele is the strongest 
genetic risk factor for AD, and negatively impacts Aβ clearance and uptake by phagocytic cells 
[67, 108]. The inheritance of a single APOE4 allele increases the risk of developing AD by 3-fold 
in men and 4-fold in women, whereas homozygous carriers are at 15-fold increased risk compared 
to non-carriers [109-111]. The ɛ2 allele protects against AD [112]. Dementia subjects who are ε2 
carriers exhibit reduced Aβ plaque deposition in the frontal and parietal cortex, compared to 
individuals with the ε3/ε3 genotype [113]. NFTs are also reduced in the cortices [113]. Moreover, 
astrocytes isolated from individuals with the APOE ε2 allele produce three times more brain-
derived neurotrophic factor (BDNF) compared to individuals with the APOE ε3 allele [114].   
 
ApoE receptors are members of the low-density lipoprotein receptor (LDLR) family responsible 
for the endocytosis of ligands, which may be recycled to the cell surface [115]. ApoE receptors 
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have been reported to modulate Aβ formation and regulate APP trafficking [116]. ApoE is a ligand 
for the microglial receptor triggering receptor expressed on myeloid cells 2 (TREM2), and it has 
been suggested that ApoE could play a role in TREM2-mediated microglial phagocytosis [117, 
118]. Polymorphisms in the TREM2 gene also significantly affect risk for LOAD [119].  
 
1.5.2 Clusterin/apolipoprotein J (CLU/APOJ)   
CLU is another common apolipoprotein of the CNS that is associated with lipid trafficking and 
metabolism. The major SNP associated with the CLU gene affecting the risk of LOAD is 
rs9331896 [120].  However, unlike APOE, the prevalence of the rs9331896 SNP in CLU that 
promotes AD is lower, with the odds ratio (95% CI) at 1.16 (1.12-1.19) [106, 121]. Clu mediates 
soluble Aβ trafficking across the blood brain barrier (BBB) and modulates Aβ fibril formation and 
neurotoxicity [122]. This was demonstrated in transgenic mouse models of a germline knockout 
of clu (cluΔ), where Aβ deposition in clu∆ mice was significantly decreased compared to wild-
type mice [123, 124]. Like ApoE, CLU transports lipids to cells which are endocytosed through 
members of the LDL receptor family. This process of endocytosis induces neurite outgrowth, 
neuronal sprouting and synapse construction [106]. CLU is up-regulated in AD brains and is also 
localised to Aβ plaques, capillaries and arterioles. Furthermore, in AD, CLU levels rise with the 
increase of insoluble Aβ42 levels, particularly in brain regions that are prone to plaque deposition 
[122]. 
 
1.5.3 Adenosine triphosphate-binding cassette transporter 7 (ABCA7) 
ABCA7 is a membrane transporter that regulates lipid transmembrane trafficking and transfers 
lipids to lipoproteins such as ApoE and CLU [125]. It is primarily expressed in neural cells such 
Chapter 1 Literature Review 
 
16 
 
as: neurons, oligodendrocytes, endothelial cells and microglia [126]. It facilitates phagocytosis of 
apoptotic cell debris within the brain and microglial clearance of Aβ [124, 125]. The common 
SNPs in the ABCA7 gene associated with modest AD susceptibility are rs3764650 and rs3752246 
[126, 127]. These SNPs are also linked with ABCA7 gene expression, β-secretase activity in cells 
expressing APP containing the Swedish mutation and atrophy of the hippocampus and cortex [127, 
128]. Although how the rs3764650 and rs3752246 SNPs affect protein function is not specifically 
examined, genetic studies suggest that the association of ABCA7 gene variants with AD risk is 
related to reduction protein levels, or reduced function [129].  
 
1.6 Genes involved in endocytosis 
 
1.6.1 Bridging integrator 1 (BIN1) 
BIN1 has been identified as the second major susceptibility locus for LOAD in GWAS [130]. The 
SNPs linked to AD in BIN1 are rs7561528 and rs744373 the latter of which is associated with 
increased global tau levels and memory deficits [120, 131]. Whilst these SNPs have been 
associated with AD risk, how they affect BIN1 function is yet to be determined. However, it should 
be noted that increased BIN1 expression was identified in the post-mortem AD brains [137]. 
Furthermore, higher BIN1 mRNA expression has been found in the brain regions of BIN1 SNP 
carriers [136, 132]. BIN1 is highly expressed in oligodendrocytes and mediates endocytosis, 
endosome trafficking and apoptosis [120, 130, 133]. The BIN1 isoforms play a role in protein 
surface endocytosis through interaction with CLU [134, 135]. Moreover, it is possible that BIN1 
is involved in tau processing, through interaction with microtubule-associated protein CLIP-170 
[136]. Its association with tau was established by investigating the BIN1 ortholog in drosophila, 
Amphiphysin [137]. Amphiphysin knockdown ablated a rough eye phenotype and tau-induced 
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toxicity produced through overexpressed human tau [137]. Despite this, BIN1 expression in the 
brain and its involvement in AD associated risk remains to be elucidated due to the conflicting 
reports on the correlation between BIN1 expression and tau pathology. Holler et al. have reported 
an association between BIN1 levels and NFT pathology in the brains of individuals with LOAD, 
with a significant effect of BIN1 polymorphisms on immunoreactivity to neurons bearing NFTs 
[138, 139]. However, other studies have shown a negative effect between BIN1 expression and tau 
pathology in cultured human neurons with little to no co-localisation between BIN1 
immunostaining and NFT pathology [134, 137]. BIN1 has been reported to have an additional role 
in mediating Aβ secretion through intracellular BACE1 trafficking [140]. Miygawa et al. reported 
that BIN1-depleted cells produced increased Aβ40 and Aβ42 through the accumulation of cellular 
BACE1 [140].     
 
 
1.7 Genes involved in the immune/inflammatory response: 
 
1.7.1 Triggering receptor expressed on myeloid cells 2 (TREM2) 
TREM2 is a member of the immunoglobulin family and has been identified as another genetic risk 
locus for LOAD. It is expressed in microglia, macrophages and dendritic cells in the CNS [141]. 
It is a transmembrane receptor located in the plasma membrane [142]. TREM2 forms a complex 
with the signalling adaptor protein DNAX-activation protein 12 (DAP12) which is phosphorylated 
within the immunoreceptor tyrosine-based activation motif (ITAM) region, resulting in the 
recruitment of spleen tyrosine kinase (Syk) [143, 144]. SYK activation triggers a cascade of 
immune and inflammatory responses, involving activation of the phosphoinositide 3-kinase 
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(PI3K) and mitogen-activated protein kinase (MAPK) pathways [143, 145]. Further functional 
effects of TREM2 involve microglial mediated phagocytosis of Aβ plaques, dead neurons, and 
myelin debris [146-148]. TREM2 also plays a role in microglial survival and proliferation [149]. 
TREM2 also binds to lipidated ApoE and CLU [117, 144, 148]. The SNP that is most significantly 
associated with AD risk is rs75932628-T which affects phagocytosis of Aβ plaques by microglia. 
It also affects binding to lipoproteins and lipids [117, 150, 151]. Absence of TREM2 induces 
production of the key pro-inflammatory mediator tumour necrosis factor α (TNF-α) in 
macrophages [125, 152].  
 
 
1.8 Myelin and neurodegeneration  
 
1.8.1 Myelin 
In the CNS, myelin is formed by oligodendrocytes and in the PNS this multilamellar plasma 
membrane is formed by Schwann cells [153]. These glial cells wrap layers of glial plasma 
membrane around axons that compact to form the myelin sheath [154]. Myelin sheaths greatly 
increase the speed and efficiency with which action potentials travel along axons within the CNS 
and PNS [155]. This underpins normal nevous system function, behaviour and higher cognitive 
functions. In addition to forming myelin, oligodendrocytes also provide essential trophic support 
to neurons [156]. Both myelin and oligodendrocytes are highly enriched with cholesterol and the 
sphingolipids galactosylceramide (GalCer) and sulfatide, which not only act as structural 
constituents, but are also involved in molecular signalling [157, 158]. Loss of myelin integrity and 
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demyelination produce severe neurodegenerative diseases including multiple sclerosis and 
inherited leukodystrophies [159]. 
 
Recently, the role of myelin deterioration in neurodegenerative disorders such as AD has begun to 
emerge. AD was originally thought to be a disease primarily involving the brain’s grey matter, 
though of late, advances in neuroimaging have revealed abnormalities in the micro- and 
macrostructure of white matter in AD risk and disease advancement [160-162]. Brickman and team 
recently reported on elevated white matter hyperintensities (WMH), observed through magnetic 
resonance imaging (MRI) [163]. Elevated WMH volume was visualised in individuals with 
autosomal dominant, fully penetrant mutations for AD up to 20 years prior to the projected onset 
of symptoms, suggesting white matter irregularities as a central feature of AD pathogenesis [164, 
165]. 
 
Loss of myelin plasticity occurs naturally with age, with myelin content peaking at middle-age, 
which is followed by the subsequent loss and breakdown of myelin thereafter [166-168]. In the 
case of AD, the process of demyelination occurs at a more rapid rate in presymptomatic individuals 
compared to healthy older individuals [168, 169]. Perturbed myelin sheath is a result of 
oligodendrocytes that differentiate later in life, which produce thinner myelin ensheathment 
compared to early myelinating oligodendrocytes [170]. This makes for structurally unsound 
myelin sheaths that are likely more vulnerable to myelin breakdown, neuronal loss and insults such 
as Aβ [171]. 
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1.9 Lipid metabolism and neurodegeneration 
The very strong association of major brain lipid transport proteins with AD risk implicates altered 
lipid metabolism or transport in the pathogenesis of the disease. Dysregulated lipid metabolism in 
the brain is a feature that is commonly overlooked in AD research. However, recent studies have 
outlined the pathogenic link between abnormal lipid homeostasis and the neuropathological 
advancement of AD. For instance, cholesterol has been reported to be a key mediator of Aβ 
production and APP processing, and of tau hyperphosphorylation [172, 173]. 
 
1.9.1 Sphingolipids 
Sphingolipids are bioactive lipids that contribute to the maintenance of membrane structural 
integrity and function, including that of myelin sheaths [174]. Sphingolipids are concentrated, 
together with cholesterol, in lipid rafts within the plasma membrane [175]. These are membrane 
microdomains required for signal transduction. Sphingolipids are most commonly built upon an 
eighteen carbon amino-alcohol sphingosine backbone, which is synthesised de novo in the 
endoplasmic reticulum (ER). Sphingosine is also produced via the salvage pathway through 
catabolism of complex sphingolipids [176] (Figure1.3). Ceramides are the major precursor for 
more complex sphingolipids, as they can glycosylate, forming glycosphingolipids, or gain a polar 
choline phosphate head group to form sphingomyelin (SM) [177]. Alternatively, ceramide can be 
deacetylated to form sphingosine.  
 
There are two main classes of sphingolipids which differ depending on the type of polar head 
group. These are the phosphosphingolipids (PSLs), including SM, and glycosphingolipids (GSLs), 
which include glucosphingolipids, galactosphingolipids, globosides and gangliosides (Figure 1.3) 
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[178, 179]. SM species are the most abundant sphingolipids in mammals. Both SM and 
diacylglycerol (DAG) are synthesised via SM synthase, which mediates the transfer of the head 
group of phosphatidylcholine to ceramide (Figure 1.3) [180]. SMs are vital for eukaryotic cell 
survival, as cultured cells incapable of producing SM are non-viable [181]. Glucosylceramide 
(GluCer) is produced by the enzyme glucosylceramide synthase from ceramide and uridine 
diphosphate (UDP)-glucose (Figure 1.3). GluCer and its more complex glycosphingolipid 
derivatives play an essential role in embryonic development and tissue differentiation [182]. 
Alternatively, the enzyme ceramide galactosyltransferase (CGT) mediates the synthesis of 
galactosylceramide (GalCer), where the galactose residue from UDP-galactose is transferred to 
ceramide (Figure 1.3). GalCer is a prototypical myelin lipid and one of the markers of 
oligodendrocytes and myelin [183]. The enzyme that catalyses GalCer synthesis, CGT, plays an 
essential role in myelin stabilisation and neuronal signal conduction. Mice that are GalCer synthase 
deficient lack GalCer and sulfatide (ST) and suffer from tremors, hind limb paralysis and early 
death [184, 185]. Variations in sphingolipids are evident in ageing brains and in individuals with 
late onset neurodegenerative diseases [186-188]. This review will focus on ceramides and 
particularly their downstream metabolite derivative, sphingosine 1-phosphate (S1P), which is a 
key regulator of neuronal and glial biology, including cell survival.         
  
Chapter 1 Literature Review 
 
22 
 
 
Figure 1.3 Overview of the sphingolipid pathway [189]. 
De novo sphingolipid pathway starts with the formation of 3-ketodihydrosphingosine from serine and palmitoyl-CoA, 
a reaction that is catalysed by serine palmitoyltransferase. Next, 3-ketodihydrosphingosine reductase reduces 3-
ketodihydrosphingosine to dihydrosphingosine. The substrate, dihydrosphingosine, produces dihydroceramide 
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through ceramide synthases. Ceramide is formed from dihydroceramide, which is catalysed by dihydroceramide 
desaturase. Ceramide can feed into several different pathways. In the Golgi, ceramides are converted into 
Sphingomyelin (SM) by sphingomyelin synthase, into glycosphingolipids by glucosylceramide synthase (GCS), or 
into Galatosylceramide (GalCer) by UDP-galactose-ceramide galactosyltransferase (UGT8). Ceramides can also be 
phosphorylated to form ceramide 1-phosphate (C1P) by ceramide kinase at the plasma membrane or Golgi. In 
catabolic pathways, ceramides can be produced from SM, glucosylceramide, galactosylceramide or C1P through the 
actions of sphingomyelinases, glucosylceramidase, galactosylceramidase or ceramide phosphatase. Ceramides can 
also be a substrate for sphingosine formation through ceramidase. Phosphorylation of sphingosine by sphingosine 
kinase 1 and 2 (SK1/2) yields sphingosine 1-phosphate (S1P). S1P can be further catabolised by S1P lyase, forming 
phosphoethanolamine and hexadecanal. In the salvage pathway, free sphingosine can be re-acylated by ceramide 
synthases, which leads to the production of ceramides. 
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1.9.2 Ceramides 
As described above, ceramides are central to sphingolipid biosynthesis and breakdown. They are 
also bioactive lipids that regulate multiple cell signalling pathways, including inflammation, 
apoptosis, synaptic function and cell cycle arrest [190-194]. Ceramides are thought to be involved 
in the pathogenesis of AD and there is considerable evidence for a pro-apoptotic role of ceramides, 
potentially mediated through PAR4 and protein kinase Cζ [195-197]. Lipidomic analysis has 
identified elevated ceramide levels in the white matter of post-mortem brain samples from 
individuals at the earliest clinically recognisable stage of AD [198, 199]. This may be related to 
break-down of more complex myelin sphingolipids, although the authors did not present evidence 
for this. Elevated ceramide levels have also been shown in a number of other studies on post-
mortem AD brains [10, 199, 200]. Increased ceramide levels have also been linked to promoting 
oxidative stress, which leads to inflammation, axonal degradation, dysregulated synaptic 
transmission, and neuronal apoptosis [200-203]. This manifests in vulnerable brain regions such 
as the hippocampus and entorhinal cortex [198, 204].  
  
In recent studies, it has been suggested that ceramides could potentially act as early disease 
biomarkers in AD [205-207]. High basal serum ceramide levels have been linked to increased risk 
of AD, and are elevated in subjects with amnesic mild cognitive impairment [206-208]. 
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1.10 Sphingosine-1-phosphate (S1P) 
S1P is an essential signalling molecule that signals through a family of five G protein-coupled 
receptors (GPCRs), S1PR1-5 [209]. It has important roles in inflammation, cell migration, 
proliferation, angiogenesis, and protection against apoptosis [210-213]. S1P is abundant in plasma, 
where it is formed intracellularly by erythrocytes and vascular endothelial cells [214]. S1P is 
highly protein bound, and commonly binds to high density lipoproteins (HDL), in particular with 
apolipoprotein M (ApoM), which delivers S1P to S1PR1 receptors at the cell surface [215]. Mice 
lacking ApoM and S1PR1 exhibit endothelial barrier defects and leaky vasculature [215, 216]. 
 
The enzymes sphingosine kinase (SK) 1 and 2 phosphorylate sphingosine to form S1P [217]. 
Whilst no overt developmental defects have been reported in mice lacking either SK1 or SK2, 
mice lacking both SK1 and 2 exhibit impaired vascular development, neural tube defects, and 
embryonic lethality [218]. SK2 is the dominant isoform in the CNS, as SK2 activity and mRNA 
levels are highly expressed in the brain compared to SK1 [219-221]. SK1 is localised to the cytosol 
and activated following recruitment to the plasma membrane, whereas SK2 is active in the ER and 
nucleus and is constitutively membrane localised [222-224]. The biological roles of the SKs differ 
according to their site of localisation. For instance, SK2 localisation in the nucleus inhibits specific 
histone deacetylases (HDAC), so affecting transcriptional responses [225-227]. Alternatively, SK2 
localises to the endoplasmic reticulum where it generates S1P which is recycled through the 
‘salvage pathway’ to generate pro-apoptotic ceramide [228].  
 
S1P can be degraded by two differing pathways: the first involves irreversible degradation to 
hexadecenal and phosphoethanolamine by the enzyme pyridoxal phosphate-dependent S1P lyase 
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(SGPL1), and the second pathway involves the reversible dephosphorylation of S1P to 
sphingosine, a process mediated by S1P phosphatases [229, 230].  
 
S1P enhances glutamate and acetylcholine secretion in mouse neurons and the worm c.elegans 
[231-234]. Glutamate neurotransmission is required for hippocampal dependant spatial memory, 
and accordingly mice lacking SK1 were reported to exhibit spatial memory deficits [232]. 
Mechanistically, interaction between S1P and pre-synaptic protein Synapsin I has been identified 
to mediate synaptic vesicle availability for exocytosis [234].  
 
S1P has also been reported to promote oligodendroglial differentiation in cultured 
oligodendrocytes [235-237]. Furthermore, SK2 which localises to the nucleus synthesises nuclear 
S1P in the brain which inhibits histone deacetylases, leading to increased histone acetylation [225]. 
Acetylated histones regulate transcription of genes that maintain hippocampal plasticity and also 
protects against ischemic brain injury in models of stroke [219, 238, 239]. In this regard, SK2 was 
shown to protect against neuronal cell death in ischaemic brain damage [240]. 
 
1.10.1 S1P and AD 
Recently our group has identified a loss of S1P levels in brain regions that are prone to 
neurodegeneration at the pre-clinical AD Braak stage III/IV, and a decrease in SK1 and SK2 
activity with disease progression [221]. The decline of S1P was evident in the hippocampus and 
temporal cortex, which is speculated to increase vulnerability in these regions to neuronal death 
[10, 221]. This verified and extended prior results showing loss of S1P in AD frontal cortex tissue 
[10]. We also identified an inverse correlation between S1P levels and age in the hippocampus of 
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cognitively normal females, supporting the potential neuroprotective effect of S1P in the context 
of neurodegeneration [241]. Dominguez and colleagues reported altered subcellular localisation 
of SK2 in AD brains, which was proposed to result in the production of nuclear S1P at the expense 
of pro-survival cytosolic S1P [242]. Ceccom and team reported decreased SK1 and increased S1P 
lyase in entorhinal cortex of AD brains [243]. This was speculated to decrease S1P levels, thereby 
promoting neurodegeneration [243]. 
 
Arguing against a neuroprotective role in AD, S1P was reported to act as an important co-factor 
for BACE1 activation in cultured neurons, and was therefore required to form Aβ [244]. 
Furthermore, deficiencies in the S1P-degrading enzyme S1P lyase, leading to unnatural S1P 
accumulation, have been reported to induce tau hyperphosphorylation [245]. Interestingly, S1P 
lyase deficiency has also been reported to increase levels of S1P in neuronal cultures, leading to 
accelerated Aβ formation through impaired lysosomal APP metabolism [246].  
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1.11 S1P receptor agonists  
The identification of S1P as a lipid mediator led to great interest in the S1P GPCR family. GPCRs 
are activated via ligand binding with hormones, neurotransmitters, lipids, and other molecules, 
leading to a conformational change in the GPCR [247]. Activated GPCRs mediate the activation 
of small GTPases including Rho, Rac and Ras, which then activate downstream effector molecules 
such as adenylate cyclase, phospholipase C and D, phosphatidylinositol 3-kinase (PI3K) and ion 
channels [248, 249]. S1PR1, S1PR2, and S1PR3 are constitutively expressed in most cell types, 
whereas S1PR4 is specific to immune cells and S1PR5 to oligodendrocytes and natural killer T-
cells [250]. S1PR1 couples exclusively to Gi, mediating inhibition of cyclic AMP formation and 
activation of Akt, which promotes cell proliferation and chemotaxis [251, 252]. S1PR2 couples to 
G12/13, which activates RhoA and inhibits Rac and Akt leading to inhibition of cell proliferation 
[253, 254]. S1PR3 couples to G12/13, Gq and Gi, generally promoting activation of the Ras/ERK, 
PI3K and Rac signalling pathways [255]. This regulates the chemotactic and pro-survival effects 
of S1P [256, 257]. S1PR4 couples to Gα12/13, engaging the RhoA/ROCK pathway which regulates 
vesicle trafficking [258]. S1PR5 couples to Gi and G12/13 which activates the Rho/ROCK pathway 
to impede oligodendrocyte precursor cells (OPC) migration [236]. S1PR1 is important for 
astrocyte inflammatory responses in the CNS, and it is believed that functional antagonism of the 
S1PR1 receptor inhibits neuroinflammation [259]. S1PR5 is believed to be an important mediator 
of oligodendrocyte survival [235]. The tissue specific and distinct signalling mechanisms of these 
GPCRs make them ideal targets for the development of agonists and antagonists selective to one 
receptor [260].      
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1.11.1 Fingolimod 
The sphingosine analogue Fingolimod (FTY720) is an FDA approved, orally-administered drug 
used for the treatment of multiple sclerosis. FTY720 is phosphorylated in vivo by SK2 to form the 
active drug FTY720-phosphate, which is an agonist at four of the five S1P receptors (S1PR1 and 
S1PR3-5). The key effect of FTY720 is immunosuppression. As it is a highly potent agonist of 
S1PR1 receptors on lymphocytes, it causes S1PR1 down-regulation and degradation, and thereby 
induces lymphopenia. This prevents CD4+ naïve and central memory T cells from entering the 
CNS [261-264]. Furthermore, S1P1 angonism diminishes astrocyte-mediated inflammation, which 
is a key pathological effector in MS and AD, allowing for restoration of astrocyte interaction with 
neuronal cells and maintenance of BBB integrity [259, 265]. In animal models these effects of 
FTY720 leads to remyelination, recovery of nerve conduction, and prevention of brain atrophy 
[266-268]. Recent studies have identified a neuroprotective effect of FTY720 in rats given 
intracranial injections of Aβ to induce an AD phenotype [269, 270]. FTY720 administration 
prevented spatial learning and memory deficits and reduced both neuron loss and inflammatory 
markers [269, 270]. FTY720 also attenuates Aβ production in neurons [271]. Furthermore, 
administration of FTY720 was reported to increase levels of reduced BDNF in a mouse model of 
Rett syndrome as well as increasing the BDNF content and volume in the striatum [272]. It is 
therefore possible that restoring impaired S1P signalling could be potential therapeutic targets for 
the treatment of AD. Potential side effects of FTY720 use in the context of neurodegenerative 
diseases include S1PR1-mediated immune suppression leading to susceptibility to serious 
infections, and transient bradycardia [261, 273]. It would therefore be beneficial to identify 
receptor subtype selective drugs that may eliminate these off-target effects.        
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1.12 Second generation S1P receptor agonists 
 
1.12.1 Siponimod (BAF312/A) 
Following the approval of FTY720 as the first S1P agonist for the treatment of MS, several second 
generation S1PR agonists and antagonists have been developed to enhance drug efficacy and 
safety. Siponimod is a next generation S1P agonist that is selective for S1PR1 and SIPR5 [261]. 
Siponimod is the first orally administered drug that has recently been approved for the treatment 
of secondary progressive MS [274]. Siponimod induces lymphopenia, as is the case with FTY720, 
by sequestering lymphocyte egress from lymph nodes and appears to have immunomodulatory 
effects [263, 264]. Unlike FTY720, siponimod has a shorter half-life which enables peripheral 
lymphocyte counts to return to baseline levels within one week after termination of treatment 
[275]. The adverse effects of bradycardia can also be alleviated through a dose titration scheme 
when the treatment is initiated [276]. Siponimod has been reported to prevent synaptic 
neurodegeneration in a murine model of MS by rescuing defective gamma-aminobutyric acid 
(GABA)ergic transmission, attenuating astrogliosis, microgliosis and inhibiting lymphocyte 
infiltration of the striatum in these animals [277]. The rescue of reduced GABAergic inhibitory 
transmission is thought to prevent excitotoxic synaptic transmission which leads to 
neurodegeneration [278].  
 
1.12.2 A-971432 S1PR5 agonist  
The drug A-971432 is selective of S1PR5 which is predominantly expressed in oligodendrocytes 
[235]. It is also expressed in endothelial cells and where it regulates tight junctions of the BBB in 
the CNS, which is essential for BBB permeability [279]. Its expression in oligodendrocytes 
suggests a potential role of A-971432 in S1PR5-mediated myelination [235]. Recent studies have 
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linked A-971432 with rescuing age-related cognitive decline and lipid accumulation in the CNS 
of murine models [280]. As well as this, chronic administration of A-971432 to a mouse model of 
Huntington’s disease (HD) delayed the progression of the disease, thereby increasing their 
lifespans by activating neuroprotective pathways such as BDNF, ERK and AKT [281]. When 
administered early in the disease process A-971432 lessened the advancement of motor deficits in 
symptomatic HD model mice and acted in maintaining BBB integrity, yet the mechanism by which 
A-971432 exercises its beneficial effects in HD is yet to be fully elucidated [281].  
 
1.12.3 Ponesimod (ACT-128800) 
Ponesimod is a S1PR1 agonist that is also selective for S1PR5 and S1P3R. Similar to FTY720 
Ponesimod decreases blood lymphocyte counts in a dose dependent manner [282]. It is currently 
being investigated for the treatment of MS and the efficacy of treatment is comparable with that 
of FTY720, however, unlike FTY720 there is a clearly defined dose-dependent response observed 
in ponesimod treatment [283-285]. Treatment of ponesimod on experimental autoimmune 
enchephalomitis (EAE) mice, a commonly used murine model of MS, showed that treatment was 
able to prevent the onset and progression of disease in these animals and increased their general 
lifespan [285]. Histological reports indicated reduced axonal degradation, demyelination of brain 
regions and inflammation [285].  Ponesimod is also being trialled as a treatment for psoriasis, a T-
cell mediated inflammatory skin disease. Its anti-inflammatory activity prevents lymphocyte 
egress from the secondary lymphoid organs and limits the recruitment of pathogenic T cells into 
the skin [285]. Ponesimod is currently undergoing phase III clinical trials for the treatment of MS.  
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1.12.4 Ozanimod (RPC1063) 
The second generation S1PR agonist ozanimod is an oral S1PR1 and S1PR5 modulator under 
development by Celgene. Unlike fingolimod, siponimod, ponesimod, and ozanimod do not require 
phosphorylation to be activated, and due to their improved S1PR specificity, adverse side effects 
such as cardiovascular abnormalities which are linked to S1PR3 agonism are not observed [286]. 
Ozanimod is currently in phase II trials for relapsing MS, it is also entering phase III trials for the 
treatment of ulcerative colitis and Crohn’s disease [287, 288]. Improved drug efficacy in these 
next-generation compounds may reduce undesired side effects
Rationale 
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1.13 Rationale for the studies described in this thesis 
 
Large scale clinical trials investigating antibodies against ç or Bace1 inhibitors for the treatment 
of AD have thus far been unsuccessful. These failures suggest that an amyloid-centric hypothesis 
for AD is over-simplistic. It is also clear that amyloid alone is not sufficient to cause AD, as people 
may present with high amyloid burden but not AD, other diseases are associated with A and NFT 
pathologies, and animal models involving A overproduction do not recapitulate the human 
condition well. An important consideration is the possibility that loss of neuroprotective factors 
sensitizes the brain to A pathology. Our group has previously demonstrated pronounced loss of 
S1P and SK2 activity with advancing Braak stage pathology in pre-clinical and clinical AD cases 
[221]. Since S1P receptor agonists are used in the therapy of multiple sclerosis and increasingly 
believed to mediate direct neuroprotective effects, this led us to investigate the effects of SK2 
deficiency on normal memory function and behavioural traits, and sensitization to Aβ pathology.  
Aims 
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1.14 Aims 
This thesis comprises of five chapters. Chapter 2 (publication) reports on the role of SK2 in basic 
behavioural parameters and memory in mice, while chapter 3 (publication) investigated the role 
of SK2 in modulating Aβ deposition, neuropathology, and memory in a mouse model of AD 
amyloidosis. Building on the results of Chapter 3, Chapter 4 investigated the role for SK2 in 
myelination, particularly maintenance of myelin with ageing, and the effect of S1P agonist 
treatment on myelin and fear responses in female mice lacking SK2. Finally, chapter 5 outlines 
the general conclusions and final remarks for these studies.       
 
The Aims of this these were: 
1) Determine whether loss of SK2 affects normal cognitive functions and behaviour in mice.  
2) Determine whether loss of SK2 sensitises to cognitive decline and neuronal atrophy caused 
by overproduction of Aβ peptides in a mouse model of AD. 
3) [Building on findings of the previous chapters] Determine whether agonists of S1P 
receptors 1 and 5 restore myelination in mice lacking SK2. 
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Chapter 4 Do S1P receptor agonists reverse hypomyelination in 
SK2 knockout mice? 
 
4.1 Introduction 
In chapter 3 we found that SK2-deficient J20 mice exhibited a severe hypomyelination in the 
hippocampus and cortex [289]. A reduction in levels of myelin proteins and prototypical myelin 
lipids in both cortex and hippocampus was also observed in 8-month and 13-month old male mice 
lacking SK2Δ. The difference in levels of myelin protein markers between WT and SK2Δ mice 
was statistically significant in unadjusted Fisher’s post-tests, but not with the more stringent 
Sidak’s test corrected for multiple comparisons, as used in Lei et al, 2019. 
 
S1P signals through five G-protein coupled receptors, one of which is the oligodendrocyte-specific 
receptor S1PR5 [235]. S1PR5 mRNA is highly expressed in white matter tracts, suggesting its 
presence in mature oligodendrocytes where it plays a role in myelination [290]. This is supported 
by publicly-available RNA sequencing data for different CNS cell types [291]. Jaillard and 
colleagues reported that S1P activation promotes survival of mature oligodendrocytes through 
phosphorylation of the pro-survival kinase Akt [235]. S1P signalling in the CNS could provide a 
potential therapeutic target for protecting oligodendrocytes and/or restoring myelination in 
demyelinating diseases such as AD and multiple sclerosis.  
 
In this chapter I firstly present western blotting, lipidomic, and electron microscopy data 
demonstrating that there is a significant myelin deficit in 12 month old male SK2Δ mice. I then 
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determined whether a similar phenotype is observed in 10 month old female mice, and investigated 
the effect of second generation S1P agonists Siponimod and A-971432 on myelin content. 
Siponimod is an S1PR1 and S1PR5 agonist that has recently been approved for the treatment of 
secondary progressive MS and has been shown to attenuate demyelination in organotypic slice 
cultures [274, 292]. A-971432 is a selective S1PR5 agonist that has been reported to restore the 
integrity of the BBB and improve cognitive deficits in aged mice [280, 293]. We hypothesized that 
S1PR1 and/or S1PR5 activation would restore full myelination and alleviate the baseline anxiety 
phenotype (chapter 2) in SK2Δ mice. 
 
 
 
4.1.1 Specific Aims of this chapter: 
1) Determine if there are significant myelin deficits in 12 month old male SK2Δ mice using 
lipidomic analysis and electron microscopy 
2) Determine if female SK2Δ mice also exhibit loss of myelin content and a baseline anxiety 
phenotype in the fear conditioning paradigm 
3) Determine if S1PR1 and/or S1PR5 agonists restore myelin content and prevent the anxiety 
phenotype in female SK2Δ mice. 
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4.2 Materials and Methods  
4.2.1 Animals  
SK2 knockout (SK2Δ) mice have been described previously [218]. The founder mice on a mixed 
C57BL6/129S6 background were bred for more than 10 generations onto a C57BL/6JArc 
background. Female SK2 knockout mice (SK2Δ: n = 29) and wild type-like control littermates 
(WT: n = 30) were bred from heterozygous SK2+/− parents and group-housed in independently 
ventilated cages (Airlaw, Smithfield, Australia) at Animal BioResources (Moss Vale, Australia). 
Genotyping was performed as described [218]. Adult mice were transported to the Bosch Institute 
Animal Behavioural Facility for testing. Mice were kept under a 12/12 h light/dark schedule [light 
phase: white light (illumination: 124 lx) – dark phase: red light (illumination: <2 lx)]. Food and 
water were provided ad libitum, except where specified. Crinkle nest and tissues were provided 
for enrichment. Research and animal care procedures were approved by the University Sydney 
Animal Care and Ethics Committee [2017/1284] in accordance with the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes. 
 
4.2.2 Drug treatment  
Female WT and SK2Δ mice were dosed with A-971432 (Tocris, Cat No. 5766, Batch No. 1), 
Siponimod (Selleckchem, Cat No. S7179, Lot. 02) at 0.5 mg/kg in drinking water, and vehicle 
control (0.2% hypromellose in drinking water), daily via oral gavage (n = 10 per genotype and 
drug treatment). Drug treatment was administered over the course of 6 weeks, commencing when 
animals were approximately 8 months of age. Blood samples were taken from the vehicle control 
(n = 8), Siponimod (n = 6) and A-971432 (n = 6) treated WT mice at the final week of treatment 
for flow cytometric analysis to quantify lymphocytes. It was not necessary to collect blood from 
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the entire cohort and the number of samples obtained per genotype were sufficient for statistical 
analysis. Animals were weighed daily and monitored for excessive weight loss. Mice were 10 
months of age at cull. 
 
4.2.3 Flow cytometry  
Blood samples for flow cytometry were subjected to red blood cell lysis using 1 mL of ACK lysis 
buffer (145 mM ammonium chloride, 0.1 mM EDTA disodium, 12 mM sodium bicarbonate in 
MilliQ water, pH 7.35) to 250 µL of blood over ice, then centrifuged at 2000 rpm for 5 min at 
room temperature. Samples were washed in 1 mL fluorescence activated cell sorting (FACS) 
buffer (1x PBS, 2.5 % (v/v) FBS, 2 mM EDTA, 2 mM NaN3), then centrifuged at 2000 rpm for 5 
min at room temperature. Supernatant was resuspended in 100 µL FACS buffer and transferred 
into a U-bottom plate. Microfuge tubes were washed with an additional 100 µL of FACS buffer 
and transferred over to the plate. The plate was centrifuged at 1600 rpm for 5 min at 4 ºC and 
supernatant was decanted. 95 µL of antibody cocktail (Table 3.2.3) was added to the wells and 
incubated at 4 ºC for 1 h. 100 µL of FACS buffer was added to each well and centrifuged at 1650 
rpm for 5 min at 4 ºC. Samples underwent 2 x wash steps of 200 µL of FACS buffer, centrifuged 
at 1650 rpm for 5 min at 4 ºC, then resuspended in 50 µL of FACS buffer containing 20 µL of 
beads and 0.5 µg/mL diamidino-2-phenylindole dihydrochloride (DAPI). Cells were filtered 
through a 50 µm filter and acquired on the five-laser LSR-Fortessa (BD Biosciences) at the 
Centenary Institute. FlowJo version 9.8.3 software (TreeStar, Ashland, Ore) was used to analyse 
output.   
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Antibody Origin Clone Company Catalogue # Lot # Dilution 
CD016/32 (24G2) Purified Rat Anti-mouse FcBlock IgG2b, κ 2.4G2 BD Pharmingen 553142 6266549 1:200 
CD45 (BR2) BUV395 Rat (LOU) Anti-mouse IgG2b, κ 30-F11 BD Horizon 564279 7012754 1:200 
CD003e BV421 Hamster Anti-mouse IgG1k 145-2C11 BD Horizon 562600 6273588 1:200 
CD011b FITC Rat Anti-mouse IgG2b, κ M1/70 BD Pharmingen 553310 5274805 1:200 
NK1.1 PE Mouse Anti-mouse IgG2a, κ PK136 BD Pharmingen 557391 4052536 1:200 
B220 (CD45R/B220) PerCP Rat Anti-mouse IgG2a, κ RA3-6B2 BD Pharmingen 553093 5275504 1:100 
CD008a APC Rat Anti-mouse IgG2a, κ 53-6.7 BD Pharmingen 553035 4050967 1:200 
CD027 APC-efluor780 Hamster (Armenian) Anti-mouse (human, rat) IgG LG.7F9 eBioscience 47-0271-82 E14703-108 1:200 
  
Table 3.2.3 Antibody list for flow cytometry         
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4.2.4 Behavioural phenotyping 
Female mice were tested at 10 months of age. All tests were conducted during the first 5 h of the 
light phase to minimise the effects of circadian rhythm on the performance of test mice. 
Behavioural tests included novel object recognition test (NORT) and fear conditioning and 
extinction (FCE). The inter-trial interval (ITI) was 48 h, and testing was performed blinded to 
genotype during testing and data analysis. Equipment and apparatus were cleaned between trials 
using 70% ethanol. 
 
4.2.5 Novel object recognition test 
The NORT evaluates the rodent’s innate preference of investigating a novel over a familiar object. 
NORT does not rely on positive or negative reinforcers and naturally assesses an index of 
recognition memory [294, 295]. The task consists of 3 phases which include: habituation, 
familiarisation (training) and test trials. The NORT apparatus consist of grey Perspex (35 x 35 x 
30 cm). Animals are habituated to the chamber for 10 min, 24 h prior to training and test trials. 
During habituation the animals are placed into the NORT chamber with two identical objects in 
opposite corners of the chamber, positioned 5 cm away from the side walls. On training day the 
test animal is placed into the centre of the same chamber with a new set of identical objects and 
allowed to explore freely for 10 min. There is a 30 min inter-trial interval between the training 
phase and test phase. The test phase of NORT replaces one of the identical objects (familiar) within 
the chamber with a novel object. The animal is again placed in the centre of the chamber and 
explores the environment for 10 min. AnyMazeTM is used to track the animal’s movements and 
score object exploration behaviours: nosing (when the position of the nose is at a distance of ≤ 1 
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cm from an object), rearing and climbing on object. The objects used were LEGO Duplo farm 
animals which were cleaned thoroughly between tests.   
 
4.2.6 Fear conditioning and extinction 
Fear conditioning is a form of associative learning whereby a previously neutral stimulus elicits a 
fear response after it has been paired with an adverse stimulus [296]. The fear conditioning and 
extinction paradigm consisted of 6 days of testing with 24 h inter-test interval. On day 1 
(conditioning day) the test animals were placed in the test chamber with a vanilla scent cue 
(MedLab - equipment details) for 120 s. A 80 dB conditioned stimulus (CS) was then presented 
for 30 s with a co-terminating 0.4 mA 2 s foot shock (unconditioned stimulus; US) twice with an 
inter-pairing interval of 120 s. The test concluded 120 s later with total test time being 420 s. Day 
2 (context test) consisted of placing the test mice back into the conditioning cages with the scent 
cue but no other stimulus for 420 s. On the third day (cue test) animals were placed into the 
conditioning cages with an altered context (black Perspex, reshaping the context space) and did 
not include the scent cue. The test duration was 720 s, with the first 120 s and last 120 s having no 
auditory stimulus. Auditory stimulus was presented after 120 s and was played continuously for 5 
min. The exact same procedure used in the context test was repeated on extinction days 1-3. Time 
spent freezing and distance travelled were measured using AnyMazeTM software. 
 
4.2.7 Western blotting  
Tissue samples (approx. 20 mg) were homogenized in 0.2 mL radioimmunoprecipitation assay 
(RIPA) buffer [10 mM Tris HCl, pH 7.4, 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid 
(EDTA), 1 mM NaF, 20 mM Na4P2O7, 0.01% SDS, 0.05% sodium deoxycholate, 1% Triton-X, 
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10% glycerol, complete protease inhibitor cocktail (Roche)] using a Biospec mini bead beater with 
acid-washed glass beads (425-600 m). The supernatant was transferred to a new tube and the 
beads washed with another 0.2 mL buffer, which was then combined with the first extract. Extracts 
were centrifuged at 1,000 × g for 10 min to clear debris, and the supernatant was transferred to 
new tubes. Protein concentration was determined with the Bicinchoninic acid (BCA) assay 
(ThermoFisher Scientific). Protein lysates (15 μg) were resolved on 4-12% NU-PAGE gels 
(ThermoFisher Scientific), transferred to polyvinylidene difluoride (PVDF) membrane, and 
immunoblotted with rabbit anti-MBP (Abcam, cat #ab40390, 1:1000 dilution), mouse anti-PLP 
(clone aa3, 1:200 dilution; a kind gift from Prof Eva-Maria Albers, University of Mainz), rabbit 
anti-MOG (Abcam, cat #ab32760, 1:1000 dilution), and chicken anti-neurofilament H (Abcam, 
cat #ab4680, 1:106 dilution). Signal was developed using Immobilon western chemiluminescent 
HRP substrate (Merck). Membranes were stripped using stripping buffer (15g/L glycine, 0.1% 
SDS, 1% Tween 20, pH 2.2), and re-probed with rabbit anti-β-actin (Abcam, cat #ab8227, 1:5000 
dilution) as a loading control. Densitometry was performed using BioRad ImageLab software. 
 
4.2.8 Lipidomic Analysis by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) 
Lipids were extracted from ~20 mg mouse brain tissue using a two-phase methyl-tert-butyl ether 
(MTBE):methanol:water (10:3:2.5 v/v/v) extraction solvent procedure [297]. Internal standards (2 
nmole each of d18:1/17:0 ceramide, d18:1/12:0 SM, d18:1/12:0 GalCer, and d18:1/12:0 ST; and 
250 pmole of d17:1 sphingosine and d17:1 S1P) were added at the start of the extraction procedure. 
Lipids were detected in positive ion mode, using multiple reaction monitoring on a TSQ Altis mass 
spectrometer equipped with Vantage high performance liquid chromatography (HPLC) 
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(ThermoFisher Scientific). Lipid peaks were identified using both precursor ion mass and 
diagnostic product ions (m/z 264.3 for all sphingosine-based lipids including S1P; m/z 250.2 for 
17:1 sphingosine and S1P internal standards; both m/z 184.1 and m/z 264.3 for SM). All lipids 
were resolved using a previously-described binary gradient [298] with some modifications. A 2.1 
 100 mm C8 column was used (1.8 M particle size, Agilent), with flow rate 0.3 mL/min. Mobile 
phase A was 0.2% formic acid, 2 mM ammonium formate in water; and B was 1% formic acid, 2 
mM ammonium formate in methanol. Total run time was 24 min, starting at 80% B and holding 
for 2 min, increasing to 100% B from 2 - 14 min, holding at 100% until 20.5 min, then returning 
to 80% B at 21 min, and holding at 80% B for a further 3 min. LC peaks were integrated using 
TraceFinder 4.1 software (ThermoFisher), and expressed as ratios to the class-specific internal 
standard. Absolute values were determined from external standard curves for each lipid class.  
 
4.2.9 Scanning electron microscopy (SEM) 
For transmission electron microscopy, mice were perfused trans-cardially using 2.5% 
glutaraldehyde, 1% paraformaldehyde in 0.15 M phosphate buffered saline (PBS). Brains were 
removed and post-fixed overnight with the same fixative. Tissue was transferred to 30% sucrose 
cyroprotectant and stored at 4 oC. Brains were cut into 1 mm thick coronal sections to locate the 
regions of interest (superior frontal cortex and hippocampus CA1, at the level of the corpus 
callosum).  Blocks were cut from these regions (1 mm x 2 mm) and were immersion fixed for 1 h 
in 2.5% glutaraldehyde 2% paraformaldehyde in 0.1 M phosphate buffer, followed by washing in 
0.1 M phosphate buffer. The tissue then underwent secondary fixation in 1% Osmium tetroxide in 
0.1 M phosphate buffer, followed by dehydration through graded alcohols, and resin infiltration. 
Following polymerization for 48 h at 60 °C, the tissue was then sectioned on an ultramicrotome 
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(Ultracut 7, Leica). Sections were cut at 90 nm thickness and mounted on copper grids and post-
stained at room temperature in 2% Uranyl acetate and Reynold’s lead citrate. Images were captured 
using a backscatter detector on a scanning electron microscope (Ziess Sigma HD FEG SEM). 
Measurements of axon lumen diameter and the outer diameter of the fibre (axon lumen plus myelin 
sheath) were then taken from >50 fibres per sample using ImageJ (US National Institutes of 
Health), with the operator blinded to the sample groups. Measurements were taken perpendicular 
to the longest axis of fibres in cross section, to compensate for those fibres cross-sectioned in an 
oblique plane. G-ratios were then calculated by dividing the axon lumen diameter by the outer 
diameter of the fibre. 
 
4.2.10 Statistical analysis 
All statistical analysis was performed using GraphPad PRISM.  
Unpaired, two-tailed t-tests were used to compare g-ratio, western blotting and lipidomic data 
between SK2Δ mice and their WT littermates (Figures 3.1, 3.2, 3.3B, 3.4B).  
One-way ANOVA analysis was used to compare drug treatment groups within percentage of live 
or dead CD45 positive cells of the flow cytometry data. This was also used to measure the effect 
of drug treatment groups on CD3 positive T cells or NK cells. Dunnett’s post-test was applied to 
perform comparisons between control and other other groups. 
Analysis of the fear conditioning and extinction parameters was performed using two-way 
ANOVA to investigate main effects of genotype and drug treatments. Turkey’s post-test was 
applied to perform comparisons between ‘drug’ within ‘genotype’ when a significant result (p < 
0.05) was detected with two-way ANOVA.  
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For statistical significance in NORT the performance of subjects in each genotype group and drug 
treatment was compared to that expected by chance (50%) using one sample t-tests. This method 
most effectively tests each genotype for a specific preference for the novel object.  
Western blot data, two-way analysis of variance (ANOVA) was applied to investigate main effects 
of genotype (WT or SK2Δ) and drug treatment (vehicle control, Siponimod, A-971432) or 
unpaired t-tests comparing genotype (WT or SK2Δ) where drug was not a factor (Figure 4.10 B,C).  
For lipidomic data, ANOVA p-values for individual lipids were adjusted for multiple comparisons 
using the false discovery rate approach of Benjamini, Krieger, and Yekutieli (threshold Q = 5%) 
[299]. When a significant result (p < 0.05) was detected with two-way ANOVA, Sidak’s post-test 
was applied to perform five comparisons: WT vehicle control-SK2 vehicle control, WT vehicle 
control-WT Siponimod, WT vehicle control-WT A-971432, SK2 vehicle control-SK2 
Siponimod and SK2 vehicle control-SK2Δ A-971432 [300]. 
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4.3 Results 
 
4.3.1 Prototypical myelin lipids are depleted in 12-month old male mice lacking SK2.  
We followed up the finding of reduced S1P and increased sphingosine levels in the 12-month old 
male SK2Δ mice (chapter 2) by examining possible changes in other sphingolipids (Figure 3.1). 
Statistically significant reductions in the major myelin constituents galactosylceramide (GalCer) 
(48% reduction, p = 0.028), and sulfatide (ST) (58%, p = 0.002) were observed in the hippocampus 
of SK2Δ mice. The lipid Sphingomyelin (SM) is also enriched in myelin, although unlike the 
oligodendrocyte-specific lipids GalCer and ST, SM is present in all cells. SM levels were reduced 
by 29.3% in SK2Δ mice, however this was not significant (p = 0.08). These myelin lipids are 
synthesised from the lipid ceramide, whose levels did not differ significantly between the two 
genotypes.  
 
Given the reduction in myelin lipids, expression of myelin basic protein (MBP), a major myelin 
protein, was examined in hippocampal protein lysates. The western blot revealed a significant 
decrease in the expression of MBP in SK2Δ mice by 47.7% compared to WT mice (p = 0.0003; 
Figure 4.2). Loss of prototypical myelin lipids and reduced expression of MBP in this preliminary 
study led us to further investigate other changes of myelin integrity in mice lacking SK2.   
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Figure 4.1 Decreased levels of myelin lipids in the hippocampus of 12-month old male SK2Δ mice. 
Total ceramide, galactosylceramide, sphingomyelin and sulfatide levels, expressed as pmole per mg of tissue. 
Statistical significance was determined by unpaired two-tailed t tests. Graphs are presented as mean ± SEM, n = 6 
mice per group. This data was generated by Dr Tim Couttas. 
 
 
Figure 4.2 MBP expression is reduced in the hippocampus of SK2Δ male mice 
Western blot and densitometric analysis of MBP in 12-month old male WT and SK2Δ hippocampus. Protein levels 
were normalised to -actin, then the mean of the control group. Statistical significance was determined by unpaired 
two-tailed t tests. Graphs show mean ± SEM, n = 6 mice per genotype.   
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4.3.2 Myelin thickness is reduced in SK2Δ mice.  
Following the hypomyelination results observed in 12-month old SK2Δ male mice, and those seen 
in chapter 3, SEM was used to examine myelin integrity in 12-month old male WT and SK2Δ 
mice. G-ratio analysis (diameter of the axon lumen/diameter of the myelinated axon) was used to 
measure myelin thickness in axons in the frontal cortex and hippocampal stratum radiatum. G-
ratios were increased from 0.72 ± 0.0068 (n = 141 fibres) in the cortex of WT mice to 0.77 ± 0.055 
(n = 151 fibres) in SK2Δ mice (p <0.0001, Figure 4.3), indicative of reduced thickness. In the 
hippocampus, g-ratios were also increased, from 0.72 ± 0.0055 (n = 161 fibres) in WT mice, to 
0.78 ± 0.060 (n =233 fibres) in SK2Δ mice (p <0.0001, Figure 4.3). SEM showed perturbed myelin 
structure in the hippocampus of SK2Δ mice, revealing mis-folded myelin sheaths and in-folded 
redundant loops (Figure 4.3A).  
 
Having identified myelin abnormalities in these 12 month old mice, we next examined myelin 
ultrastructure in groups of 3 male WT and SK2Δ mice at both 2 and 15 months of age, aiming to 
determine if myelin ultrastructure was also abnormal from the end of the developmental 
myelination period. Significantly increased g-ratios were observed in the 15-month old SK2Δ 
group compared to all other groups in the hippocampus and cortex (Figure 4.4A). The g-ratios in 
the corpus callosum were elevated significantly in the 15-month old SK2Δ compared to 2-month 
old WT and SK2 groups (Figure 4.4A). These data indicate an age-dependent loss of myelin 
thickness in mice lacking SK2. Structural abnormalities consisting of axonal infolding and 
outfolding were also observed in the hippocampus, cortex, and corpus callosum of both 15-month 
and 2-month old male SK2Δ mice (Figure 4.4B).  
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Figure 4.3 Myelin sheath integrity is compromised in 12-month old male SK2Δ mice.  
(A) SEM of myelin axonal lumen in hippocampal stratum radiatum and frontal cortex between genotypes, and (B) g-
ratios of myelin fibres in hippocampus and cortex. Statistics were determined by unpaired two-tailed t tests comparing 
WT against SK2Δ mice. n = 2 mice per genotype. This data was generated by Dr Thomas Duncan (blinded to 
genotype). 
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Figure 4.4 Age-related myelin deficits observed in SK2Δ male mice. 
 (A) Mean g-ratio and axon diameter in hippocampus, frontal cortex and corpus callosum of 2-month old and 15-
month old WT and SK2Δ mice (3 mice per group). Data were derived from measurements on a minimum of 30 axons 
per region per mouse. (B) SEM images of hippocampus, cortex and corpus callosum showing myelin defects in 2-
month old and 15-month old SK2Δ mice. Statistics were determined by one-way ANOVA comparing the four groups, 
with Tukey’s post-test comparing group means. n = 3 mice per group. This data was generated by Dr Thomas Duncan 
(blinded to age and genotype).
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4.3.3 Investigating hypomyelination in SK2Δ mice.  
Based on the results showing an age dependent hypomyelination phenotype in male SK2Δ mice, 
we performed an experiment to determine if the same was seen in 10 month old female mice, and 
if this phenotype can be reversed with S1P receptor agonist administration. Groups of 10 female 
SK2Δ mice, or their WT littermates, were administered Siponimod, A-971432, or vehicle control 
for 6 weeks immediately prior to culling at 10 month of age. 
 
 
4.3.3.1 Siponimod treatment effectively induced lymphopenia in blood. 
Potent S1PR1 agonists such as Siponimod induce lymphopenia through functional antagonism of 
S1PR1 receptors on lymphocytes, which inhibits their egress from the lymph nodes into the 
circulation [264, 301]. This allowed us to test whether Siponimod was achieving a physiologically-
effective dose during the drug administration period (Figure 4.5). The effect of drug treatment on 
total live leukocyte numbers (CD45 positive) cells in blood was significantly affected by drug 
treatment (F = 24.07, p <0.0001), with a significant 22.7-fold reduction in the Siponimod group (p 
<0.0001) and 5.2-fold reduction in the A-971432 group (p = 0.004), compared to the control group 
(Figure 4.5A). The percentage of CD3-positive cells (T-cells) in blood were diminished from 8.9% 
in the vehicle control group to 0.9% in the Siponimod treatment group (p <0.0001), whereas the 
A-971432 group did not show any significant difference compared to the control group (p > 0.05) 
(Figure 4.5B). The overall levels of NK1-positive natural killer cells were not significantly affected 
between drug groups (Figure 4.5).  
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Figure 4.5 Female mice treated with Siponimod exhibit peripheral lymphopenia. 
Flow cytometry of total leukocytes (CD45 positive) and CD3 positive cells (T-cells) in blood from animals in 
control, A-971432 and siponimod treatment groups. (A) Total number of viable leukocytes (CD45+ cells) per 100 
microlitres of blood. (B) CD3+ and NK1-positive natural killer cells, as a percentage of total CD45+ cells. One-way 
ANOVA detected an effect of drug treatment, and Siponimod treatment (p <0.0001; Fig 4.5A,B). Control n = 8, A-
971432 n = 6, Siponimod n = 6. * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.0001. Flow cytometry was 
performed by Quintin Lee.  
(B) (A) 
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4.3.4 S1P receptor agonists did not alleviate the freezing deficit in SK2Δ mice.  
Anxiety deficits were previously observed in male mice lacking SK2 that underwent the fear 
conditioning paradigm (chapter 2). Increased baseline freezing (first 2 min of the fear conditioning 
phase prior to receiving the foot-shock) and overall freezing in the cue, context and extinction tests 
were observed in SK2∆ compared to WT mice (chapter 2). The baseline freezing deficit, prior to 
administering the fear stimulus (foot shock), was not observed in the female SK2Δ mice used in 
this study (Figure 4.6A), as two-way ANOVA identified no effect of ‘drug’ or ‘genotype’ on the 
total time animals spent freezing at baseline. All groups responded to the foot shock with increased 
freezing (Figure 4.6A-D). 
 
The cue test was then applied, testing the response of the mice to the auditory cue from the 
conditioning phase, but in the absence of any foot shock. This tests the mice’ auditory memory of 
the adverse event. 
 
SK2Δ mice displayed significantly higher overall freezing in the cue test, and an effect of both 
‘genotype’ [F(1, 53) = 4.509, p = 0.0384] and ‘drug’ [F (2, 53) = 3.609, p = 0.0339] was observed 
in the total time animals spent freezing over the entire 7 min of the test (Figure 4.7A,C). In the 2 
min before cue presentation, there was an effect of genotype only [F(1, 53) = 5.009, p = 0.0294], 
with SK2Δ mice showing significantly higher freezing compared to the WT, in agreement with 
previous results using male mice (chapter 2) (Figure 4.7D). In the 3-7 min period, during the 
auditory cue, significant effects were observed for both ‘genotype’ [F(1,53) = 5.154, p = 0.0273] 
and ‘drug’ [F(2,53) = 5.211, p = 0.0086]. Again, SK2Δ mice spent a significantly higher proportion 
of the time freezing. However, the post-test comparisons revealed no significant differences 
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between drug treatment groups within WT or SK2Δ genotypes. There was no effect of ‘genotype’ 
or ‘drug’ observed in the final 2 min following cessation of the cue.   
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Figure 4.6 WT and SK2Δ mice show equivalent freezing response in the conditioning phase of the fear 
conditioning paradigm.  
(A-C) Fear conditioning across 1 min blocks.  (D) Percentage freezing before, during and after the foot shock, 
delivered with an auditory cue. Mean ± SEM are shown for (A) vehicle-treated WT and SK2Δ mice, (B) WT mice 
treated with vehicle control (VC), A-971432 (A97) or Siponimod (BAF), and (C) SK2Δ mice treated with vehicle 
control (VC), A-971432 (A97) or Siponimod (BAF). In (D), boxes show 25th-75th percentiles, vertical bars show the 
range of the data, and horizontal bars indicate the median. All groups n = 10 mice.  
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Figure 4.7 Contextual fear-associated memory to altered context and auditory cue across treatment groups.  
(A-C) Time spent freezing (s) in the fear conditioning cue test, across 1-min blocks, (D) percentage of time spent 
freezing before, during and after cue presentation. Mean ± SEM are shown for (A) vehicle-treated WT and SK2Δ 
mice, (B) WT mice treated with vehicle control (VC), A-971432 (A97) or iponimod (BAF), and (C) SK2Δ mice 
treated with vehicle control (VC), A-971432 (A97) or Siponimod (BAF). In (D), boxes show 25th-75th percentiles, 
vertical bars show the range of the data, and horizontal bars indicate the median. n = 10 mice per group.  
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The context test places the mice in the same cage as the conditioning phase, however, unlike the 
conditioning phase there is no auditory or aversive stimulus involved. This tests the animals’ 
retention of fear memory. As observed in the cue test, SK2Δ mice spent significantly increased 
total time freezing in the context test compared to the WT controls (Figure 4.8A-C). In 2-way 
ANOVA, there was a significant effect of ‘genotype’ over the entire 7 min period of the test [F(1, 
53) = 5.489, p = 0.0229], but not ‘drug’ (p > 0.05). Unlike in the cue test, there was no effect of 
‘genotype’ or ‘drug’ in the first 2 min of the context test (p > 0.05).   
 
The subsequent extinction days share the exact same procedure as the context test. This examines 
the subjects’ ability to extinguish fear memory over three consecutive days. The WT and SK2Δ 
mice were compared across context and extinction days 1-3, which revealed an effect of ‘genotype’ 
F(1,72) = 14.57, p = 0.0003] and an effect of ‘test day’ [F(3,72) = 13.72, p<0.0001] in two-way 
ANOVA (Figure 4.8D). The post-tests revealed that the SK2Δ mice spent more time freezing on 
extinction day 2 compared to WT mice (p = 0.03; Figure 4.8A,D). The effect of the drug treatments 
across context test and extinction days 1-3, was then investigated in the WT mice. This revealed 
an effect of ‘test day’ [F(3,108) = 8.966, p<0.0001], with post-tests showing statistically significant 
reduced time freezing in the vehicle control treated WT mice in each extinction day compared to 
the context test. These were context vs. extinction day 1 (p = 0.0015), context vs extinction day 2 
(p = 0.0008), and context vs extinction day 3 (p = 0.004) (Figure 4.8B,D). However, time spent 
freezing did not decrease from extinction day 1 to extinction day 3. There were no statistically 
significant changes in freezing time from context test day to extinction test days in the Siponimod 
and A-971432 groups (Figure 4.8D). This may be attributed to much greater variability in freezing 
time of Siponimod and A-971432-treated mice in the context test. Testing the effect of the drug 
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treatments within the SK2Δ groups revealed an effect of both ‘test day’ [F(3,104) = 11.71, 
p<0.001] and ‘drug’ [F(2,104) = 4.986, p = 0.0086]. The between-group comparisons revealed 
statistically significant reductions in freezing time in each SK2Δ treatment group from the context 
test day to extinction day 1. However, there were no further reductions in time spent freezing on 
subsequent days of the extinction test paradigm.  
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Figure 4.8 Contextual fear-associated memory and contextual fear extinction across drug treatments.  
(A-C) Contextual fear conditioning across 1-min blocks [s], D) percentage freezing on context and extinction days 1-
3 [% of total time]. Mean ± SEM are shown for (A) vehicle-treated WT and SK2Δ mice, (B) WT mice treated with 
vehicle control (VC), A-971432 (A97) or Siponimod (BAF), and (C) SK2Δ mice treated with vehicle control (VC), 
A-971432 (A97) or Siponimod (BAF). In (D), boxes show 25th-75th percentiles, vertical bars show the range of the 
data, and horizontal bars indicate the median. n = 10 mice per group. 
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4.3.5 Neither WT nor SK2Δ mice showed a preference for the novel object in the novel 
object recognition test.   
Novel object recognition is a common test for recognition memory. However, in this test neither 
WT nor SK2∆ showed a preference for the novel object compared to what was expected by chance, 
in the vehicle control or A-971432 groups (Figure 4.9A). Only the WT mice receiving Siponimod 
showed a significant preference for nosing the novel object compared to chance in the WT group 
(p = 0.0468). This was not observed in the SK2∆ Siponimod group (p > 0.05).  
 
In addition to nosing, another behavioural measure is rearing on the objects. There was no 
significant preference for rearing on the novel object compared to what was expected by chance 
in either WT or SK2∆, and regardless of drug treatment (Figure 4.9B). In summary, the NORT 
paradigm could not reliably test recognition memory in this study as the WT vehicle control mice 
did not exhibit a statistically significant preference for the novel over the familiar object.      
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Figure 4.9 Behavioural interactions with novel and familiar objects.  
Percentage of time animals spent nosing (A) and rearing (B) the novel object in the NORT. Box-and-whisker plots 
show full range of the data, as well as 25th-75th percentiles (boxes), and median value (horizontal bar). Statistical 
significance was determined by one sample t-tests tests comparing the measure of interest to that expected by chance 
(50%, dotted line) for each genotype.  
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4.3.6 Hypomyelination was not evident in mice lacking SK2. 
In the preceding chapter and prior studies with male SK2Δ mice, we observed loss of myelin 
proteins and lipids [289] (Figure 4.10A-C). Expression of myelin protein markers in the 
hippocampus and cortex of this cohort of 10-month old female mice was determined by western 
blotting. Mean levels of MBP, myelin oligodendrocyte glycoprotein (MOG) and myelin 
proteolipid protein (PLP) were relatively uniform, with no significant difference in either 
hippocampus or cortex between WT and SK2Δ. The myelin protein levels were also unaffected by 
drug treatments (Figure 4.10A-C).  
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Figure 4.10 Loss of myelin markers was not detected in female SK2Δ mice and agonist treatment did not 
affect myelin protein expression.  
Western blots (A) and densitometric quantification (B and C) of myelin markers in hippocampus and cortex of 10-
month old female mice. Drug treatments are presented as vehicle control (VC), A-971432 (A97), and siponimod 
(BAF) (A). Protein levels were normalised to -actin in each sample, then to the mean of the control group. Graphs 
show mean ± SEM, n = 6 mice per genotype. Statistical significance was determined by one-way ANOVA with 
Sidak’s post-test. 
(A) 
(B) 
(C) 
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4.3.7 No loss of major myelin lipids, but elevated sphingadiene-containing lipids in 
SK2Δ mice. 
S1P, sphingosine and other sphingolipids with a standard 18:1 sphingosine base backbone 
(ceramide, SM, GalCer, and ST) in the hippocampus were quantified using LC-MS/MS (Figure 
4.11 and Table 4.2). After adjusting for multiple comparisons, only S1P was significantly affected 
by genotype (Table 4.4). Mean hippocampal S1P levels were 67% lower in SK2Δ compared to 
WT mice (p = 0.0106), whilst the SK2 substrate sphingosine was 39% higher (p = 0.0770). These 
findings are in agreement with previous results (chapters 2 and 3). Surprisingly, neither genotype 
nor S1P receptor agonists had a significant effect on major myelin lipid constituents GalCer, ST 
and SM.  
 
Levels of sphingolipids with a less common 18:2 sphingadiene base backbone were also 
determined (Table 4.3 and Figure 4.12). After adjusting the results of 2-way ANOVAs for multiple 
comparisons, sphingosine, total GalCer, total ST and total SM were all significantly affected by 
genotype, with greatly elevated levels of these sphingadiene-base lipids in SK2Δ compared to WT 
mice (Table 4.4). Within the SK2Δ mouse treatment groups, levels of sphingadiene and 
sphingadiene-containing lipids were consistently lower in the A-971432 treatment group. Using 
2-way ANOVA the effect of drug treatment was not significant for any lipids.  
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Figure 4.11 Altered sphingosine and S1P levels in SK2Δ hippocampus.  
Total sphingosine, S1P and 18:1 sphingosine base lipids levels in pmoles per mg of tissue. Statistical significance was 
determined by two-way ANOVA with Dunnett’s post-test, shown in Table 4.2. Mean ± SEM are shown. n = 6 mice 
per group. 
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 Mean ± SEM (pmoles lipid/mg tissue) ANOVA results 
 WT SK2Δ   
 control A-971432 siponimod control A-971432 siponimod F 
value 
P value 
Sphingosine 0.094 ± 0.01 0.092 ± 0.017 0.105 ± 0.006 0.155 ± 0.016  0.116 ± 0.016 0.169 ± 0.026 3.76 0.0092# 
S1P 0.204 ± 0.018 0.203 ± 0.043 0.266 ± 0.013 0.067 ± 0.036* 0.133 ± 0.032 0.042 ± 0.016 9.07 <0.0001# 
         
Ceramide         
C16:0 0.02 ± 0.004 0.014 ± 0.001 0.013 ± 0.001 0.015 ± 0.002 0.016 ± 0.003 0.021 ± 0.003 1.45 0.24 
C16.1 4.3E-04 ± 6.7E-
05 
6.1E-04 ± 1.0E-
04 
5.0E-04 ± 9.7E-05 6.0E-04 ± 1.5E-
04 
5.6E-04 ± 3.9E-
05 
5.0E-04 ± 7.9E-
05 
0.52 0.76 
C18:0 2.71 ± 0.40 2.10 ±0.14 2.04 ± 0.22 2.71 ± 0.51 2.53 ± 0.37 4.03 ± 0.8 2.48 0.05# 
C18.1 8.8E-05 ± 1.2E-
05 
2.3E-04 ± 6.9E-
05 
1.5E-04 ± 2.19E-
05 
1.4E-04 ± 6.4E-
05 
1.3E-04 ± 3.2E-
05 
3.8E-04 ± 1.4E-
04 
2.09 0.09 
C20:0 0.098 ± 0.013 0.077 ± 0.006 0.077 ± 0.012 0.078 ± 0.015 0.092 ± 0.013 0.13 ± 0.038 1.15 0.36 
C22:0 0.028 ± 0.005 0.019 ± 0.003 0.025 ± 0.005 0.021 ± 0.007 0.023 ± 0.004 0.041 ± 0.018 0.87 0.51 
C22:1 0.028 ± 0.004 0.025 ± 0.004 0.028 ± 0.005 0.021 ± 0.004 0.022 ± 0.004 0.03 ± 0.008 0.53 0.75 
C24:0 0.04 ± 0.008 0.024 ± 0.002 0.03 ± 0.005 0.02 ± 0.006 0.022 ± 0.003 0.036 ± 0.014 1.151 0.356 
C24:1 0.024 ± 0.007 0.017 ± 0.002 0.022 ± 0.004 0.016 ± 0.004 0.02 ± 0.005 0.03 ± 0.009 0.83 0.54 
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Total 3.0 ± 0.4 2.3 ± 0.1 2.2 ± 0.2 2.9 ± 0.5 2.7 ± 0.4 4.3 ± 0.9 2.34 0.07 
         
GalCer         
C16:0 0.063 ± 0.013 0.059 ± 0.016 0.079 ± 0.013 0.044 ± 0.012 0.058 ± 0.013 0.053 ± 0.01 0.81 0.56 
C18:0 0.52 ± 0.08 0.58 ± 0.15 0.63 ± 0.11 0.48 ± 0.12 0.57 ± 0.12 0.57 ± 0.07 0.23 0.94 
C20:0 0.167 ± 0.031 0.201 ± 0.057 0.2 ± 0.037 0.152 ± 0.046 0.192 ± 0.050 0.167 ± 0.019 0.24 0.94 
C22:0 5.5 ± 1.0 5.4 ± 1.5 6.9 ± 1.4 3.8 ± 1.1 5.1 ± 1.2 4.6 ± 0.6 0.76 0.59 
C22:0-OH 10.9 ± 1.9 11.5 ± 2.6 12.6 ± 2.8 11.9 ± 2.8 10 ± 2.2 12.4 ± 1.1 0.18 0.97 
C22:1 0.34 ± 0.06 0.43 ± 0.11 0.48 ± 0.07 0.33 ± 0.06 0.42 ± 0.09 0.34 ± 0.05 0.63 0.68 
C22:1-OH 0.70 ± 0.13 0.78 ± 0.17 0.84 ± 0.12 0.81 ± 0.13 0.86 ± 0.17 0.86 ± 0.07 0.20 0.96 
C24:0 4.7 ± 0.9 5 ± 1.4 5.8 ± 1.1 3.4 ± 1.1 4.6 ± 1.2 4.3 ± 0.9 0.52 0.76 
C24:0-OH 15.4 ± 2.6 16.2 ± 3.2 14 ± 3.1 13.7 ± 3.1 14.3 ± 3.0 15.8 ± 1.9 0.13 0.98 
C24:1 14.6 ± 2.0 16.7 ± 4.0 17.9 ± 2.3 12.6 ± 2.7 16.1 ± 3.3 13.8 ± 1.8 0.50 0.77 
C24:1-OH 3.3 ± 0.5 3.6 ± 0.8 3.8 ± 0.5 3.1 ± 0.6 3.6 ± 0.8 3.4 ± 0.4 0.17 0.97 
Total 57.3 ± 8.0 62.9 ± 13.0 62.1 ± 10.6 51.3 ± 10.7 59.2 ± 12.2 57.9 ± 2.2 0.17 0.97 
         
SM          
C16:0 0.58 ± 0.13 0.74 ± 0.11 0.55 ± 0.07 0.58 ± 0.17 0.66 ± 0.14 0.72 ± 0.17 0.34 0.89 
C18:0 20.9 ± 1.9 22.7 ± 1.7 22 ± 0.7 17.2 ± 1.9 19.2 ± 1.5 20.3 ± 1.1 1.68 0.17 
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C20:0 0.89 ± 0.08 0.90 ± 0.18 0.94 ± 0.12 0.54 ± 0.12 0.77 ± 0.13 0.66 ± 0.08 1.62 0.19 
C22:0 1.47 ± 0.23 1.06 ± 0.23 1.77 ± 0.31 0.79 ± 0.22 1.2 ± 0.25 1.03 ± 0.18 2.13 0.09 
C24:0 0.67 ± 0.10 0.56 ± 0.14 0.75 ± 0.12 0.43 ± 0.13 0.53 ± 0.09 0.64 ± 0.15 0.80 0.56 
Total 24.5 ± 2.3 26 ± 2.2 26 ± 1.0 19.5 ± 2.4 22.4 ± 1.9 23.3 ± 1.5 1.58 0.20 
         
Sulfatide         
C18:0 0.72 ± 0.10 0.73 ± 0.14 0.89 ± 0.11 0.6 ± 0.10 0.73 ± 0.10 0.69 ± 0.09 0.71 0.62 
C20:0 0.11 ± 0.02 0.14 ± 0.02 0.15 ± 0.02 0.11 ± 0.02 0.12 ± 0.02 0.11 ± 0.02 0.92 0.48 
C20:0-OH 0.09 ± 0.01 0.11 ± 0.03 0.14 ± 0.03 0.1 ± 0.02 0.11 ± 0.02 0.11 ± 0.01 0.59 0.71 
C22:0 1.38 ± 0.09 1.83 ± 0.27 1.84 ± 0.20 1.46 ± 0.24 1.67 ± 0.23 1.42 ± 0.25 0.89 0.50 
C22:0-OH 0.65 ± 0.09 0.86 ± 0.24 0.77 ± 0.17 0.68 ± 0.19 0.85 ± 0.21 0.68 ± 0.09 0.27 0.93 
C24:0 7.57 ± 1.03 7.74 ± 1.50 9.92 ± 1.17 6.05 ± 1.18 7.47 ± 0.90 6.56 ± 0.60 1.48 0.23 
C24:0-OH 3.68 ± 0.50 3.51 ± 0.68 4.66 ± 0.62 3.01 ± 0.67 3.29 ± 0.37 3.16 ± 0.33 1.17 0.34 
C24:1 9.9 ± 1.5 10.5 ± 1.8 13.6 ± 1.9 7.5 ± 1.4 9.2 ± 1.3 6.9 ± 1.1 2.45 0.06 
C24:1-OH 0.52 ± 0.08 0.50 ± 0.07 0.67 ± 0.05 0.46 ± 0.09 0.47 ± 0.05 0.46 ± 0.07 1.31 0.29 
Total 24.6 ± 3.3 25.9 ± 4.6 32.6 ± 4.0 20.0 ± 3.8 23.9 ± 3.1 20.0 ± 2.2 1.69 0.17 
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Table 4.2 Increased sphingosine and decreased S1P 18:1 base levels in SK2Δ hippocampus.   
Levels of S1P, sphingosine, and other sphingolipids in the hippocampus of WT and SK2Δ mice undergoing drug treatment with: vehicle control, A-971432 and 
Siponimod. All lipids shown have the common 18:1 sphingosine base. F and p values for two-way ANOVA are indicated; # indicates p < 0.05. After adjusting 
ANOVA p values for multiple comparisons, sphingosine and S1P were significant at Q < 0.05, indicated by Bold font. Dunnett’s post-test was used to compare 
group means to the WT vehicle control group for individual lipids significant at p < 0.05 in univariate ANOVA, * p < 0.05; and to compare group means to SK2Δ 
vehicle control group for individual lipids.  
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Figure 4.12 Hippocampal sphingadiene and 18:2 sphingadiene base lipids are increased in SK2Δ mice.  
Total sphingadiene, sphingadiene-1-phosphate, and 18:2 sphingadiene base lipids levels in pmole per mg. Statistical 
significance was determined by two-way ANOVA with Dunnett’s post-test (Table 4.3). Mean ± SEM are shown. n = 
6 mice per group. 
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 Mean ± SEM (pmoles lipid/mg tissue) ANOVA results 
 WT SK2Δ   
 Control A-971432 siponimod control A-971432 siponimod F value P value 
Sphingadiene 0.013 ± 0.001 0.024 ± 0.009 0.015 ± 0.001 0.047 ± 0.006** 0.029 ± 0.008 0.043 ± 0.008 4.83 0.0023# 
Sphingadiene 1-phosphate 0.0094 ± 0.0007 0.0108 ± 0.0017 0.0134 ± 0.0007 0.0065 ± 0.0012 0.0084 ± 0.0011 0.0045 ± 0.0006 8.37 <0.0001# 
         
Ceramide         
C18:1 0.011 ± 0.001 0.017 ± 0.004 0.013 ± 0.001 0.041 ± 0.008 0.03 ± 0.009 0.052 ± 0.018 3.386 0.0153# 
C24:1 0.085 ± 0.009 0.141 ± 0.036 0.098 ± 0.007 0.34 ± 0.069* 0.242 ± 0.061 0.365 ± 0.091 4.916 0.0021# 
Total 0.1 ± 0.01 0.16 ± 0.04 0.11 ± 0.01 0.38 ± 0.08** 0.27 ± 0.07 0.42 ± 0.11 4.735 0.0026# 
         
GalCer         
C18:0 0.0021 ± 0.0003 0.0031 ± 0.0011 0.0025 ± 0.0003 0.0052 ± 0.0007* 0.0039 ± 0.0008 0.006 ± 0.0009 4.128 0.0057# 
C18:1 0.009 ± 0.002 0.014 ± 0.003 0.013 ± 0.002 0.028 ± 0.003** 0.019 ± 0.006 0.022 ± 0.003 4.157 0.0055# 
C20:0 0.005 ± 0.001 0.009 ± 0.002 0.006 ± 0.001 0.023 ± 0.005*** 0.016 ± 0.004 0.019 ± 0.002 6.462 0.0003# 
C22:0 0.024 ± 0.003 0.039 ± 0.012 0.03 ± 0.003 0.094 ± 0.014*** 0.062 ± 0.015 0.093 ± 0.011 8.19 <0.0001# 
C24:0 0.006 ± 0.001 0.01 ± 0.002 0.007 ± 0.001 0.022 ± 0.003*** 0.016 ± 0.004 0.023 ± 0.003 7.507 0.0001# 
C24:1 0.9 ± 0.1 1.5 ± 0.3 1.1 ± 0.1 3.4 ± 0.6*** 2.4 ± 0.7 3.0 ± 0.3 6.292 0.0004# 
C24:1 - OH 0.12 ± 0.01 0.21 ± 0.06 0.15 ± 0.02 0.52 ± 0.08*** 0.36 ± 0.10* 0.5 ± 0.07 8.192 <0.0001# 
Total 1.0 ± 0.1 1.7 ± 0.4 1.3 ± 0.1 4.1 ± 0.7** 2.9 ± 0.8 3.6 ± 0.4 6.654 0.0003# 
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SM         
C16:0  0.033 ± 0.005 0.036 ± 0.005 0.038 ± 0.004 0.069 ± 0.011 0.055 ± 0.014 0.08 ± 0.021 2.658 0.0419# 
C18:0 2.6 ± 0.2 3.9 ± 0.6 3.1 ± 0.2 6.0 ± 0.7** 4.5 ± 0.8 5.9 ± 0.8 5.314 0.0013# 
C20:0 0.027 ± 0.006 0.041 ± 0.006 0.036 ± 0.007 0.055 ± 0.012 0.045 ± 0.008 0.045 ± 0.006 1.512 0.2158 
C22:0 0.27 ± 0.08 0.35 ± 0.09 0.42 ± 0.13 0.41 ± 0.11 0.46 ± 0.13 0.32 ± 0.04 0.501 0.773 
C24:0 1.7 ± 0.2 1.7 ± 0.3 2.1 ± 0.2 1.3 ± 0.2 1.6 ± 0.2 1.7 ± 0.3 1.297 0.2916 
Total 4.7 ± 0.3 5.9 ± 0.6 5.7 ± 0.3 7.8 ± 0.7** 6.7 ± 0.9 8 ± 0.9 3.747 0.0094# 
         
ST         
C24:0 0.021 ± 0.002 0.041 ± 0.008 0.032 ± 0.004 0.077 ± 0.008**** 0.048 ± 0.009* 0.053 ± 0.007 8.224 <0.0001# 
C24:1 0.1 ± 0.01 0.14 ± 0.05 0.13 ± 0.01 0.27 ± 0.04* 0.23 ± 0.06 0.29 ± 0.05 3.628 0.011# 
Total 0.12 ± 0.01 0.19 ± 0.06 0.16 ± 0.01 0.35 ± 0.05** 0.28 ± 0.07 0.34 ± 0.05 4.344 0.0043# 
 
Table 4.3 Total sphingadiene base lipid levels are increased in mice lacking SK2Δ.  
Levels of sphingadiene, sphingadiene 1-phosphate, and 18:2 base lipids in the hippocampus of WT and SK2Δ mice undergoing drug treatment with: vehicle control, 
A-971432 and Siponimod. All lipids shown have the common 18:2 sphingosine base. F and p values for two-way ANOVA are indicated; # indicates p < 0.05. 
After adjusting ANOVA p values for multiple comparisons, lipids that were significant at Q < 0.05 are indicated by Bold font. Dunnett’s post-test was used to 
compare group means to the WT vehicle control group for individual lipids significant at p < 0.05 in univariate ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.005, 
**** p < 0.0001.  
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2-way ANOVA results 
Sph 18:1 F-stat P-value  Post-test comparisons P-value 
Interaction F (2, 30) = 3.550 0.0413*  
Drug F (2, 30) = 0.6213 0.5440 
Genotype F (1, 30) = 37.01 <0.0001 **** 
Sph 18:2   WT control vs SK2 control 0.0093** 
Interaction F (2, 30) = 2.961 0.0670  
Drug F (2, 30) = 0.1689 0.8454 
Genotype F (1, 30) = 17.89 0.0002*** 
   
S1P 18:1   WT control vs SK2 control 0.0316* 
Interaction F (2, 30) = 0.8766 0.4266  
Drug F (2, 30) = 1.975 0.1564 
Genotype F (1, 30) = 13.10 0.0011* 
S1P 18:2   
Interaction F (2, 30) = 5.552 0.0089** 
Drug F (2, 30) = 1.214 0.3113 
Genotype F (1, 30) = 28.32 <0.0001**** 
   
Cer d18:1   SK2Δ control vs SK2Δ 
Siponimod 
0.0494* 
Interaction F (2, 30) = 2.546 0.0952  
Drug F (2, 30) = 1.23 0.3065 
Genotype  F (1, 30) = 4.119 0.0513 
Cer d18:2   WT control vs SK2 control 0.0035** 
Interaction F (2, 30) = 1.35 0.2745  
Drug F (2, 30) = 0.2982 0.7443 
Genotype  F (1, 30) = 20.38 <0.0001 **** 
   
HexCer d18:1   
Interaction F (2, 30) = 
0.007214 
0.9928 
Drug F (2, 30) = 0.2553 0.7763 
Genotype  F (1, 30) = 0.3151 0.5787 
HexCer d18:2   WT control vs SK2 control 0.0019** 
Interaction F (2, 30) = 1.928 0.1630  
Drug F (2, 30) = 0.1261 0.8820 
Genotype  F (1, 30) = 29.16 <0.0001 **** 
   
SM d18:1   
Interaction F (2, 30) = 0.172 0.8428 
Drug F (2, 30) = 1.058 0.3598 
Genotype  F (1, 30) = 5.445 0.0265 
SM d18:2   WT control vs SK2 control 0.0021** 
Interaction F (2, 30) = 1.705 0.1989  
Drug F (2, 30) = 0.4736 0.6274 
Genotype  F (1, 30) = 14.38 0.0007 *** 
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Table 4.4 Main effect of genotype affects sphingadiene base lipids in hippocampus.  
Table shows specific results for 2-way ANOVA for total levels of d81:1 and d18:2 sphingosine, S1P, ceramides, 
HexCer SM and ST. The post-tests compared WT vehicle control to SK2Δ vehicle control; WT vehicle control to WT 
A-971432 and WT Siponimod and SK2Δ vehicle control to SK2Δ A-971432 and SK2Δ Siponimod. Satistical 
significant values are listed * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.0001. n = 6 mice per treatment group.  
ST d18:1   
Interaction F (2, 30) = 1.164 0.3260 
Drug F (2, 30) = 0.6425 0.5331 
Genotype  F (1, 30) = 4.832 0.0358 * 
ST d18:2   WT control vs SK2 control 0.0015** 
Interaction F (2, 30) = 1.061 0.3586  
Drug F (2, 30) = 0.06402 0.9381 
Genotype  F (1, 30) = 19.47 0.0001 *** 
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4.5 Discussion 
 
This study uncovered significant myelin deficits, including reduced myelin thickness and loss of 
myelin lipid and protein markers in male SK2Δ mice. I then investigated whether female SK2Δ 
mice display similar myelin deficits, and whether this hypomyelination could be alleviated with 
S1P agonist treatment. As S1PR5 is expressed almost exclusively in oligodendrocytes in the brain, 
we used the S1PR5-selective agonist A-971432 [235, 280, 291]. We also used the S1PR1/S1PR5 
dual agonist Siponimod [301], a new S1P receptor agonist that in 2019 became the first oral drug 
to receive approval for secondary progressive multiple sclerosis [274]. Our data indicated that 
there are no significant deficits in myelin proteins or lipids in 10 month old female SK2Δ mice. 
However, lipids containing an unusual 18:2 sphingadine base were significantly increased in brain 
tissue of SK2Δ mice.  
 
Loss of myelin protein content in SK2Δ mice was suggested in studies described in the previous 
chapter (chapter 3), although the reductions in myelin proteins were statistically significant only 
in J20.SK2Δ, not SK2Δ mice. However, in unadjusted Fisher’s post-tests, MBP, MOG and PLP 
were significantly reduced in the hippocampus/cortex of both SK2Δ and J20.SK2Δ mice at 13 
months of age. On further examination of this phenotype using archived brain tissue from the male 
SK2Δ mice used for chapter 2, we found significant reductions in myelin lipids and diminished 
MBP protein levels in the hippocampus. Electron microscopy showed reduced myelin thickness 
(higher g-ratios) in 12- and 15-month old SK2Δ mice, as well as structural abnormalities including 
in-folding and out-folding of the myelin structure, redundant loops and vacuolation. Reduced 
myelin thickness was not observed in 2-month old male SK2Δ mice, whereas some abnormalities 
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in myelin structure were evident. In mice, developmental myelination begins at birth and is mostly 
complete by post-natal day 60 [302]. Our results therefore suggest that the myelin deficits in male 
SK2Δ mice are age-dependent. This awaits more vigorous clarification with western blotting and 
lipidomic analysis, although I note that ongoing studies in our laboratory have essentially 
confirmed that ageing is necessary for clear myelin deficits to manifest in male SK2Δ mice. 
 
Lipidomic profiling in this study (Tables 4.2 and 4.3) and our published reports [220, 289] 
consistently showed reduced S1P and a dramatic increase in the SK2 substrate, sphingosine, in 
hippocampal and cortical tissue of SK2Δ mice. A study by Takasugi and colleagues identified 
SK2-generated S1P as a positive regulator of the proteolytic activity of BACE1, the enzyme 
involved in the first proteolytic step leading to generation of Aβ peptides from full length APP, in 
cultured primary neurons [244]. This proposed role for SK2 in BACE1 activation is supported by 
our results (chapter 3), as we demonstrated reduced Aβ levels in J20 mice lacking SK2, although 
we did not formally demonstrate reduced BACE1 activity in these mice. In addition to cleavage of 
APP, BACE1 regulates myelination and myelin sheath thickness in both the CNS and PNS through 
proteolytic maturation of the growth factor neuregulin-1 (NRG-1) [303, 304]. BACE1-null mice 
exhibit hypomyelination, abnormal myelin structure and an accumulation of unprocessed NRG-1 
[305, 306].  Previous reports identified NRG-1 type III as the major isoform localised to the axonal 
surface, where it is thought to be responsible for the activation of phosphoinositide 3-kinase (PI3K) 
and protein kinase B (Akt) activity [304-307]. It is hypothesised that the lack of processed, 
activated NRG-1 type III modifies the transducing activity in this pathway which alters the 
expression of major myelin proteins [304, 306, 308]. If S1P is indeed required for BACE1 activity, 
the absence of SK2 may interfere with myelination by reducing cleavage of NRG-1 and other 
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BACE1 substrates required for myelination. We found no evidence for differences in NRG1 type 
III cleavage between WT and SK2Δ mice by western blotting (data not shown), but acknowledge 
that further research is needed to verify the antibodies and determine with certainty whether SK2 
modulates NRG1 activation. 
 
Another potential mediator of oligodendrocyte cell stress in the absence of SK2 is the increased 
sphingosine, rather than reduced S1P, content. In direct contrast to S1P, which is a pro-survival 
signalling molecule, elevated sphingosine is pro-apoptotic [309, 310]. Furthermore, elevated levels 
of sphingosine and its derivative psychosine are also associated with Krabbe disease which is 
characterised by oligodendrocyte cell death and demyelination [311]. Sphingosine is also readily 
converted back to pro-apoptotic ceramides by ceramide synthases. Our lipidomic analysis did not 
indicate higher ceramide content in brains of SK2Δ mice. However, the overall ceramide content 
in brain tissue samples is heavily influenced by myelin content, so subtle changes to ceramide 
content in oligodendrocyte cell bodies that are independent of myelin are difficult to ascertain. 
 
Myelination in humans peaks in middle-age, after which myelin content declines with increasing 
age [167, 168]. Structural deficits in myelin are associated with later-differentiating 
oligodendrocytes, which produce thinner myelin sheaths in contrast to earlier myelinating 
oligodendrocytes [170, 312]. Myelin breakdown in individuals presymptomatic for AD occurs 
more rapidly in carriers of the APOE4 allele, suggesting that faster myelin deterioration could be 
an important mechanism through which this allele confers increased risk for AD [168, 169]. There 
is evidence that demyelination leads to tau hyperphosphorylation and neurodegeneration in 
multiple sclerosis and in inherited leukodystrophies [171, 313]. Slowing the process of 
Chapter 4 Do S1P receptor agonists reverse hypomyelination in SK2 knockout mice? 
106 
 
neurodegeneration and cognitive decline by restoration of myelination might therefore be a 
potential therapeutic route for the treatment of AD. Although this thesis did not establish clearly 
that SK2 and/or S1P receptors are necessary for myelination or myelin maintenance with ageing, 
ongoing studies in our laboratory will address these questions.  
 
The animals in this study underwent behavioural testing for recognition and fear-associated 
memory in order to determine firstly whether the anxiety phenotype that we previously observed 
in male SK2Δ mice is also seen in females; and secondly whether the agonist treatments alleviate 
this phenotype. In agreement with our findings with male mice (chapter 2), female SK2Δ mice 
displayed significantly more freezing behaviour than WT mice in both the cue and context tests of 
the fear conditioning paradigm (Figure 4.4-4.5). As observed previously [220], the SK2Δ mice 
curiously spend more time freezing in the first 2 min prior to presentation of the cue (sound 
stimulus) in the cue test. This is unexpected, as the cage in which the cue test is performed is an 
altered environment for the mice and should not be associated with a fear response. This suggests 
that the SK2 mice respond adversely to handling or new environments compared to the WT mice, 
supported by our prior results showing increased freezing in the elevated plus maze [220].  
 
Our results indicate that 6 weeks of sustained treatment with S1PR1 and S1PR5 receptor agonists 
does not correct the anxiety phenotype in SK2Δ mice. The SK2Δ mice treated with the S1PR5 
agonist A-971432 exhibited reduced freezing throughout the fear extinction test days compared to 
the context test. However, it should be noted that the A-971432-treated mice spent more time 
freezing compared to the other treatment groups on the context day, which explains the reduced 
freezing on the extinction test days. A-971432 has been reported to reverse age-related cognitive 
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deficits in male C57BL/6J in the T-maze paradigm, which may be due to a restoration of 
endothelial integrity within the BBB; and to restore normal motor function in a Huntington’s 
disease model mouse [280, 281]. Despite this, A-971432 did not have a clear effect on the 
enhanced fear response in SK2Δ mice. The anxiety phenotype in SK2Δ mice could potentially be 
mediated through loss of intracellular S1P signalling, particularly through the inhibition of histone 
deacetylases (HDAC). In the nucleus SK2 produces S1P which inhibits HDAC1 and HDAC2, 
thereby enhancing histone acetylation [225, 314]. HDAC2 activity, in particular, negatively affects 
synaptic plasticity and perturbs memory and learning [315]. Reduced histone acetylation was 
previously shown in SK2Δ mice [225], and this was associated with deficits in fear memory 
extinction [225]. In contrast, we have consistently observed enhanced fear responses in SK2Δ 
mice, rather than any deficit in fear extinction ([220] and this chapter). Although we demonstrated 
a preference for the novel object in WT mice in the NORT in chapter 3 [289], in this study we 
failed to establish this preference in the WT vehicle control group (Figure 4.6A-B). This indicates 
that the NORT paradigm was technically flawed in this study and we could not legitimately 
determine recognition memory using this test. Behavioural testing for this study was performed in 
a different animal facility to those used in the previous chapters, which may have impacted on the 
validity of the test.  
 
Myelin is comprised largely of cholesterol and sphingolipids, which are lipids based on the 
ceramide structure [157, 158]. Interestingly, we did not observe a reduction of myelin 
sphingolipids in female SK2Δ mice, instead observing significantly increased levels of 
sphingolipids with a sphingadiene (d18:2) base backbone. The increased levels 18:2 sphingosine, 
ceramides, SM, GalCer, and ST in SK2 deficient female mice (Table 4.3) has been confirmed in 
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other cohorts of SK2Δ mice by our lab (unpublished). Common sphingolipids are based on a d18:1 
sphingosine backbone. Less common lipids with a d18:2 sphingadiene base backbone are not 
usually assayed in lipidomic analyses, but have recently been incorporated in our lab’s methods. 
These lipids contain an additional double bond at the C14-C15 position of the sphingoid base 
backbone, and are predominantly found in soybean and wheat [316]. Sphingadienes are not 
thought to be produced in appreciable amounts in humans [317-320].  
 
SK2 catalyses the penultimate step in the catabolism of sphingolipids in endosomes and 
lysosomes, producing the signalling lipid S1P that is a substrate for irreversible sphingolipid 
degradation by S1P lyase [176] (Figure 1.3). Thus, the accumulation of sphingadiene lipids in 
SK2Δ mice may be a consequence of inefficient degradation of these lipids via SK2 and S1P lyase 
in the brain, particularly given that SK2 is the dominant sphingosine kinase isoform in the brain. 
In the absence of functional SK2, SK1 alone may be insufficient for catabolic processing of the 
more complex sphingadiene base structure. This is supported by a study showing that 
sphingadienes accumulate markedly in flies lacking the drosophila S1P lyase homologue Sply 
[317]. Ongoing, unpublished work in our laboratory has confirmed that sphingadienes are 
degraded more slowly than sphingosine-based lipids, and the absence of SK2 therefore appears to 
block the catabolism of these sphingadiene lipids in the brain. 
 
The sphingolipids GalCer and ST are essential for the structural and functional integrity of myelin 
[184, 185]. At present it is unknown whether the balance between sphingosine-based and 
sphingadiene-based myelin sphingolipids is important in maintaining myelin integrity, and 
whether an accumulation of 18:2 lipids produces structural defects in myelin over time. The 
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additional double bond in sphingadiene lipids reduces their hydrophobicity and could introduce a 
bend in the otherwise straight lipid acyl chain that is essential to tight packing of myelin [158]. It 
is therefore possible that loss of myelin integrity with increasing age in male SK2Δ mice is related 
to sphingadiene accumulation. On the other hand, we observed significant sphingadiene lipid 
accumulation without myelin loss in the female mice used for this study, suggesting that the two 
phenotypes are not necessarily coupled. 
 
Dienes in ceramides are linked to cytotoxicity. Stuckhoff and colleauges reported that the 
additional trans double bond at C6-7 in ceramides confers greater cytotoxicity in breast cancer cell 
lines [321]. The first double bond (C4-C5) is necessary for the apoptotic effect of ceramides, as 
dihydroceramides, which have no double bond in their sphingoid base backbone, are not pro-
apoptotic [322-324]. Sphingadienes have been reported to prevent intestinal tumorigenesis in 
mouse models of colon cancer, and induce colon cancer cell death in vitro by acting through 
inhibition of the Akt pathway to induce autophagy and apoptosis [317].  SK2 inhibition has also 
been reported to inhibit Akt/PI3K signalling and promote autophagy in cancer cells [325-327]. It 
is possible that SK2 inhibition increases sphingadiene lipid levels which act on the Akt pathway 
to influence autophagic responses, and this could explain the enhanced sensitivity of 
oligodendrocytes to amyloid beta (chapter 3). However this is highly speculative at this point and 
requires further investigation. In general, there is very little known about the physiological and 
pathological effects of sphingadiene lipids.  
 
Previous studies have reported elevated ceramide at the earliest clinical stage of AD relative to 
controls [198, 200]. There are no reports on 18:2 sphingadiene ceramides in the context of AD. 
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Given our prior demonstration of reduced SK2 activity in AD [221], further research is also 
required to investigate whether early detection of sphingolipid changes, including accumulation of 
sphingadiene lipids, could be used as biomarkers of neurodegeneration and AD. 
 
Peripheral lymphopenia was observed in the Siponimod treated mice, as expected. This is a 
consequence of functional S1PR1 antagonism [275], indicating that Siponimod was effectively 
absorbed (Figure 4.2). As we have yet to develop an assay for A-971432 we could not report on 
A-971432 absorption. However, the flow cytometry data did reveal an overall decrease in the 
percentage of live CD45+ cells. Interestingly, treatment of SK2Δ mice with A-971432 alleviated 
the increased sphingadiene lipid levels in SK2Δ mice. SK2 presumably catalyses sphingadiene 1-
phosphate synthesis from sphingadiene, and the reductions of sphingadiene-1-phosphate in SK2Δ 
mice were also less prominent in the A-971432 treatment group. A-971432 is reported as a highly 
specific agonist of the oligodendrocyte-specific S1PR5 receptor [280]. We therefore speculate that 
A-971432 normalises sphingadiene lipid levels through S1PR5 agonism. If we assume that 
sphingadiene accumulation in SK2Δ mice is attributed to inefficient catabolism of these lipids, this 
would imply a significant role for S1PR5 in sphingolipid internalisation into endosomes and/or 
catabolism in late endosomes and lysosomes. This is an important topic for future investigation. 
 
Suprisingly, loss of myelin lipids and reduced myelin protein expression observed in the male mice 
were not identified in the female cohort in this study. Unfortunately, this meant that the S1PR1/5 
agonist treatment testing for the reversal of demyelination in female SK2Δ mice was redundant. It 
is unclear why the female cohort differed from the male mice so drastically. Age can most likely 
be ruled out as a major factor, since the 8 month old male SK2Δ mice from chapter 3 revealed a 
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clear trend reduction in MBP, PLP, and MOG, as well as the myelin lipids ST, SM and GalCer. A 
possible explanation for the marked difference in myelin loss between females and males could be 
associated with sex hormones. Oestrogen has been reported to exhibit neuroprotective effects and 
is thought to play a role in myelination. Interestingly, oestrogen receptors are expressed in 
oligodendrocytes, neurons, and other resident cells in the CNS [328]. The neuroprotective effects 
of oestrogen are thought to be linked to their capability to stimulate synaptogenesis by inducing 
neurotrophic factors, and protecting against neuron and oligodendrocyte apoptosis by inhibiting 
excitotoxicity [329]. Oestrogen treatment has been reported to protect against demyelination and 
induce remyelination in the corpus callosum of a mouse model of multiple sclerosis, and in 
ovariectomised wild-type mice treated with cuprizone [330-332]. A study by Luo and colleagues 
also revealed that oestrogen replacement therapy on ovariectomised rats significantly increased 
the density of myelinated fibres and the total volume of myelin sheaths in white matter, which may 
be contributing to improved spatial learning and memory [333]. Moreover, post-menopausal 
supplementation of oestrogen was associated with decreased white matter lesions and increased 
white matter volumes in humans [334, 335]. The female mice used in this study should have 
reached, or have been close to, reproductive senescence, which occurs between 9-12 months of 
age. However, changes in ovarian hormones varies between colonies and is not consistent. It 
should be noted that studies have also reported on the promyelinating effects of testosterone [332, 
336]. In summary, further investigation of myelin loss in female and male SK2Δ mice at different 
ages, particularly in females aged > 12 months, is needed to clearly describe the difference in age-
related myelin deficits between males and females, and the relationship of this difference to sex 
hormones.       
 
Chapter 4 Do S1P receptor agonists reverse hypomyelination in SK2 knockout mice? 
112 
 
4.6 Conclusion 
Preliminary data for this study, and data from chapter 3, revealed reductions in myelin lipid and 
protein content in aged male SK2Δ mice, associated with myelin thinning observed using electron 
microscopy. The electron microscopy data suggest that there is an age-dependent myelin 
deterioration phenotype in these mice. Strangely, we did not identify any deficits in myelin protein 
expression or decline in 18:1 base prototypical myelin lipids (GalCer and ST) in female SK2Δ 
mice. Hormonal differences between sexes could provide a possible explanation as to why myelin 
lipid and protein deficits are only observed in males. However, this will require further 
investigation as both oestrogen and testosterone have been reported to promote myelination. The 
observation of elevated sphingadiene lipids in the female SK2Δ mice has now been confirmed in 
male SK2Δ mice (unpublished data). Further studies are needed to establish the functional 
significance of these changes, including whether they affect myelin structure. It is possible that 
SK1 cannot efficiently process the diene lipids in these knockout mice, resulting in accumulation 
of undegraded 18:2 lipids. As myelin deficits were not identified in this female cohort, it would 
therefore be beneficial to attempt S1P agonist treatment on male SK2Δ mice > 12 months of age, 
where myelin deficits have now been established. In this regard, our laboratory has now 
commenced a similar study using the demyelinating agent cuprizone in young mice [337]. This 
will allow us to better understand the role of SK2 and S1PR5 in oligodendrocyte protection and 
myelination, and whether demyelination can be rescued through S1P receptor agonism.
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Chapter 5 Conclusion and Final Remarks 
 
SK1 and SK2 mediate the phosphorylation of sphingosine to form S1P, and SK2 is the principal 
isoform in the brain, where its activity and mRNA levels are higher compared to SK1 [219, 221]. 
SK2 is expressed in all human tissues and cell types to some degree, with the highest expression 
in kidney and liver [338]. The biological effects of SK2 differ depending on its subcellular 
localisation. For instance, when localised to the nucleus SK2 inhibits HDAC, and prevents DNA 
synthesis [225, 227]. SK2 localisation to the mitochondria promotes apoptosis and mediates 
growth suppression through bcl-2 homologous antagonist killer (Bak) and bcl-2-like protein 4 
(Bax) [339, 340]. In response to stress conditions, SK2 localises to the ER, generating S1P through 
the ‘salvage’ pathway and producing pro-apoptotic ceramide [228]. However, SK2 is clearly 
necessary for protection against cell atrophy in cerebral ischaemia [240]. Our group has previously 
reported loss of S1P and SK2 activity with increasing Braak stage pathology in AD [221], as well 
as an inverse correlation between age and S1P levels in the hippocampus of females leading us to 
speculate that loss of S1P is a sensitising influence for AD [241].  
 
In this thesis we revealed that SK2 is the predominant sphingosine kinase isoform in the CNS, by 
showing that it accounts for ~85% of S1P synthesis in the brain. Behavioural studies in 12 month 
old male (chapter 2) and 10 month female (chapter 4) SK2Δ mice identified increased freezing 
response, particularly in the fear conditioning paradigm. As this occurred prior to aversive 
stimulus, it is indicative of higher general anxiety in this strain [341, 342]. Behavioural studies in 
12 month old male (chapter 2) and 10 month female (chapter 4) SK2Δ mice identified increased 
freezing response, particularly in the fear conditioning paradigm. As this occurred prior to 
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aversive stimulus, it is indicative of higher general anxiety in this strain [341, 342]. We revealed a 
severe hypomyelination phenotype in male mice lacking SK2, and establish SK2 as an important 
mediator of oligodendrocyte survival in vivo. We demonstrated that SK2 plays a major role in Aβ 
production from APP in vivo, whilst also showing that the absence of SK2 sensitises to loss of 
hippocampal volume and oligodendrocytes in a mouse model of Aβ overproduction. Finally, we 
have identified a significant increase of 18:2 base sphingadiene lipids in both male and female 
SK2Δ mice, implying an important role for SK2 in catabolism of complex sphingolipids. 
 
Chapters 2 and 3 only examined behavioural and myelin deficits in male mice lacking SK2, which 
identifies a limitation of these studies. Considering the severe myelin and impaired memory 
phenotype observed in the male J20.SK2Δ mice, it would be interesting to observe the effect of 
this genotype in female mice given the differing myelin pathology between the sexes. In chapter 
4, we confirmed the abnormal anxiety phenotype in female SK2del mice, which also showed 
heightened levels of freezing in the fear conditioning paradigm. Thus, we confirmed that both male 
and female mice exhibit an anxiety phenotype, but the myelination deficit is limited to male mice. 
Whether SK2 deficiency also sensitizes female mice to demyelination in the presence of an 
amyloidogeneic transgene or other demyelinating insult remains to be determined.  
 
It would be interesting in future work to determine if the anxiety phenotype of SK2Δ mice is 
associated with myelin deficiencies. Several single nucleotide polymorphisms in myelin genes 
predominantly expressed in oligodendrocytes have been identified as risk factors of schizophrenia 
[343]. These myelin genes are also heavily associated with performance and memory speed due to 
myelin loss [344]. Perturbed myelin integrity has also been reported to severely reduce cognitive 
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function in individuals with MS, where myelin degradation directly correlates with cognitive 
decline [345, 346]. However, the anxiety phenotype was observed in female SK2Δ mice despite 
the lack of an obvious hypomyelination phenotype. One approach to resolving these questions may 
be through creation of oligodendrocyte-specific and neuron-specific SK2 knockout lines. If 
specific deletion of SK2 in oligodendrocytes reproduces the hypomyelination phenotype, this will 
allow us to dissect oligodendrocyte- and myelin-specific roles of SK2 from its role in other neural 
cell types, including neurons. 
 
Research in this thesis did not delve deeply into the role of S1P receptors, with the exception of 
the final chapter where S1PR1 and 5 agonists were administered in an attempt to rescue the effect 
of hypomyelination in female mice lacking SK2. Unfortunately, hypomyelination was only 
observed in male mice, which may potentially be attributed to the differences of sex hormones and 
their effect on myelination. To gain a stronger understanding of the role of SK2 and S1P receptors 
in protecting oligodendrocytes from stress and promoting myelination, future studies in our lab 
will employ the cuprizone model of actue demyelination followed by spontaneous remyelination 
[347]. Further investigations are needed to determine if the role for SK2 in myelination is related 
to S1P receptor signalling deficits, or to deficits in intracellular SK2 functions. 
 
Our study has identified a paradoxical function of SK2-generated S1P in the context of AD. SK2-
generated S1P has previously been reported to regulate BACE1 activity [244], which plays a role 
in both amyloidogenic and non-amyloidogenic pathways. The non-amyloidogenic pathway 
involves cleavage of NRG-1, which in its cleaved, active form is required for myelination [34]. 
BACE1 is also involved in the first step of Aβ production via proteolysis of APP [28]. This thesis 
revealed that loss of SK2 sensitised to a neurodegenerative phenotype, despite reduced Aβ content 
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in male J20 mice. Reduced Aβ content in these SK2Δ J20 mice also resulted in drastic 
improvements in epileptiform activity and cross-frequency coupling measured by hippocampal 
EEG. However, loss of hippocampal volume, myelin proteins, and oligodendrocytes, as well as 
spatial and recognition memory deficits, were worse in J20 mice lacking SK2, indicating that S1P 
generated by SK2 is neuroprotective in the context of familial AD mutations and Aβ 
overproduction. In future studies it would be highly informative to cross SK2 or SK1 deficient 
mice with the newer familial AD mouse models bearing knock-in mutations in the APP gene [348]. 
 
Furthermore, findings from this thesis highlight a likely new role for SK2 activity in endosomal 
lipid metabolism, with implications for AD pathogenesis. Dysregulated cholesterol trafficking 
affects the development of key pathological features of AD, which are hyperphosphorylated tau 
and Aβ [172, 349, 350]. Inhibition of the endosomal cholesterol transporter, NPC1, inhibited 
phosphorylation of sphingosine in both glial and neuronal cells. This suggests that S1P is mostly 
produced by sphingosine in acidic endosomes, where it may influence BACE1 processing of APP. 
BACE1 cleavage of APP also occurs in endosomes [351]. We can therefore speculate that 
recruitment of SK2 to late endosomes is impaired in AD due to lipid metabolic deficits such as 
impaired cholesterol export from these organelles. This prevents SK2 from activating BACE1. 
The inability of SK2 to access late endosomes and lysosomes may also affect sphingadiene lipid 
catabolism in those organelles, leading to robust accumulation of sphingadiene lipids. In addition 
to our lab establishing the molecular basis for sphingadiene accumulation in SK2Δ mice, we 
should measure sphingadiene ceramides in AD to determine if they are a marker of AD. 
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Results from this thesis identified contradicting myelin pathology between male and female mice 
lacking SK2. This lends support to the importance of sex hormones in regulating oligodendrocyte 
survival and myelination with ageing. The mechanism behind this will require further 
investigation, including a more thorough examination of myelination in both younger and older 
SK2Δ mice of both sexes. Our results from this study revealed an increase of 18:2 base ceramides, 
GalCer, SM and ST in both male and female SK2Δ mice. We speculate that the catabolism of these 
sphingadiene-containing lipids is inherently slower than that of sphingosine-containing lipids. As 
sphingolipid catabolism requires sphingosine kinase activity, and our studies confirmed that SK2 
is the dominant isoform catalysing S1P synthesis in the brain, it seems probable that the absence 
of SK2 creates a bottleneck that results in accumulation of sphingadiene-containing lipids. Again, 
a thorough examination of accumulation of these lipids over time in SK2Δ mice is needed to 
determine if the sphingadiene accumulation is an age-dependent phenotype. 
 
In conclusion, this thesis has revealed a novel role for SK2 in regulating oligodendrocyte survival 
and myelination, and confirms its role as an endogenous mediator of Aβ formation from APP 
[289]. Results from this thesis strongly support the hypothesis that loss of SK2 sensitises to 
neurodegeneration. We speculate that the decline of S1P and other neuroprotective lipid metabolic 
enzymes may play a greater role in promoting neurodegeneration in AD than the absolute levels 
of Aβ. Our findings urge further consideration of the role of age-related oligodendrocyte attrition 
as a diver of neurodegeneration. Our results also support S1P receptors as potential pharmaceutical 
targets in neurodegenerative conditions, however this requires verification in future studies, as it 
was not determined in this thesis whether the adverse effects of SK2 deficiency were mediated 
through loss of S1P receptor signalling. 
References 
118 
 
References 
1. Association, A.s., 2019 Alzheimer’s disease facts and figures. Alzheimers Dement, 2019. 
15(3): p. 321-87. 
2. Duong, S., T. Patel, and F. Chang, Dementia: What pharmacists need to know. Canadian 
Pharmacists Journal/Revue des Pharmaciens du Canada, 2017. 150(2): p. 118-129. 
3. Association, A.s., 2016 Alzheimer's disease facts and figures. Alzheimers Dement, 2016. 
12(4): p. 459-509. 
4. Dharmarajan, T.S. and S.G. Gunturu, Alzheimer's disease: a healthcare burden of 
epidemic proportion. Am Health Drug Benefits, 2009. 2(1): p. 39-47. 
5. Lane, C.A., J. Hardy, and J.M. Schott, Alzheimer's disease. Eur J Neurol, 2018. 25(1): p. 
59-70. 
6. Jost, B.C. and G.T. Grossberg, The natural history of Alzheimer's disease: a brain bank 
study. J Am Geriatr Soc, 1995. 43(11): p. 1248-55. 
7. Guerreiro, R. and J. Bras, The age factor in Alzheimer's disease. Genome Med, 2015. 7: 
p. 106. 
8. Zhu, X.C., et al., Rate of early onset Alzheimer's disease: a systematic review and meta-
analysis. Ann Transl Med, 2015. 3(3): p. 38. 
9. Holtzman, D.M., J.C. Morris, and A.M. Goate, Alzheimer's disease: the challenge of the 
second century. Sci Transl Med, 2011. 3(77): p. 77sr1. 
10. He, X., et al., Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol 
Aging, 2010. 31(3): p. 398-408. 
11. Wen, Q., et al., White matter alterations in early-stage Alzheimer's disease: A tract-
specific study. Alzheimers Dement (Amst), 2019. 11: p. 576-587. 
References 
119 
 
12. Hickman, S.E., E.K. Allison, and J. El Khoury, Microglial dysfunction and defective 
beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci, 2008. 
28(33): p. 8354-60. 
13. Scheff, S.W., et al., Synaptic alterations in CA1 in mild Alzheimer disease and mild 
cognitive impairment. Neurology, 2007. 68(18): p. 1501-8. 
14. Kaiser, N.C., et al., Neuropsychological and neuroimaging markers in early versus late-
onset Alzheimer's disease. Am J Alzheimers Dis Other Demen, 2012. 27(7): p. 520-9. 
15. Moller, C., et al., Different patterns of gray matter atrophy in early- and late-onset 
Alzheimer's disease. Neurobiol Aging, 2013. 34(8): p. 2014-22. 
16. Reisberg, B., et al., Memantine in moderate-to-severe Alzheimer's disease. New England 
Journal of Medicine, 2003. 348(14): p. 1333-1341. 
17. Cui, J., et al., Targeting the γ-/β-secretase interaction reduces β-amyloid generation and 
ameliorates Alzheimer’s disease-related pathogenesis. Cell Discovery, 2015. 1(1): p. 
15021. 
18. Salloway, S., et al., Amyloid positron emission tomography and cerebrospinal fluid 
results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, 
randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Alzheimers 
Res Ther, 2018. 10(1): p. 96. 
19. Salloway, S., et al., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's 
disease. N Engl J Med, 2014. 370(4): p. 322-33. 
20. Hardy, J.A. and G.A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis. 
Science, 1992. 256(5054): p. 184-5. 
References 
120 
 
21. Alzheimer’s_Association, 2019 Alzheimer’s disease facts and figures. Alzheimers 
Dement, 2019. 15: p. 321-387. 
22. Moran, J.A., Alzheimer's Disease & Down Syndrome. National Down Syndrome Society, 
2017: p. 1-55. 
23. Aizenstein, H.J., et al., Frequent amyloid deposition without significant cognitive 
impairment among the elderly. Arch Neurol, 2008. 65(11): p. 1509-17. 
24. Wilkins, H.M. and R.H. Swerdlow, Amyloid precursor protein processing and 
bioenergetics. Brain Res Bull, 2017. 133: p. 71-79. 
25. Grimm, M.O., et al., APP Function and Lipids: A Bidirectional Link. Front Mol 
Neurosci, 2017. 10: p. 63. 
26. Kimberly, W.T., et al., Gamma-secretase is a membrane protein complex comprised of 
presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A, 2003. 100(11): p. 
6382-7. 
27. Thinakaran, G. and E.H. Koo, Amyloid precursor protein trafficking, processing, and 
function. J Biol Chem, 2008. 283(44): p. 29615-9. 
28. Vassar, R., BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers 
Res Ther, 2014. 6(9): p. 89. 
29. Yang, A., et al., Attenuation of beta-Amyloid Toxicity In Vitro and In Vivo by Accelerated 
Aggregation. Neurosci Bull, 2017. 33(4): p. 405-412. 
30. Grutzendler, J., et al., Various dendritic abnormalities are associated with fibrillar 
amyloid deposits in Alzheimer's disease. Ann N Y Acad Sci, 2007. 1097: p. 30-9. 
31. Zhao, R., et al., Microglia limit the expansion of beta-amyloid plaques in a mouse model 
of Alzheimer's disease. Mol Neurodegener, 2017. 12(1): p. 47. 
References 
121 
 
32. Holler, C.J., et al., BACE2 expression increases in human neurodegenerative disease. 
Am J Pathol, 2012. 180(1): p. 337-50. 
33. Bennett, B.D., et al., Expression analysis of BACE2 in brain and peripheral tissues. J 
Biol Chem, 2000. 275(27): p. 20647-51. 
34. Luo, X., et al., Cleavage of neuregulin-1 by BACE1 or ADAM10 protein produces 
differential effects on myelination. J Biol Chem, 2011. 286(27): p. 23967-74. 
35. Zhao, J., et al., Beta-site amyloid precursor protein cleaving enzyme 1 levels become 
elevated in neurons around amyloid plaques: implications for Alzheimer's disease 
pathogenesis. J Neurosci : the official journal of the Society for Neuroscience, 2007. 
27(14): p. 3639-3649. 
36. Citron, M., et al., Mutation of the beta-amyloid precursor protein in familial Alzheimer's 
disease increases beta-protein production. Nature, 1992. 360(6405): p. 672-4. 
37. Moussa, C.E., Beta-secretase inhibitors in phase I and phase II clinical trials for 
Alzheimer's disease. Expert Opin Investig Drugs, 2017. 26(10): p. 1131-1136. 
38. Dehmelt, L. and S. Halpain, The MAP2/Tau family of microtubule-associated proteins. 
Genome Biol, 2005. 6(1): p. 204. 
39. Ittner, L.M., et al., Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's 
disease mouse models. Cell, 2010. 142(3): p. 387-97. 
40. Ittner, A., et al., Site-specific phosphorylation of tau inhibits amyloid-β toxicity in 
Alzheimer’s mice. Science, 2016. 354(6314): p. 904-908. 
41. Götz, J., A. Ittner, and L.M. Ittner, Tau-targeted treatment strategies in Alzheimer's 
disease. Br J Pharmacol, 2012. 165(5): p. 1246-59. 
42. Morris, M., et al., The many faces of tau. Neuron, 2011. 70(3): p. 410-26. 
References 
122 
 
43. Al-Bassam, J., et al., MAP2 and tau bind longitudinally along the outer ridges of 
microtubule protofilaments. The Journal of Cell Biology, 2002. 157(7): p. 1187-1196. 
44. Lee, V.M., M. Goedert, and J.Q. Trojanowski, Neurodegenerative tauopathies. Annu Rev 
Neurosci, 2001. 24: p. 1121-59. 
45. Goedert, M., et al., Multiple isoforms of human microtubule-associated protein tau: 
sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron, 
1989. 3(4): p. 519-26. 
46. Kovacs, G.G., Tauopathies. Handb Clin Neurol, 2017. 145: p. 355-368. 
47. Leyns, C.E.G. and D.M. Holtzman, Glial contributions to neurodegeneration in 
tauopathies. Mol Neurodegener, 2017. 12(1): p. 50. 
48. Braak, H. and E. Braak, Staging of Alzheimer's disease-related neurofibrillary changes. 
Neurobiol Aging, 1995. 16(3): p. 271-8; discussion 278-84. 
49. Hyman, B.T., et al., National Institute on Aging-Alzheimer's Association guidelines for 
the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement, 2012. 8(1): 
p. 1-13. 
50. Hoover, B.R., et al., Tau mislocalization to dendritic spines mediates synaptic 
dysfunction independently of neurodegeneration. Neuron, 2010. 68(6): p. 1067-81. 
51. Echeverry, M., et al., Differences and Implications of Animal Models for the Study of 
Alzheimer's Disease. 2018. p. 1-40. 
52. Heneka, M.T., et al., Neuroinflammation in Alzheimer's disease. Lancet Neurol, 2015. 
14(4): p. 388-405. 
53. Sofroniew, M.V. and H.V. Vinters, Astrocytes: biology and pathology. Acta 
Neuropathologica, 2010. 119(1): p. 7-35. 
References 
123 
 
54. Fellin, T., et al., Neuronal synchrony mediated by astrocytic glutamate through activation 
of extrasynaptic NMDA receptors. Neuron, 2004. 43(5): p. 729-43. 
55. Navarrete, M., et al., Astrocytes mediate in vivo cholinergic-induced synaptic plasticity. 
PLoS Biol, 2012. 10(2): p. e1001259. 
56. Vargas, M.R., et al., Nrf2 Activation in Astrocytes Protects against Neurodegeneration in 
Mouse Models of Familial Amyotrophic Lateral Sclerosis. J Neurosci, 2008. 28(50): p. 
13574-13581. 
57. Chen, Y., et al., Astrocytes protect neurons from nitric oxide toxicity by a glutathione-
dependent mechanism. J Neurochem, 2001. 77(6): p. 1601-10. 
58. Shih, A.Y., et al., Coordinate regulation of glutathione biosynthesis and release by Nrf2-
expressing glia potently protects neurons from oxidative stress. J Neurosci, 2003. 23(8): 
p. 3394-406. 
59. Burda, J.E. and M.V. Sofroniew, Reactive gliosis and the multicellular response to CNS 
damage and disease. Neuron, 2014. 81(2): p. 229-48. 
60. Kamphuis, W., et al., GFAP isoforms in adult mouse brain with a focus on neurogenic 
astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One, 
2012. 7(8): p. e42823. 
61. Jesse, S., et al., Glial fibrillary acidic protein and protein S-100B: different concentration 
pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and 
Creutzfeldt-Jakob disease. J Alzheimers Dis, 2009. 17(3): p. 541-51. 
62. Griffin, W.S., et al., Brain interleukin 1 and S-100 immunoreactivity are elevated in 
Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A, 1989. 86(19): p. 
7611-5. 
References 
124 
 
63. Meda, L., P. Baron, and G. Scarlato, Glial activation in Alzheimer's disease: the role of 
Abeta and its associated proteins. Neurobiol Aging, 2001. 22(6): p. 885-93. 
64. Verkhratsky, A. and V. Parpura, Recent advances in (patho)physiology of astroglia. Acta 
Pharmacol Sin, 2010. 31(9): p. 1044-54. 
65. Voskuhl, R.R., et al., Reactive astrocytes form scar-like perivascular barriers to 
leukocytes during adaptive immune inflammation of the CNS. J Neurosci, 2009. 29(37): 
p. 11511-22. 
66. Wisniewski, H.M. and J. Wegiel, Spatial relationships between astrocytes and classical 
plaque components. Neurobiol Aging, 1991. 12(5): p. 593-600. 
67. Koistinaho, M., et al., Apolipoprotein E promotes astrocyte colocalization and 
degradation of deposited amyloid-beta peptides. Nat Med, 2004. 10(7): p. 719-26. 
68. Wyss-Coray, T., et al., Prominent neurodegeneration and increased plaque formation in 
complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A, 2002. 99(16): p. 
10837-42. 
69. Cacabelos, R., et al., Brain interleukin-1 beta in Alzheimer's disease and vascular 
dementia. Methods and findings in experimental and clinical pharmacology, 1994. 16(2): 
p. 141-151. 
70. Cavanagh, C., et al., Inhibiting tumor necrosis factor-α before amyloidosis prevents 
synaptic deficits in an Alzheimer's disease model. Neurobiology of aging, 2016. 47: p. 
41-49. 
71. Browne, T.C., et al., IFN-γ Production by Amyloid β–Specific Th1 Cells Promotes 
Microglial Activation and Increases Plaque Burden in a Mouse Model of Alzheimer’s 
Disease. The Journal of Immunology, 2013. 190(5): p. 2241-2251. 
References 
125 
 
72. Marchetti, B., et al., Glucocorticoid receptor–nitric oxide crosstalk and vulnerability to 
experimental Parkinsonism: pivotal role for glia–neuron interactions. Brain Research 
Reviews, 2005. 48(2): p. 302-321. 
73. Abdullah, L., et al., APOE ε4 specific imbalance of arachidonic acid and 
docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild 
Cognitive Impairment/Alzheimer's Disease. Aging (Albany NY), 2017. 9(3): p. 964-985. 
74. Tarkowski, E., et al., Intrathecal inflammation precedes development of Alzheimer's 
disease. J Neurol Neurosurg Psychiatry, 2003. 74(9): p. 1200-5. 
75. Belkhelfa, M., et al., IFN-gamma and TNF-alpha are involved during Alzheimer disease 
progression and correlate with nitric oxide production: a study in Algerian patients. J 
Interferon Cytokine Res, 2014. 34(11): p. 839-47. 
76. Buffo, A., C. Rolando, and S. Ceruti, Astrocytes in the damaged brain: molecular and 
cellular insights into their reactive response and healing potential. Biochem Pharmacol, 
2010. 79(2): p. 77-89. 
77. Epperly, T., M.A. Dunay, and J.L. Boice, Alzheimer Disease: Pharmacologic and 
Nonpharmacologic Therapies for Cognitive and Functional Symptoms. Am Fam 
Physician, 2017. 95(12): p. 771-778. 
78. Small, G.W. and S. Greenfield, Current and Future Treatments for Alzheimer Disease. 
Am J Geriatr Psychiatry, 2015. 23(11): p. 1101-5. 
79. Yiannopoulou, K.G. and S.G. Papageorgiou, Current and future treatments for 
Alzheimer's disease. Ther Adv Neurol Disord, 2013. 6(1): p. 19-33. 
80. Birks, J., Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev, 
2006(1): p. Cd005593. 
References 
126 
 
81. Raschetti, R., et al., Cholinesterase inhibitors in mild cognitive impairment: a systematic 
review of randomised trials. PLoS Med, 2007. 4(11): p. e338. 
82. McShane, R., A. Areosa Sastre, and N. Minakaran, Memantine for dementia. Cochrane 
Database Syst Rev, 2006(2): p. Cd003154. 
83. Tariot, P.N., et al., Memantine Treatment in Patients With Moderate to Severe Alzheimer 
Disease Already Receiving DonepezilA Randomized Controlled Trial. JAMA, 2004. 
291(3): p. 317-324. 
84. Cummings, J.L., T. Morstorf, and K. Zhong, Alzheimer's disease drug-development 
pipeline: few candidates, frequent failures. Alzheimers Res Ther, 2014. 6(4): p. 37. 
85. Briggs, R., S.P. Kennelly, and D. O'Neill, Drug treatments in Alzheimer's disease. Clin 
Med (Lond), 2016. 16(3): p. 247-53. 
86. Farlow, M.R., M.L. Miller, and V. Pejovic, Treatment options in Alzheimer's disease: 
maximizing benefit, managing expectations. Dement Geriatr Cogn Disord, 2008. 25(5): p. 
408-22. 
87. Aisen, P.S., et al., Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, 
double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci, 
2011. 7(1): p. 102-11. 
88. Jaturapatporn, D., et al., Aspirin, steroidal and non-steroidal anti-inflammatory drugs for 
the treatment of Alzheimer's disease. Cochrane Database Syst Rev, 2012(2): p. 
Cd006378. 
89. Porrini, V., et al., CHF5074 (CSP-1103) induces microglia alternative activation in 
plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. 
Neuroscience, 2015. 302: p. 112-20. 
References 
127 
 
90. Vandenberghe, R., et al., Bapineuzumab for mild to moderate Alzheimer's disease in two 
global, randomized, phase 3 trials. Alzheimers Res Ther, 2016. 8(1): p. 18. 
91. Relkin, N.R., et al., A phase 3 trial of IV immunoglobulin for Alzheimer disease. 
Neurology, 2017. 88(18): p. 1768-1775. 
92. Bulic, B., et al., Chemical Biology, Molecular Mechanism and Clinical Perspective of 
gamma-Secretase Modulators in Alzheimer's Disease. Curr Neuropharmacol, 2011. 9(4): 
p. 598-622. 
93. Green, R.C., et al., Effect of tarenflurbil on cognitive decline and activities of daily living 
in patients with mild Alzheimer disease: a randomized controlled trial. Jama, 2009. 
302(23): p. 2557-64. 
94. Tayeb, H.O., et al., Bapineuzumab and solanezumab for Alzheimer's disease: is the 
'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther, 2013. 13(7): p. 1075-84. 
95. Sperling, R.A., et al., Toward defining the preclinical stages of Alzheimer's disease: 
recommendations from the National Institute on Aging-Alzheimer's Association 
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011. 
7(3): p. 280-92. 
96. Jarmolowicz, A.I., H.-Y. Chen, and P.K. Panegyres, The Patterns of Inheritance in Early-
Onset Dementia:Alzheimer’s Disease and Frontotemporal Dementia. American Journal 
of Alzheimer's Disease & Other Dementias®, 2015. 30(3): p. 299-306. 
97. Ringman, J.M., et al., Proteomic changes in cerebrospinal fluid of presymptomatic and 
affected persons carrying familial Alzheimer disease mutations. Arch Neurol, 2012. 
69(1): p. 96-104. 
References 
128 
 
98. Jonsson, T., et al., A mutation in APP protects against Alzheimer's disease and age-
related cognitive decline. Nature, 2012. 488(7409): p. 96-9. 
99. Elshourbagy, N.A., et al., Apolipoprotein E mRNA is abundant in the brain and adrenals, 
as well as in the liver, and is present in other peripheral tissues of rats and marmosets. 
Proc Natl Acad Sci U S A, 1985. 82(1): p. 203-7. 
100. Carlin, C., et al., Involvement of apolipoprotein E in multiple sclerosis: absence of 
remyelination associated with possession of the APOE epsilon2 allele. J Neuropathol Exp 
Neurol, 2000. 59(5): p. 361-7. 
101. Boyles, J.K., et al., Apolipoprotein E associated with astrocytic glia of the central 
nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin 
Invest, 1985. 76(4): p. 1501-13. 
102. Grehan, S., E. Tse, and J.M. Taylor, Two Distal Downstream Enhancers Direct 
Expression of the Human Apolipoprotein E Gene to Astrocytes in the Brain. J Neurosci, 
2001. 21(3): p. 812-822. 
103. Keren-Shaul, H., et al., A Unique Microglia Type Associated with Restricting 
Development of Alzheimer's Disease. Cell, 2017. 169(7): p. 1276-1290.e17. 
104. Boschert, U., et al., Apolipoprotein E expression by neurons surviving excitotoxic stress. 
Neurobiol Dis, 1999. 6(6): p. 508-14. 
105. Aoki, K., et al., Increased expression of neuronal apolipoprotein E in human brain with 
cerebral infarction. Stroke, 2003. 34(4): p. 875-80. 
106. Rebeck, G.W., The role of APOE on lipid homeostasis and inflammation in normal 
brains. J Lipid Res, 2017. 58(8): p. 1493-1499. 
References 
129 
 
107. Misiak, M.M., et al., Apo E4 alleles and impaired olfaction as predictors of Alzheimer's 
disease. Clin Exp Psychol, 2017. 3(4). 
108. Harris, F.M., et al., Astroglial regulation of apolipoprotein E expression in neuronal 
cells. Implications for Alzheimer's disease. J Biol Chem, 2004. 279(5): p. 3862-8. 
109. Farrer, L.A., et al., Effects of age, sex, and ethnicity on the association between 
apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer 
Disease Meta Analysis Consortium. Jama, 1997. 278(16): p. 1349-56. 
110. Corder, E.H., et al., Gene dose of apolipoprotein E type 4 allele and the risk of 
Alzheimer's disease in late onset families. Science, 1993. 261(5123): p. 921-3. 
111. Altmann, A., et al., Sex modifies the APOE-related risk of developing Alzheimer disease. 
Ann Neurol, 2014. 75(4): p. 563-73. 
112. Corder, E.H., et al., Protective effect of apolipoprotein E type 2 allele for late onset 
Alzheimer disease. Nat Genet, 1994. 7(2): p. 180-4. 
113. Lippa, C.F., et al., Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype 
influences pathologic phenotype. Neurology, 1997. 48(2): p. 515-9. 
114. Sen, A., T.J. Nelson, and D.L. Alkon, ApoE isoforms differentially regulates cleavage 
and secretion of BDNF. Mol Brain, 2017. 10(1): p. 19. 
115. Holtzman, D.M., J. Herz, and G. Bu, Apolipoprotein E and apolipoprotein E receptors: 
normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med, 2012. 
2(3): p. a006312. 
116. Castellano, J.M., et al., Human apoE isoforms differentially regulate brain amyloid-beta 
peptide clearance. Sci Transl Med, 2011. 3(89): p. 89ra57. 
References 
130 
 
117. Atagi, Y., et al., Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on 
Myeloid Cells 2 (TREM2). J Biol Chem, 2015. 290(43): p. 26043-50. 
118. Bailey, C.C., L.B. DeVaux, and M. Farzan, The Triggering Receptor Expressed on 
Myeloid Cells 2 Binds Apolipoprotein E. J Biol Chem, 2015. 290(43): p. 26033-42. 
119. Gratuze, M., C.E.G. Leyns, and D.M. Holtzman, New insights into the role of TREM2 in 
Alzheimer’s disease. Molecular Neurodegeneration, 2018. 13(1): p. 66. 
120. Karch, C.M. and A.M. Goate, Alzheimer's disease risk genes and mechanisms of disease 
pathogenesis. Biol Psychiatry, 2015. 77(1): p. 43-51. 
121. Van Cauwenberghe, C., C. Van Broeckhoven, and K. Sleegers, The genetic landscape of 
Alzheimer disease: clinical implications and perspectives. Genetics in Medicine, 2016. 
18(5): p. 421. 
122. Miners, J.S., P. Clarke, and S. Love, Clusterin levels are increased in Alzheimer's disease 
and influence the regional distribution of Abeta. Brain Pathol, 2017. 27(3): p. 305-313. 
123. DeMattos, R.B., et al., Clusterin promotes amyloid plaque formation and is critical for 
neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A, 
2002. 99(16): p. 10843-8. 
124. Misra, A., S.S. Chakrabarti, and I.S. Gambhir, New genetic players in late-onset 
Alzheimer's disease: Findings of genome-wide association studies. Indian J Med Res, 
2018. 148(2): p. 135-144. 
125. Rezazadeh, M., et al., Genetic discoveries and advances in late-onset Alzheimer's 
disease. J Cell Physiol, 2019. 
126. McQuade, A. and M. Blurton-Jones, Microglia in Alzheimer's Disease: Exploring How 
Genetics and Phenotype Influence Risk. J Mol Biol, 2019. 
References 
131 
 
127. Vasquez, J.B., et al., Alzheimer's Disease Genetics and ABCA7 Splicing. J Alzheimers 
Dis, 2017. 59(2): p. 633-641. 
128. Ramirez, L.M., et al., Common variants in ABCA7 and MS4A6A are associated with 
cortical and hippocampal atrophy. Neurobiol Aging, 2016. 39: p. 82-9. 
129. Aikawa, T., M.L. Holm, and T. Kanekiyo, ABCA7 and Pathogenic Pathways of 
Alzheimer's Disease. Brain Sci, 2018. 8(2). 
130. Andrew, R.J., et al., Reduction of the expression of the late-onset Alzheimer's disease 
(AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model. J Biol 
Chem, 2019. 
131. Franzmeier, N., et al., The BIN1 rs744373 SNP is associated with increased tau-PET 
levels and impaired memory. Nature Communications, 2019. 10(1): p. 1766. 
132. Wang, H.F., et al., Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease 
Risk by Altering Neuronal Degeneration. J Alzheimers Dis, 2016. 52(1): p. 179-90. 
133. De Rossi, P., et al., Predominant expression of Alzheimer's disease-associated BIN1 in 
mature oligodendrocytes and localization to white matter tracts. Mol Neurodegener, 
2016. 11(1): p. 59. 
134. Calafate, S., et al., Loss of Bin1 Promotes the Propagation of Tau Pathology. Cell Rep, 
2016. 17(4): p. 931-940. 
135. Zhou, Y., et al., Intracellular clusterin interacts with brain isoforms of the bridging 
integrator 1 and with the microtubule-associated protein Tau in Alzheimer's disease. 
PLoS One, 2014. 9(7): p. e103187. 
References 
132 
 
136. Meunier, B., et al., The membrane-tubulating potential of amphiphysin 2/BIN1 is 
dependent on the microtubule-binding cytoplasmic linker protein 170 (CLIP-170). 
European journal of cell biology, 2009. 88(2): p. 91-102. 
137. Chapuis, J., et al., Increased expression of BIN1 mediates Alzheimer genetic risk by 
modulating tau pathology. Mol Psychiatry, 2013. 18(11): p. 1225-34. 
138. Holler, C.J., et al., Bridging integrator 1 (BIN1) protein expression increases in the 
Alzheimer's disease brain and correlates with neurofibrillary tangle pathology. J 
Alzheimers Dis, 2014. 42(4): p. 1221-7. 
139. De Rossi, P., et al., BIN1 localization is distinct from Tau tangles in Alzheimer's disease. 
Matters (Zur), 2017. 2017. 
140. Miyagawa, T., et al., BIN1 regulates BACE1 intracellular trafficking and amyloid-beta 
production. Hum Mol Genet, 2016. 25(14): p. 2948-2958. 
141. Li, J.T. and Y. Zhang, TREM2 regulates innate immunity in Alzheimer's disease. J 
Neuroinflammation, 2018. 15(1): p. 107. 
142. Sims, R., et al., Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-
mediated innate immunity in Alzheimer's disease. Nat Genet, 2017. 49(9): p. 1373-1384. 
143. Ulrich, J.D., et al., Elucidating the Role of TREM2 in Alzheimer's Disease. Neuron, 2017. 
94(2): p. 237-248. 
144. Takatori, S., et al., Genetic Risk Factors for Alzheimer Disease: Emerging Roles of 
Microglia in Disease Pathomechanisms. Adv Exp Med Biol, 2019. 1118: p. 83-116. 
145. Colonna, M. and Y. Wang, TREM2 variants: new keys to decipher Alzheimer disease 
pathogenesis. Nat Rev Neurosci, 2016. 17(4): p. 201-7. 
References 
133 
 
146. Poliani, P.L., et al., TREM2 sustains microglial expansion during aging and response to 
demyelination. J Clin Invest, 2015. 125(5): p. 2161-70. 
147. Wang, Y., et al., TREM2 lipid sensing sustains the microglial response in an Alzheimer's 
disease model. Cell, 2015. 160(6): p. 1061-71. 
148. Yeh, F.L., et al., TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and 
Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron, 2016. 91(2): p. 328-
40. 
149. Ulland, T.K., et al., TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's 
Disease. Cell, 2017. 170(4): p. 649-663.e13. 
150. Melchior, B., et al., Dual induction of TREM2 and tolerance-related transcript, 
Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for 
Alzheimer's disease. ASN Neuro, 2010. 2(3): p. e00037. 
151. Jonsson, T., et al., Variant of TREM2 associated with the risk of Alzheimer's disease. N 
Engl J Med, 2013. 368(2): p. 107-16. 
152. Gorenjak, V., et al., The polymorphism rs6918289 located in the downstream region of 
the TREM2 gene is associated with TNF-alpha levels and IMT-F. Sci Rep, 2018. 8(1): p. 
7160. 
153. Salzer, J.L. and B. Zalc, Myelination. Curr Biol, 2016. 26(20): p. R971-r975. 
154. Hartline, D.K. and D.R. Colman, Rapid conduction and the evolution of giant axons and 
myelinated fibers. Curr Biol, 2007. 17(1): p. R29-35. 
155. Fields, R.D., A new mechanism of nervous system plasticity: activity-dependent 
myelination. Nature Reviews Neuroscience, 2015. 16(12): p. 756-767. 
References 
134 
 
156. Simons, M. and K.A. Nave, Oligodendrocytes: Myelination and Axonal Support. Cold 
Spring Harb Perspect Biol, 2015. 8(1): p. a020479. 
157. O'Brien, J.S. and E.L. Sampson, Lipid composition of the normal human brain: gray 
matter, white matter, and myelin. J Lipid Res, 1965. 6(4): p. 537-44. 
158. Schmitt, S., L.C. Castelvetri, and M. Simons, Metabolism and functions of lipids in 
myelin. Biochim Biophys Acta, 2015. 1851(8): p. 999-1005. 
159. Perlman, S.J. and S. Mar, Leukodystrophies. Adv Exp Med Biol, 2012. 724: p. 154-71. 
160. Frey, B.M., et al., Characterization of White Matter Hyperintensities in Large-Scale 
MRI-Studies. Front Neurol, 2019. 10: p. 238. 
161. Racine, A.M., et al., Associations between white matter microstructure and amyloid 
burden in preclinical Alzheimer's disease: A multimodal imaging investigation. 
Neuroimage Clin, 2014. 4: p. 604-14. 
162. Scheltens, P., et al., Histopathologic correlates of white matter changes on MRI in 
Alzheimer's disease and normal aging. Neurology, 1995. 45(5): p. 883-8. 
163. Brickman, A.M., et al., Regional white matter hyperintensity volume, not hippocampal 
atrophy, predicts incident Alzheimer disease in the community. Arch Neurol, 2012. 
69(12): p. 1621-7. 
164. Lee, S., et al., White matter hyperintensities are a core feature of Alzheimer's disease: 
Evidence from the dominantly inherited Alzheimer network. Ann Neurol, 2016. 79(6): p. 
929-39. 
165. Nasrabady, S.E., et al., White matter changes in Alzheimer’s disease: a focus on myelin 
and oligodendrocytes. Acta Neuropathologica Communications, 2018. 6(1): p. 22. 
References 
135 
 
166. Hill, R.A., A.M. Li, and J. Grutzendler, Lifelong cortical myelin plasticity and age-
related degeneration in the live mammalian brain. Nat neuroscience, 2018. 21(5): p. 683-
695. 
167. Benes, F.M., et al., Myelination of a key relay zone in the hippocampal formation occurs 
in the human brain during childhood, adolescence, and adulthood. Arch Gen Psychiatry, 
1994. 51(6): p. 477-84. 
168. Bartzokis, G., P.H. Lu, and J. Mintz, Human brain myelination and amyloid beta 
deposition in Alzheimer's disease. Alzheimers Dement, 2007. 3(2): p. 122-5. 
169. Ringman, J.M., et al., Diffusion tensor imaging in preclinical and presymptomatic 
carriers of familial Alzheimer's disease mutations. Brain, 2007. 130(Pt 7): p. 1767-76. 
170. Peters, A., The effects of normal aging on myelinated nerve fibers in monkey central 
nervous system. Front Neuroanat, 2009. 3: p. 11. 
171. Bartzokis, G., Age-related myelin breakdown: a developmental model of cognitive 
decline and Alzheimer's disease. Neurobiol Aging, 2004. 25(1): p. 5-18; author reply 49-
62. 
172. van der Kant, R., et al., Cholesterol Metabolism Is a Druggable Axis that Independently 
Regulates Tau and Amyloid-beta in iPSC-Derived Alzheimer's Disease Neurons. Cell 
Stem Cell, 2019. 24(3): p. 363-375.e9. 
173. Barrett, P.J., et al., The amyloid precursor protein has a flexible transmembrane domain 
and binds cholesterol. Science, 2012. 336(6085): p. 1168-71. 
174. Giles, C., et al., Differential regulation of sphingolipid metabolism in plasma, 
hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents. 
J Neurochem, 2017. 141(3): p. 413-422. 
References 
136 
 
175. Simons, K. and R. Ehehalt, Cholesterol, lipid rafts, and disease. J Clin Invest, 2002. 
110(5): p. 597-603. 
176. Merrill, A.H., Jr., Sphingolipid and glycosphingolipid metabolic pathways in the era of 
sphingolipidomics. Chem Rev, 2011. 111(10): p. 6387-422. 
177. Iqbal, J., et al., Sphingolipids and Lipoproteins in Health and Metabolic Disorders. 
Trends Endocrinol Metab, 2017. 28(7): p. 506-518. 
178. Mencarelli, C. and P. Martinez-Martinez, Ceramide function in the brain: when a slight 
tilt is enough. Cell Mol Life Sci, 2013. 70(2): p. 181-203. 
179. Brodowicz, J., et al., Ceramide and Its Related Neurochemical Networks as Targets for 
Some Brain Disorder Therapies. Neurotox Res, 2018. 33(2): p. 474-484. 
180. Gault, C.R., L.M. Obeid, and Y.A. Hannun, An overview of sphingolipid metabolism: 
from synthesis to breakdown. Adv Exp Med Biol, 2010. 688: p. 1-23. 
181. Tafesse, F.G., et al., Both sphingomyelin synthases SMS1 and SMS2 are required for 
sphingomyelin homeostasis and growth in human HeLa cells. J Biol Chem, 2007. 
282(24): p. 17537-47. 
182. Yamashita, T., et al., A vital role for glycosphingolipid synthesis during development and 
differentiation. Proc Natl Acad Sci U S A, 1999. 96(16): p. 9142-7. 
183. Ozgen, H., et al., Oligodendroglial membrane dynamics in relation to myelin biogenesis. 
Cell Mol Life Sci, 2016. 73(17): p. 3291-310. 
184. Coetzee, T., et al., Myelination in the absence of galactocerebroside and sulfatide: 
normal structure with abnormal function and regional instability. Cell, 1996. 86(2): p. 
209-19. 
References 
137 
 
185. Bosio, A., E. Binczek, and W. Stoffel, Functional breakdown of the lipid bilayer of the 
myelin membrane in central and peripheral nervous system by disrupted 
galactocerebroside synthesis. Proceedings of the National Academy of Sciences of the 
United States of America, 1996. 93(23): p. 13280-13285. 
186. Piccinini, M., et al., Deregulated sphingolipid metabolism and membrane organization in 
neurodegenerative disorders. Mol Neurobiol, 2010. 41(2-3): p. 314-40. 
187. Haughey, N.J., Sphingolipids in neurodegeneration. Neuromolecular Med, 2010. 12(4): 
p. 301-5. 
188. van Echten-Deckert, G. and J. Walter, Sphingolipids: critical players in Alzheimer's 
disease. Prog Lipid Res, 2012. 51(4): p. 378-93. 
189. Mullen, T.D., Y.A. Hannun, and L.M. Obeid, Ceramide synthases at the centre of 
sphingolipid metabolism and biology. Biochem J, 2012. 441(3): p. 789-802. 
190. Yabu, T., et al., Stress-induced ceramide generation and apoptosis via the 
phosphorylation and activation of nSMase1 by JNK signaling. Cell Death Differ, 2015. 
22(2): p. 258-73. 
191. Gomez-Munoz, A., et al., Control of inflammatory responses by ceramide, sphingosine 1-
phosphate and ceramide 1-phosphate. Prog Lipid Res, 2016. 61: p. 51-62. 
192. Pettus, B.J., C.E. Chalfant, and Y.A. Hannun, Ceramide in apoptosis: an overview and 
current perspectives. Biochim Biophys Acta, 2002. 1585(2-3): p. 114-25. 
193. Rohrbough, J., et al., Ceramidase Regulates Synaptic Vesicle Exocytosis and Trafficking. 
J Neurosci, 2004. 24(36): p. 7789-7803. 
194. Jayadev, S., et al., Role for ceramide in cell cycle arrest. J Biol Chem, 1995. 270(5): p. 
2047-52. 
References 
138 
 
195. Wang, G., et al., Direct binding to ceramide activates protein kinase Czeta before the 
formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J Biol 
Chem, 2005. 280(28): p. 26415-24. 
196. Yuyama, K., S. Mitsutake, and Y. Igarashi, Pathological roles of ceramide and its 
metabolites in metabolic syndrome and Alzheimer's disease. Biochim Biophys Acta, 
2014. 1841(5): p. 793-8. 
197. Wang, G., et al., Astrocytes secrete exosomes enriched with proapoptotic ceramide and 
prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in 
Alzheimer disease (AD). J Biol Chem, 2012. 287(25): p. 21384-95. 
198. Han, X., et al., Substantial sulfatide deficiency and ceramide elevation in very early 
Alzheimer's disease: potential role in disease pathogenesis. J Neurochem, 2002. 82(4): p. 
809-18. 
199. Filippov, V., et al., Increased ceramide in brains with Alzheimer's and other 
neurodegenerative diseases. J Alzheimers Dis, 2012. 29(3): p. 537-47. 
200. Cutler, R.G., et al., Involvement of oxidative stress-induced abnormalities in ceramide 
and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci 
U S A, 2004. 101(7): p. 2070-5. 
201. Jana, A., E.L. Hogan, and K. Pahan, Ceramide and neurodegeneration: susceptibility of 
neurons and oligodendrocytes to cell damage and death. J Neurol Sci, 2009. 278(1-2): p. 
5-15. 
202. Bonda, D.J., et al., Oxidative stress in Alzheimer disease: a possibility for prevention. 
Neuropharmacology, 2010. 59(4-5): p. 290-4. 
References 
139 
 
203. Andrieu-Abadie, N., et al., Ceramide in apoptosis signaling: relationship with oxidative 
stress. Free Radic Biol Med, 2001. 31(6): p. 717-28. 
204. Šimić, G., et al., Volume and number of neurons of the human hippocampal formation in 
normal aging and Alzheimer's disease. Journal of Comparative Neurology, 1997. 379(4): 
p. 482-494. 
205. Czubowicz, K., et al., The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer's 
Disease and Other Neurodegenerative Disorders. Mol Neurobiol, 2019. 56(8): p. 5436-
5455. 
206. Mielke, M.M., et al., Plasma ceramides are altered in mild cognitive impairment and 
predict cognitive decline and hippocampal volume loss. Alzheimers Dement, 2010. 6(5): 
p. 378-85. 
207. Mielke, M.M., et al., Serum ceramides increase the risk of Alzheimer disease: the 
Women's Health and Aging Study II. Neurology, 2012. 79(7): p. 633-41. 
208. Mielke, M.M., et al., Serum sphingomyelins and ceramides are early predictors of 
memory impairment. Neurobiol Aging, 2010. 31(1): p. 17-24. 
209. Rosen, H., et al., Sphingosine-1-phosphate and its receptors: structure, signaling, and 
influence. Annu Rev Biochem, 2013. 82: p. 637-62. 
210. Mandala, S., et al., Alteration of lymphocyte trafficking by sphingosine-1-phosphate 
receptor agonists. Science, 2002. 296(5566): p. 346-9. 
211. Maceyka, M. and S. Spiegel, Sphingolipid metabolites in inflammatory disease. Nature, 
2014. 510(7503): p. 58-67. 
References 
140 
 
212. Wang, Z., et al., The Effect of Sphingosine 1-Phosphate/Sphingosine 1-Phosphate 
Receptor on Neutrophil Function and the Relevant Signaling Pathway. Acta Haematol, 
2015. 134(1): p. 49-56. 
213. Moriue, T., et al., Sphingosine 1-phosphate attenuates H2O2-induced apoptosis in 
endothelial cells. Biochem Biophys Res Commun, 2008. 368(4): p. 852-7. 
214. Proia, R.L. and T. Hla, Emerging biology of sphingosine-1-phosphate: its role in 
pathogenesis and therapy. J Clin Invest, 2015. 125(4): p. 1379-87. 
215. Christoffersen, C., et al., Endothelium-protective sphingosine-1-phosphate provided by 
HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A, 2011. 108(23): p. 9613-8. 
216. Jung, B., et al., Flow-regulated endothelial S1P receptor-1 signaling sustains vascular 
development. Dev Cell, 2012. 23(3): p. 600-10. 
217. Cannavo, A., et al., Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: 
Signaling and Actions in the Cardiovascular System. Frontiers in Pharmacology, 2017. 
8(556). 
218. Mizugishi, K., et al., Essential role for sphingosine kinases in neural and vascular 
development. Mol Cell Biol, 2005. 25(24): p. 11113-21. 
219. Blondeau, N., et al., Distribution of sphingosine kinase activity and mRNA in rodent 
brain. J Neurochem, 2007. 103(2): p. 509-17. 
220. Lei, M., et al., Contextual fear conditioning is enhanced in mice lacking functional 
sphingosine kinase 2. Behav Brain Res, 2017. 333: p. 9-16. 
221. Couttas, T.A., et al., Loss of the neuroprotective factor Sphingosine 1-phosphate early in 
Alzheimer's disease pathogenesis. Acta Neuropathol Commun, 2014. 2: p. 9. 
References 
141 
 
222. Pitson, S.M., et al., Phosphorylation-dependent translocation of sphingosine kinase to the 
plasma membrane drives its oncogenic signalling. J Exp Med, 2005. 201(1): p. 49-54. 
223. van Echten-Deckert, G., et al., Sphingosine-1-phosphate: boon and bane for the brain. 
Cell Physiol Biochem, 2014. 34(1): p. 148-57. 
224. Don, A.S. and H. Rosen, A lipid binding domain in sphingosine kinase 2. Biochem 
Biophys Res Commun, 2009. 380(1): p. 87-92. 
225. Hait, N.C., et al., Active, phosphorylated fingolimod inhibits histone deacetylases and 
facilitates fear extinction memory. Nat Neurosci, 2014. 17(7): p. 971-80. 
226. Hait, N.C., et al., Regulation of histone acetylation in the nucleus by sphingosine-1-
phosphate. Science, 2009. 325(5945): p. 1254-7. 
227. Igarashi, N., et al., Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. 
J Biol Chem, 2003. 278(47): p. 46832-9. 
228. Maceyka, M., et al., SphK1 and SphK2, sphingosine kinase isoenzymes with opposing 
functions in sphingolipid metabolism. J Biol Chem, 2005. 280(44): p. 37118-29. 
229. Spiegel, S. and S. Milstien, Sphingosine-1-phosphate: an enigmatic signalling lipid. 
Nature Reviews Molecular Cell Biology, 2003. 4(5): p. 397-407. 
230. Kumar, A. and J.D. Saba, Lyase to live by: sphingosine phosphate lyase as a therapeutic 
target. Expert Opin Ther Targets, 2009. 13(8): p. 1013-25. 
231. Kajimoto, T., et al., Involvement of sphingosine-1-phosphate in glutamate secretion in 
hippocampal neurons. Mol Cell Biol, 2007. 27(9): p. 3429-40. 
232. Kanno, T., et al., Regulation of synaptic strength by sphingosine 1-phosphate in the 
hippocampus. Neuroscience, 2010. 171(4): p. 973-80. 
References 
142 
 
233. Chan, J.P., Z. Hu, and D. Sieburth, Recruitment of sphingosine kinase to presynaptic 
terminals by a conserved muscarinic signaling pathway promotes neurotransmitter 
release. Genes Dev, 2012. 26(10): p. 1070-85. 
234. Riganti, L., et al., Sphingosine-1-Phosphate (S1P) Impacts Presynaptic Functions by 
Regulating Synapsin I Localization in the Presynaptic Compartment. J Neurosci, 2016. 
36(16): p. 4624-4634. 
235. Jaillard, C., et al., Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on 
Process Retraction and Cell Survival. J Neurosci, 2005. 25(6): p. 1459-1469. 
236. Novgorodov, A.S., et al., Activation of sphingosine-1-phosphate receptor S1P5 inhibits 
oligodendrocyte progenitor migration. The FASEB Journal, 2007. 21(7): p. 1503-14. 
237. Coelho, R.P., et al., The immunomodulator FTY720 has a direct cytoprotective effect in 
oligodendrocyte progenitors. J Pharmacol Exp Ther, 2007. 323(2): p. 626-35. 
238. Wei, Y., et al., Fingolimod provides long-term protection in rodent models of cerebral 
ischemia. Ann Neurol, 2011. 69(1): p. 119-29. 
239. Hasegawa, Y., et al., Activation of sphingosine 1-phosphate receptor-1 by FTY720 is 
neuroprotective after ischemic stroke in rats. Stroke, 2010. 41(2): p. 368-74. 
240. Pfeilschifter, W., et al., Activation of sphingosine kinase 2 is an endogenous protective 
mechanism in cerebral ischemia. Biochem Biophys Res Commun, 2011. 413(2): p. 212-
7. 
241. Couttas, T.A., et al., Age-Dependent Changes to Sphingolipid Balance in the Human 
Hippocampus are Gender-Specific and May Sensitize to Neurodegeneration. J 
Alzheimers Dis, 2018. 63(2): p. 503-514. 
References 
143 
 
242. Dominguez, G., et al., Neuronal sphingosine kinase 2 subcellular localization is altered 
in Alzheimer's disease brain. Acta Neuropathol Commun, 2018. 6(1): p. 25. 
243. Ceccom, J., et al., Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate 
lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in 
Alzheimer's disease. Acta Neuropathol Commun, 2014. 2: p. 12. 
244. Takasugi, N., et al., BACE1 activity is modulated by cell-associated sphingosine-1-
phosphate. J Neurosci, 2011. 31(18): p. 6850-7. 
245. Hagen, N., et al., Sphingosine-1-phosphate links glycosphingolipid metabolism to 
neurodegeneration via a calpain-mediated mechanism. Cell Death Differ, 2011. 18(8): p. 
1356-65. 
246. Karaca, I., et al., Deficiency of sphingosine-1-phosphate lyase impairs lysosomal 
metabolism of the amyloid precursor protein. J Biol Chem, 2014. 289(24): p. 16761-72. 
247. Culhane, K.J., et al., Transmembrane signal transduction by peptide hormones via family 
B G protein-coupled receptors. Frontiers in Pharmacology, 2015. 6(264). 
248. Ryu, Y., et al., Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, 
negatively regulates cellular Rac activity and cell migration in vascular smooth muscle 
cells. Circ Res, 2002. 90(3): p. 325-32. 
249. Fritsch, R., et al., RAS and RHO families of GTPases directly regulate distinct 
phosphoinositide 3-kinase isoforms. Cell, 2013. 153(5): p. 1050-63. 
250. Subei, A.M. and J.A. Cohen, Sphingosine 1-phosphate receptor modulators in multiple 
sclerosis. CNS Drugs, 2015. 29(7): p. 565-75. 
251. Okamoto, H., et al., EDG1 is a functional sphingosine-1-phosphate receptor that is 
linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, 
References 
144 
 
Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate 
cyclase inhibition. J Biol Chem, 1998. 273(42): p. 27104-10. 
252. Windh, R.T., et al., Differential coupling of the sphingosine 1-phosphate receptors Edg-
1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G 
proteins. J Biol Chem, 1999. 274(39): p. 27351-8. 
253. Du, W., et al., S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, 
negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res, 
2010. 70(2): p. 772-81. 
254. Schuppel, M., et al., Sphingosine 1-phosphate restrains insulin-mediated keratinocyte 
proliferation via inhibition of Akt through the S1P2 receptor subtype. J Invest Dermatol, 
2008. 128(7): p. 1747-56. 
255. Sugimoto, N., et al., Inhibitory and stimulatory regulation of Rac and cell motility by the 
G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled 
sphingosine-1-phosphate receptor isoform. Mol Cell Biol, 2003. 23(5): p. 1534-45. 
256. Arikawa, K., et al., Ligand-dependent inhibition of B16 melanoma cell migration and 
invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of 
cellular RAC activity. J Biol Chem, 2003. 278(35): p. 32841-51. 
257. Okamoto, H., et al., Inhibitory regulation of Rac activation, membrane ruffling, and cell 
migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not 
EDG1 or EDG3. Mol Cell Biol, 2000. 20(24): p. 9247-61. 
258. Dillmann, C., et al., S1PR4 Signaling Attenuates ILT 7 Internalization To Limit IFN-α 
Production by Human Plasmacytoid Dendritic Cells. The Journal of Immunology, 2016. 
196(4): p. 1579-1590. 
References 
145 
 
259. Choi, J.W., et al., FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis 
requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl 
Acad Sci U S A, 2011. 108(2): p. 751-6. 
260. Harris, C.M., A.D. Hobson, and N.S. Wilson, Agonists and Antagonists of the S1P5 
Receptor, and Methods of Use Thereof. 2010, Google Patents. 
261. Bigaud, M., et al., Second generation S1P pathway modulators: research strategies and 
clinical developments. Biochim Biophys Acta, 2014. 1841(5): p. 745-58. 
262. Choi, J.W. and J. Chun, Lysophospholipids and their receptors in the central nervous 
system. Biochim Biophys Acta, 2013. 1831(1): p. 20-32. 
263. Brinkmann, V., et al., The immune modulator FTY720 targets sphingosine 1-phosphate 
receptors. J Biol Chem, 2002. 277(24): p. 21453-7. 
264. Matloubian, M., et al., Lymphocyte egress from thymus and peripheral lymphoid organs 
is dependent on S1P receptor 1. Nature, 2004. 427(6972): p. 355-60. 
265. Osborn, L.M., et al., Astrogliosis: An integral player in the pathogenesis of Alzheimer's 
disease. Prog Neurobiol, 2016. 144: p. 121-41. 
266. Groves, A., Y. Kihara, and J. Chun, Fingolimod: direct CNS effects of sphingosine 1-
phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J 
Neurol Sci, 2013. 328(1-2): p. 9-18. 
267. Balatoni, B., et al., FTY720 sustains and restores neuronal function in the DA rat model 
of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull, 2007. 
74(5): p. 307-16. 
268. Foster, C.A., et al., Brain penetration of the oral immunomodulatory drug FTY720 and 
its phosphorylation in the central nervous system during experimental autoimmune 
References 
146 
 
encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol 
Exp Ther, 2007. 323(2): p. 469-75. 
269. Hemmati, F., et al., Neurorestorative effect of FTY720 in a rat model of Alzheimer's 
disease: comparison with memantine. Behav Brain Res, 2013. 252: p. 415-21. 
270. Asle-Rousta, M., et al., FTY720 (fingolimod) attenuates beta-amyloid peptide (Abeta42)-
induced impairment of spatial learning and memory in rats. J Mol Neurosci, 2013. 50(3): 
p. 524-32. 
271. Takasugi, N., et al., FTY720/fingolimod, a sphingosine analogue, reduces amyloid-beta 
production in neurons. PLoS One, 2013. 8(5): p. e64050. 
272. Deogracias, R., et al., Fingolimod, a sphingosine-1 phosphate receptor modulator, 
increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. 
Proceedings of the National Academy of Sciences, 2012. 109(35): p. 14230-14235. 
273. Calabresi, P.A., et al., Safety and efficacy of fingolimod in patients with relapsing-
remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-
controlled, phase 3 trial. Lancet Neurol, 2014. 13(6): p. 545-56. 
274. Kappos, L., et al., Siponimod versus placebo in secondary progressive multiple sclerosis 
(EXPAND): a double-blind, randomised, phase 3 study. Lancet, 2018. 391(10127): p. 
1263-1273. 
275. Gergely, P., et al., The selective sphingosine 1-phosphate receptor modulator BAF312 
redirects lymphocyte distribution and has species-specific effects on heart rate. Br J 
Pharmacol, 2012. 167(5): p. 1035-47. 
References 
147 
 
276. Shakeri-Nejad, K., et al., Effects of Therapeutic and Supratherapeutic Doses of 
Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects. Clin Ther, 2015. 
37(11): p. 2489-2505.e2. 
277. Gentile, A., et al., Siponimod (BAF312) prevents synaptic neurodegeneration in 
experimental multiple sclerosis. J Neuroinflammation, 2016. 13(1): p. 207. 
278. Kim, Y.S. and B.E. Yoon, Altered GABAergic Signaling in Brain Disease at Various 
Stages of Life. Exp Neurobiol, 2017. 26(3): p. 122-131. 
279. van Doorn, R., et al., Sphingosine 1-phosphate receptor 5 mediates the immune 
quiescence of the human brain endothelial barrier. Journal of Neuroinflammation, 2012. 
9(1): p. 133. 
280. Hobson, A.D., et al., Discovery of A-971432, An Orally Bioavailable Selective 
Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of 
Neurodegenerative Disorders. J Med Chem, 2015. 58(23): p. 9154-70. 
281. Di Pardo, A., et al., Stimulation of S1PR5 with A-971432, a selective agonist, preserves 
blood-brain barrier integrity and exerts therapeutic effect in an animal model of 
Huntington's disease. Hum Mol Genet, 2018. 27(14): p. 2490-2501. 
282. Piali, L., et al., The selective sphingosine 1-phosphate receptor 1 agonist ponesimod 
protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther, 2011. 
337(2): p. 547-56. 
283. Kappos, L., et al., Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J 
Med, 2006. 355(11): p. 1124-40. 
284. Kappos, L., et al., A placebo-controlled trial of oral fingolimod in relapsing multiple 
sclerosis. N Engl J Med, 2010. 362(5): p. 387-401. 
References 
148 
 
285. D'Ambrosio, D., M.S. Freedman, and J. Prinz, Ponesimod, a selective S1P1 receptor 
modulator: a potential treatment for multiple sclerosis and other immune-mediated 
diseases. Ther Adv Chronic Dis, 2016. 7(1): p. 18-33. 
286. Scott, F.L., et al., Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 
(S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity. Br J 
Pharmacol, 2016. 173(11): p. 1778-92. 
287. Sabino, J., et al., New biologics and small molecules in inflammatory bowel disease: an 
update. Therapeutic Advances in Gastroenterology, 2019. 12: p. 1756284819853208. 
288. Cohen, J.A., et al., Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded 
extension of a randomized phase II study. Mult Scler, 2019. 25(9): p. 1255-1262. 
289. Lei, M., et al., Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against 
Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. 
J Neurosci, 2019. 39(48): p. 9645-9659. 
290. Im, D.S., et al., Characterization of the human and mouse sphingosine 1-phosphate 
receptor, S1P5 (Edg-8): structure-activity relationship of sphingosine1-phosphate 
receptors. Biochemistry, 2001. 40(46): p. 14053-60. 
291. Zhang, Y., et al., An RNA-Sequencing Transcriptome and Splicing Database of Glia, 
Neurons, and Vascular Cells of the Cerebral Cortex. J Neurosci, 2014. 34(36): p. 11929-
11947. 
292. O'Sullivan, C., et al., The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates 
demyelination in organotypic slice cultures. J Neuroinflammation, 2016. 13: p. 31. 
293. van der Kam, E., et al., The use of selective sphingosine-1-phosphate receptor 5 agonist 
for the treatment of neurodegenerative disorders such as Alzheimer’s disease and 
References 
149 
 
lysosomal storage diseases such as Neimann-Pick C disease. Alzheimer's & Dementia: 
The Journal of the Alzheimer's Association, 2014. 10(4): p. P281. 
294. Antunes, M. and G. Biala, The novel object recognition memory: neurobiology, test 
procedure, and its modifications. Cogn Process, 2012. 13(2): p. 93-110. 
295. Dere, E., J.P. Huston, and M.A.D.S. Silva, The pharmacology, neuroanatomy and 
neurogenetics of one-trial object recognition in rodents. Neuroscience & Biobehavioral 
Reviews, 2007. 31(5): p. 673-704. 
296. Sigurdsson, T., et al., Long-term potentiation in the amygdala: a cellular mechanism of 
fear learning and memory. Neuropharmacology, 2007. 52(1): p. 215-27. 
297. Matyash, V., et al., Lipid extraction by methyl-tert-butyl ether for high-throughput 
lipidomics. J Lipid Res, 2008. 49(5): p. 1137-46. 
298. Wong, J.W.H., et al., MMSAT: Automated Quantification of Metabolites in Selected 
Reaction Monitoring Experiments. Anal Chem, 2012. 84(1): p. 470-474. 
299. Benjamini, Y., A.M. Krieger, and D. Yekutieli, Adaptive linear step-up procedures that 
control the false discovery rate. Biometrika, 2006. 93(3): p. 491-507. 
300. Šidák, Z., Rectangular Confidence Regions for the Means of Multivariate Normal 
Distributions. Journal of the American Statistical Association, 1967. 62(318): p. 626-633. 
301. Pan, S., et al., Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor 
Modulator. ACS Med Chem Lett, 2013. 4(3): p. 333-7. 
302. Snaidero, N. and M. Simons, Myelination at a glance. J Cell Sci, 2014. 127(Pt 14): p. 
2999-3004. 
References 
150 
 
303. Cellerino, A., et al., Reduced size of retinal ganglion cell axons and hypomyelination in 
mice lacking brain-derived neurotrophic factor. Mol Cell Neurosci, 1997. 9(5-6): p. 397-
408. 
304. Taveggia, C., et al., Neuregulin-1 type III determines the ensheathment fate of axons. 
Neuron, 2005. 47(5): p. 681-94. 
305. Willem, M., et al., Control of peripheral nerve myelination by the beta-secretase BACE1. 
Science, 2006. 314(5799): p. 664-6. 
306. Hu, X., et al., Bace1 modulates myelination in the central and peripheral nervous system. 
Nat Neurosci, 2006. 9(12): p. 1520-5. 
307. Michailov, G.V., et al., Axonal neuregulin-1 regulates myelin sheath thickness. Science, 
2004. 304(5671): p. 700-3. 
308. Hu, X., et al., Neurological dysfunctions associated with altered BACE1-dependent 
Neuregulin-1 signaling. J Neurochem, 2016. 136(2): p. 234-49. 
309. Cuvillier, O., Sphingosine in apoptosis signaling. Biochim Biophys Acta, 2002. 1585(2-
3): p. 153-62. 
310. Kågedal, K., et al., Sphingosine-induced apoptosis is dependent on lysosomal proteases. 
Biochem J, 2001. 359(Pt 2): p. 335-43. 
311. Jatana, M., S. Giri, and A.K. Singh, Apoptotic positive cells in Krabbe brain and 
induction of apoptosis in rat C6 glial cells by psychosine. Neurosci Lett, 2002. 330(2): p. 
183-7. 
312. Franklin, R.J. and S.A. Goldman, Glia Disease and Repair-Remyelination. Cold Spring 
Harb Perspect Biol, 2015. 7(7): p. a020594. 
References 
151 
 
313. Tarasiuk, J., et al., Increased concentration of the CSF Tau protein and its 
phosphorylated form in the late juvenile metachromatic leukodystrophy form: a case 
report. J Neural Transm (Vienna), 2012. 119(7): p. 759-62. 
314. Efstathopoulos, P., et al., Fingolimod induces neurogenesis in adult mouse hippocampus 
and improves contextual fear memory. Translational Psychiatry, 2015. 5(11): p. e685-
e685. 
315. Guan, J.S., et al., HDAC2 negatively regulates memory formation and synaptic plasticity. 
Nature, 2009. 459(7243): p. 55-60. 
316. Sullards, M.C., Analysis of sphingomyelin, glucosylceramide, ceramide, sphingosine, and 
sphingosine 1-phosphate by tandem mass spectrometry. Methods Enzymol, 2000. 312: p. 
32-45. 
317. Fyrst, H., et al., Identification and characterization by electrospray mass spectrometry of 
endogenous Drosophila sphingadienes. J Lipid Res, 2008. 49(3): p. 597-606. 
318. Herr, D.R., et al., Sply regulation of sphingolipid signaling molecules is essential for 
Drosophila development. Development, 2003. 130(11): p. 2443-2453. 
319. Colsch, B., et al., Characterization of the ceramide moieties of sphingoglycolipids from 
mouse brain by ESI-MS/MS: Identification of ceramides containing sphingadienine. 
Journal of lipid research, 2004. 45: p. 281-6. 
320. Quehenberger, O., et al., Lipidomics reveals a remarkable diversity of lipids in human 
plasma. J Lipid Res, 2010. 51(11): p. 3299-305. 
321. Struckhoff, A.P., et al., Novel ceramide analogs as potential chemotherapeutic agents in 
breast cancer. J Pharmacol Exp Ther, 2004. 309(2): p. 523-32. 
References 
152 
 
322. Bielawska, A., et al., Selectivity of ceramide-mediated biology. Lack of activity of 
erythro-dihydroceramide. J Biol Chem, 1993. 268(35): p. 26226-32. 
323. Karasavvas, N., et al., Stereospecific induction of apoptosis in U937 cells by N-octanoyl-
sphingosine stereoisomers and N-octyl-sphingosine. The ceramide amide group is not 
required for apoptosis. Eur J Biochem, 1996. 236(2): p. 729-37. 
324. He, L., et al., Enantioselective synthesis of a novel trans double bond ceramide analogue 
via catalytic asymmetric dihydroxylation of an enyne. The role of the trans double bond 
of ceramide in the fusion of Semliki Forest virus with target membranes. Journal of the 
American Chemical Society, 1999. 121(16): p. 3897-3903. 
325. Ding, X., et al., Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 
is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma 
cells. Oncotarget, 2016. 7(15): p. 20080-92. 
326. Pyne, N.J., et al., Role of sphingosine 1-phosphate receptors, sphingosine kinases and 
sphingosine in cancer and inflammation. Adv Biol Regul, 2016. 60: p. 151-159. 
327. Beljanski, V., C. Knaak, and C.D. Smith, A novel sphingosine kinase inhibitor induces 
autophagy in tumor cells. J Pharmacol Exp Ther, 2010. 333(2): p. 454-64. 
328. Kipp, M., et al., Multiple sclerosis: neuroprotective alliance of estrogen-progesterone 
and gender. Front Neuroendocrinol, 2012. 33(1): p. 1-16. 
329. Gold, S.M. and R.R. Voskuhl, Estrogen treatment in multiple sclerosis. J Neurol Sci, 
2009. 286(1-2): p. 99-103. 
330. Crawford, D.K., et al., Oestrogen receptor beta ligand: a novel treatment to enhance 
endogenous functional remyelination. Brain, 2010. 133(10): p. 2999-3016. 
References 
153 
 
331. Morales, L.B., et al., Treatment with an estrogen receptor alpha ligand is neuroprotective 
in experimental autoimmune encephalomyelitis. J Neurosci, 2006. 26(25): p. 6823-33. 
332. Patel, R., et al., Attenuation of corpus callosum axon myelination and remyelination in 
the absence of circulating sex hormones. Brain Pathol, 2013. 23(4): p. 462-75. 
333. Luo, Y., et al., 17β-estradiol replacement therapy protects myelin sheaths in the white 
matter of middle-aged female ovariectomized rats: a stereological study. Neurobiology 
of aging, 2016. 47: p. 139-148. 
334. Ha, D.M., J. Xu, and J.S. Janowsky, Preliminary evidence that long-term estrogen use 
reduces white matter loss in aging. Neurobiol Aging, 2007. 28(12): p. 1936-40. 
335. Erickson, K.I., et al., Selective sparing of brain tissue in postmenopausal women 
receiving hormone replacement therapy. Neurobiol Aging, 2005. 26(8): p. 1205-13. 
336. Hussain, R., et al., The neural androgen receptor: a therapeutic target for myelin repair 
in chronic demyelination. Brain, 2013. 136(Pt 1): p. 132-46. 
337. Torkildsen, O., et al., The cuprizone model for demyelination. Acta Neurol Scand Suppl, 
2008. 188: p. 72-6. 
338. Liu, H., et al., Molecular cloning and functional characterization of a novel mammalian 
sphingosine kinase type 2 isoform. J Biol Chem, 2000. 275(26): p. 19513-20. 
339. Liu, H., et al., Sphingosine kinase type 2 is a putative BH3-only protein that induces 
apoptosis. J Biol Chem, 2003. 278(41): p. 40330-6. 
340. Chipuk, J.E., et al., Sphingolipid metabolism cooperates with BAK and BAX to promote 
the mitochondrial pathway of apoptosis. Cell, 2012. 148(5): p. 988-1000. 
341. Stiedl, O. and J. Spiess, Effect of tone-dependent fear conditioning on heart rate and 
behavior of C57BL/6N mice. Behav Neurosci, 1997. 111(4): p. 703-11. 
References 
154 
 
342. van Gaalen, M.M. and T. Steckler, Behavioural analysis of four mouse strains in an 
anxiety test battery. Behav Brain Res, 2000. 115(1): p. 95-106. 
343. Hakak, Y., et al., Genome-wide expression analysis reveals dysregulation of myelination-
related genes in chronic schizophrenia. Proc Natl Acad Sci U S A, 2001. 98(8): p. 4746-
51. 
344. Voineskos, A.N., et al., Oligodendrocyte genes, white matter tract integrity, and 
cognition in schizophrenia. Cereb Cortex, 2013. 23(9): p. 2044-57. 
345. Kujala, P., R. Portin, and J. Ruutiainen, The progress of cognitive decline in multiple 
sclerosis. A controlled 3-year follow-up. Brain, 1997. 120 ( Pt 2): p. 289-97. 
346. Gootjes, L., et al., Regional distribution of white matter hyperintensities in vascular 
dementia, Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord, 2004. 
18(2): p. 180-8. 
347. Matsushima, G.K. and P. Morell, The neurotoxicant, cuprizone, as a model to study 
demyelination and remyelination in the central nervous system. Brain pathology, 2001. 
11(1): p. 107-116. 
348. Saito, T., et al., Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci, 
2014. 17(5): p. 661-3. 
349. Shibuya, Y., et al., Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated 
lysosomal proteolysis and increases Abeta1-42 clearance. J Neurosci, 2014. 34(43): p. 
14484-501. 
350. Shibuya, Y., et al., Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances 
autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces 
References 
155 
 
human P301L-tau content at the presymptomatic stage. Neurobiol Aging, 2015. 36(7): p. 
2248-2259. 
351. van der Kant, R. and L.S. Goldstein, Cellular functions of the amyloid precursor protein 
from development to dementia. Dev Cell, 2015. 32(4): p. 502-15. 
 
 
